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Chronic Obstructive Pulmonary Disease (COPD) is defined by the Global Initiative for Chronic 
Obstructive Lung Diseases (GOLD) as ‘a common preventable and treatable disease that is 
characterized by persistent airflow limitation that is usually progressive and associated with 
enhanced chronic inflammatory response in the airways and the lung to noxious particles or 
gases’ [1]. Exacerbations, comorbidities, and systemic effects are very common in COPD [1, 
2]. A clinical diagnosis of COPD should be considered when a patient presents with dyspnea, 
chronic cough, sputum production and/or wheezing, and a history of exposure to risk factors 
[1, 2]. The main risk factor for COPD is tobacco smoking and to a lesser extent indoor air 
pollution, dust and chemicals, and outdoor air pollution [1]. The diagnosis of COPD is 
confirmed if there is persistent airflow limitation, defined as a post-bronchodilator FEV1/FVC 
ratio <0.70 [1]. On the basis of the post-bronchodilator FEV1 percentage of predicted, the 
severity of airflow limitation is defined as mild, moderate, severe, or very severe (Table 1). 
 
Table 1 Characterization of severity of airflow limitation in COPD 
 Characteristics 
I. Mild FEV1 ≥ 80% of predicted 
FEV1/FVC < 70% 
II. Moderate FEV1 ≤ 80% and FEV1 ≥ 50% of predicted 
FEV1/FVC < 70% 
III. Severe FEV1 ≤ 50% and FEV1 ≥ 30% of predicted 
FEV1/FVC < 70% 
IV. Very severe FEV1 ≤ 30% predicted 
FEV1/FVC < 70% 
FEV1, forced expiratory volume in one second; FVC, forced vital capacity [1] 
 
The estimated prevalence of COPD in 2000 was 210 million people worldwide [3]. 
COPD is currently the fifth leading cause of death and it is estimated that it will be the fourth 
leading cause of death worldwide in 2030 [4]. In the Netherlands, approximately 2.4% of 
men and 1.7% of women are diagnosed with COPD [5]. These percentages are probably an 
underestimation, because COPD is typically not diagnosed before it is clinically apparent and 
moderately advanced. One reason for the late diagnosis is that COPD is a chronic, 
progressive disease. It develops slowly, and patients tend to attribute symptoms or 
decreased exercise tolerance to aging [6]. In general, patients do not consult their general 
practitioner until they experience symptoms and/or are confronted by variability in lung 
function that affects their daily life [7] and not for the presence of respiratory symptoms or a 
(gradually ) reduced lung function. Another possible reason for the late diagnosis in the 
Netherlands is that case-finding is not standard, and screening is recommended only for 
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those patients who are (ex-) smokers, who are older than 40 years with chronic cough 
and/or use of inhaled medication, or who had >2 infections of the lower airways in the past 
year [5]. Once a patient is diagnosed with COPD, treatment can be started. The majority of 
patients with COPD are treated by their general practitioner in primary care, with the 
exception of patients who do not respond to treatment, who have an unclear diagnosis, who 
are hospitalized, or who have advanced disease. These patients are generally referred to a 
pulmonologist in secondary care. The focus of treatment is mainly on controlling the disease, 
to improve physiological functioning. However, from the patient’s point of view, treatment 
should be aimed at the illness, at reducing fatigue, dyspnea, and impairments. Current 
guidelines integrate these aims: ‘treatment of COPD is aimed at reducing the impact of the 
symptoms and long term lung function decline, as well as prevention of future 
exacerbations, improvement of exercise tolerance and health status’ [1, 2]. Treatment is 
with pharmacological (i.e., bronchodilators, corticosteroids, vaccines, antibiotics) and/or 
non-pharmacological (pulmonary rehabilitation, oxygen therapy, surgical treatment, 
smoking cessation, physical activity, education, self-management) interventions.  
Unfortunately, as some of the consequences of COPD are permanent, because of the 
chronic and progressive nature of the disease, patients must adapt by changing their 
behavior. This not only diminishes perceived fatigue, dyspnea, and impairments but also has 
a positive effect on disease progression. Although the ultimate goal of treatment is the same 
for all patients, the way this goal is achieved is different for each patient. COPD is a very 
heterogeneous disease not only with respect to its different physiological manifestations but 
also with respect to how individual patients perceive the disease and its side effects. 
Everybody interprets a given situation in their own way, depending on their somatic, 
cognitive emotional, behavioral, and social appraisal. These aspects cannot be neglected 
when treating a chronic disease. 
Indeed, there has been a shift in guidelines on the diagnosis and treatment of COPD – 
from focusing exclusively on treatment of the disease to focusing on treatment of the illness, 
which encompasses not only disease management but also the somatic, cognitive emotional, 
behavioral, and social effects on the patient. In the past, treatment was guided (solely) by 
the severity of the airflow limitation [8, 9], but nowadays treatment is guided by disease 
severity, a combination of airflow limitation, health status, and risk of future events (such as 
exacerbations and hospital admissions) [1, 2]. This is completely in line with the change from 
the biomedical model to the biopsychosocial model for the treatment of chronic disease. 
In the past, the body and mind were seen as separate entities, with ‘illness of the 
body’ being treated by medical doctors, guided by measurable biological and physiological 
variables, and ‘illness of the mind’ being treated by psychiatrists/ psychologists, guided by 
the psychological and social context. For many years, these two fields existed alongside each 
other, both neglecting the relations that exist between the biological, psychological, and 
social dimensions of health in the patient. In 1977 Engel [10] introduced a blueprint for the 
biopsychosocial model for the treatment of disease, to replace the inadequate biomedical 
model in medicine. Whereas with the biomedical model treatment is guided solely by 
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measurable biological variables, the biopsychosocial model incorporates psychological, 
social, and behavioral dimensions of disease. Engel stated that all three dimensions 
(biological, psychological, and social) have a unique influence on the development, 
progression, and experience of disease, and thus should be measured to provide adequate 
treatment.  
From this point of view, numerous studies have investigated the impact of disease on 
patients, expressed in terms of quality of life, health-related quality of life, and health status. 
These concepts are often used interchangeably, which has led to conceptual confusion in the 
literature. Some definitions of these concepts are based on the definition of the World 
Health Organization, which defines health as ‘a state of complete physical, mental, and social 
well being, and not merely the absence of disease or infirmity’ [11]. Although all three 
concepts are used to investigate a patient’s health, they have a different focus. Both quality 
of life and health status measure the same domains (biological, psychological, and social), 
but at a different level, namely, only subjectively versus also objectively, respectively [12, 
13]. Moreover, quality of life is defined as ‘how satisfied a person is with life’ in the 
biological, psychological, and social domains [12-17], and health-related quality of life as 
satisfaction with health (physiological functioning) [18]. Health status measures the same 
aspects, but also focuses on the objective impact of the disease [12, 13] and not solely on 
the patient’s satisfaction. It is important to know the real (objective) and perceived 
(subjective) impact of disease on a patient’s health to get a clear picture. 
The conceptual model of health status of Wilson and Cleary [19] includes both the 
objective and subjective evaluation of the impact of disease on diverse dimensions. In line 
with the biopsychosocial view, their model includes the following domains: biological and 
physiological processes, and the perception of symptoms, functioning, general health, and 
overall quality of life (Figure 1). This model is not a causal model in which one aspect leads to 
the other, but is a phenomenological model. It includes several dimensions that all have a 
unique place and are at best moderately related.  
 
Figure 1 Conceptual model of health status developed by Wilson and Cleary [19] 
 
In line with this model, our research group developed the Nijmegen Integral 
Assessment Framework (NIAF) [20] to measure a person’s integral health status. On the 
basis of theoretical models and clinical considerations, we defined concepts and then 
empirically tested these concepts with relevant tests and instruments in 168 outpatients. 
Factor analysis revealed that integral health status compromises at least four main domains: 
physiological functioning, symptoms, functional impairment, and quality of life, each of  
biological 
and 
physiological 
processes 
perception 
of symptoms 
functioning 
general 
health 
perception 
overall 
quality of life 
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Figure 2 The Nijmegen Integral Assessment Framework (NIAF): A conceptual model of integral health 
status in patients with Chronic Obstructive Pulmonary Disease developed by Vercoulen et al. [20] 
Note: *added as subdomain in 2010  
 
which can be subdivided into many sub-domains (see Figure 2 and Table 1). There were low-
to-moderate correlations between the sub-domains, indicating that all sub-domains 
measure unique aspects of health status. Since these sub-domains are relatively unrelated, 
all sub-domains need to be measured in order to gain a complete picture of a patient’s 
integral health status. 
The various instruments developed to describe the impact of disease on a patient can 
be broadly divided into disease-specific and generic questionnaires. They both have their 
strengths and weaknesses. Whereas disease-specific instruments have a narrow focus and 
are often centered on the core symptoms of the disease, generic instruments cover universal 
symptoms and have a broader focus, which makes it possible to compare the impact on 
health status between different diseases. Frequently used disease-specific instruments in 
COPD are the St George Respiratory Questionnaire (SGRQ) [26], the Quality of Life 
Respiratory Illness Questionnaire (Qol-RiQ) [27], the Clinical COPD Questionnaire (CCQ) [28], 
and the COPD Assessment Test (CAT) [29]. The Short Form 36 (SF-36) [30] and the Sickness 
Impact Profile (SIP) [22] are two generic instruments frequently used in COPD research. 
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These instruments measure general symptoms, activity limitations, and/or emotions, and 
are typically used to describe the impact of disease in patient populations and the effects of 
interventions at a group level. These instruments have proven their merit in a research 
setting but are less useful in a clinical setting, because the questionnaires are long, time-
consuming or difficult to score, and often lack reference values, which makes it difficult to 
interpret findings; moreover, some instruments measure only limited aspects of health. As 
the domains of health status are only moderately related, it is essential to measure all 
domains in order to get a complete picture of the patient [20, 31-32]. Only then is tailored 
treatment possible, which is necessary because usual care is often insufficiently effective.  
 
 
Aim and outline of the thesis  
 
COPD is a chronic progressive disease that influences patients’ integral health status. 
Guidelines recommend that treatment be guided by disease severity, a composite of severity 
of airflow limitation, risk of future exacerbations, and impact on health status. There is, 
therefore, a need for an instrument that measures the various aspects of integral health 
status and which is easy to use and interpret and which can be completed within a limited 
time. The studies described in the chapters of this thesis focus on the measurement of 
integral health status – on the development of a relevant instrument for patients with COPD, 
its application in clinical care, and its usefulness for other chronic diseases. The Nijmegen 
Integral Assessment Framework (NIAF) can be used to guide the measurement of integral 
health status [20]. It covers the four main domains physiological functioning, symptoms, 
functional impairment, and quality of life, subdivided into 15 unique and relatively unrelated 
sub-domains (Figure 2, Table 2).  
 Chapter 2 focuses on fatigue. Although fatigue is the second most reported symptom 
in COPD [33-36], there has been little research interest in the role of fatigue in COPD or its 
possible association with aspects of integral health status. As the NIAF also did not 
incorporate fatigue, the study described in this chapter investigates the prevalence, severity, 
and natural course of fatigue in patients with COPD, and the association between fatigue 
and the sub-domains of integral health status.  
Chapter 3 describes the development of a short version of the NIAF that can be used 
in a clinical setting: the Nijmegen Clinical Screening Instrument (NCSI). The NIAF contains 
many tests and instruments, which make it time-consuming to administer, score, and 
interpret. Moreover, there are no cut-off scores to determine whether scores are normal or 
abnormal. These aspects are essential for an instrument to be used in clinical practice. 
In Chapter 4, the NIAF is compared with the St George Respiratory Questionnaire 
(SGRQ), a disease-specific instrument frequently used to investigate COPD populations. The 
SGRQ has been used widely to measure health status, but as it contains only three subscales 
(symptoms, activity, impacts) and a total score, it can be questioned whether it covers all 
aspects of health status. 
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Table 2 Main domains and sub-domains of the Nijmegen Integral Assessment Framework (NIAF), their 
definition and corresponding  instruments, subscales/measurement 
Main 
domain  
 
Sub-domain 
 
Definition 
 
Instrument: subscale/measurement 
P
h
ys
io
lo
gi
ca
l F
u
n
ct
io
n
in
g 
Exercise Capacity  Vmax 29, Sensor Medics:  
VO2 maximum% predicted 
  Heart rate maximum% predicted 
  TLCO % predicted 
  BE delta 
Static Lung Volumes  Masterscreen PFT spirometer/ diffusion, 
Jaeger : TLC % predicted 
  RV % predicted 
Airflow  Masterscreen PFT spirometer/ diffusion, 
Jaeger: 
Post-bronchodilator FEV1% predicted 
  MEF50 % predicted 
  VE % predicted 
Gas Exchange   Vmax 29, Sensor Medics: Delta (A-a)DO2 
(kPa) 
  Vmax 29, Sensor Medics  Delta PaCO2 
(kPa) 
Muscle Strength  Validyne CD23: PE max%  predicted 
  Validyne CD23: PI max % predicted 
  Quadriceps % predicted 
Body Composition  BMI 
  Bodystat: FFMI 
Sy
m
p
to
m
s 
Subjective Symptoms The patient’s overall burden of 
pulmonary symptoms 
 
PARS-D [20]: Global Dyspnea Activity 
 PARS-D  [20]: Dyspnea Activity 
 PARS-D[20]: Global Dyspnea Burden 
 QoL-RIQ [21]: Breathing Problems 
Dyspnea Emotions The level of frustration, depressive 
feelings, and anxiety a patient 
experiences when dyspnoeic 
DEQ [20]: Mood 
 DEQ[20]: Frustration  
 DEQ[20]: Anxiety 
Expected Dyspnea The level of dyspnea a patient 
expects to experience during specific 
activities no longer performed  
PARS-D [20]: Expected Dyspnea  
Fu
n
ct
io
n
al
 Im
p
ai
rm
en
t 
Actual Activity The actual physical activity a patient 
performs during two weeks 
Accelerometer: Mean 
Behavioral Impairment The extent to which a person cannot 
perform specific and concrete 
activities as a result of having the 
disease 
SIP [22]: Home Management 
SIP [22]: Ambulation 
SIP [22]: Body Care & Movement 
SIP [22]: Mobility 
Subjective Impairment The experienced degree of 
impairment in general, and in social 
functioning 
QoL-RIQ [21]: General Activities  
QoL-RIQ [21]: Social Activities 
 Global impairment[19] 
 SIP [22]: Social Interaction 
 SIP [22]: Burden 
Q
u
al
it
y 
o
f 
Li
fe
 
General QoL Mood, anxiety, and the satisfaction 
of a person with his/her life as a 
whole 
BDI [23]: Primary Care  
 SWLS [24]:Total  
 SCL [25]: Anxiety  
HRQol  Satisfaction related to physiological 
functioning and the future 
Satisfaction Physical [20] 
 Satisfaction Future [20] 
Satisfaction Relations Satisfaction with the (absent) 
relationships with spouse and others 
Satisfaction Spouse [20] 
 Satisfaction Social [20] 
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Chapter 5 describes the identification of clinical phenotypes based on health status. 
These clinical phenotypes reflect adaptation to the disease. To date, phenotypes have been  
identified mainly on the basis of different underlying pathophysiological mechanisms. In 
contrast, in this study the focus is on behavioral aspects and whether there are differences 
(changes in integral health status) between these clinical phenotypes in their response to 
care as usual and to inpatient pulmonary rehabilitation. 
To examine whether the NCSI can also be used for patients with other diseases, two 
studies investigate its use in a group of patients with asthma (Chapter 6) and in a group of 
patients with Q-fever (Chapter 7). As the NCSI consists of disease-specific and generic 
subscales, it can theoretically be used in these patients because they have similar symptoms. 
In addition to the NCSI, the usefulness of other questionnaires, such as the Asthma Control 
Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ), is also investigated in 
patients with asthma. Lastly, the general findings and implications for clinical practice and 
future research are presented in Chapter 8. 
 
Abbreviations used in table 2: 
 % predicted, percentage of predicted value; BDI, Beck Depression Inventory; BE, Base Excess; BMI, 
Body Mass Index; DEQ, Dyspnea Emotions Questionnaire; FEV1, Forced Expiratory Volume in one 
second postbronchodilator value; FFMI, Fat Free Mass Index; MEF50, mid-expiratory Flow at 50% of 
forced vital capacity; PARS-D, Physical Activity Rating Scale –Dyspnea; PImax, maximal inspiratory 
mouth pressure; PEmax, maximal expiratory mouth pressure; QoL-RIQ, Quality of Life for Respiratory 
Illness Questionnaire; RV, Residual Volume; TLC, Total Lung Capacity; TLCO, transfer capacity (of lung) 
for carbon monoxide; SCL, Symptom Checklist; SIP, Sickness Impact Profile; SWLS, Satisfaction With 
Life Scale; VE, minute ventilation ;VO2max, maximal oxygen uptake. 
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ABSTRACT 
 
Objective  
To examine the difference between patients with normal and patients with abnormal fatigue 
on aspects of health status, and investigate the natural course of fatigue in patients with 
Chronic Obstructive Pulmonary Disease (COPD). 
 
Methods  
Fatigue, physiological functioning, functional impairment, symptoms, and Quality of Life 
(QoL) were measured in 168 patients with COPD, and longitudinal data on fatigue of 77 
patients were collected. 
 
Results  
Fifty percent of patients had abnormal fatigue. Patients with abnormal fatigue reported 
significantly more problems on the sub-domains of functional impairment (except actual 
physical activity), symptoms, and QoL as compared to patients with normal fatigue. With 
respect to physiological functioning patients with normal fatigue scores had better exercise 
capacity. Four years later the percentage of patients with abnormal fatigue was increased to 
64%. In 1/3 of the patients an increase of more than the minimal clinically important 
difference was found. 
 
Conclusions  
Many COPD patients suffer from abnormal fatigue. Patients with abnormal fatigue have 
more limitations on many aspects of health status, especially on symptoms, functional 
impairment, and QoL.  
 
Practice implication  
Fatigue should be evaluated in usual care with a questionnaire that corrects for normal 
fatigue in order to tailor treatment to patients’ needs. 
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INTRODUCTION  
 
Chronic Obstructive Pulmonary Disease (COPD) is a progressive and disabling disease, which 
is accompanied by a variety of symptoms. In guidelines, dyspnea, cough, and sputum 
production are marked as key symptoms of COPD [1]. Although not marked as a key 
symptom, fatigue was reported by patients with COPD as the second most important 
symptom of COPD, after dyspnea [2-4]. 
Of patients with severe COPD 47-58% reported to experience fatigue every day or 
several days a week [5,6]. Patients described their fatigue as a feeling of general tiredness 
[7] and as ‘feeling drained of energy’ [8]. In addition, they reported that the experienced 
fatigue put restrictions upon their lives and made them dependent upon others [8]. Patients 
also reported that the feeling of fatigue was irritating, frustrating [7], and interfered with 
their ability to concentrate [9].  
In the past years, several empirical studies have been performed in which fatigue was 
merely used as an outcome measure of an intervention [10-13]. Relatively few studies have 
studied the relationships between fatigue and many aspects of health status. Some studies 
showed fatigue to be significantly related to impaired postbronchodilator forced expiratory 
volume in one second (FEV1) [14], reduction in exercise capacity [14], and more problems in 
Quality of Life (QoL) [14,15]. Moderate, but significant, correlations were found between 
fatigue on the one hand and anxiety [16] and depression [15,16] on the other. Correlations 
of 0.32 to 0.69 between fatigue and dyspnea have been reported [5,15,17,18]. Other studies 
did not find significant relationships between fatigue and exercise capacity [16,19], or FEV1 
[15,16,19-21]. 
Studies on the natural course of severity of fatigue in patients with COPD using 
standardized measures are lacking. Besides the fact that fatigue is a highly non-specific 
symptom and a key symptom in many psychiatric and somatic diseases, fatigue is also a 
normal phenomenon that healthy persons experience as well. Hence, in determining the 
severity of fatigue a correction for normal fatigue has to be made. 
The aims of the present study are to investigate the prevalence of ‘normal’ and 
‘abnormal’ fatigue, and the relationship between fatigue and health status in patients with 
COPD. In addition, we investigated the natural course of fatigue in COPD.  
 
 
METHODS 
 
Participants 
One-hundred-sixty-eight COPD patients were recruited from three different pulmonary 
outpatient clinics in the Netherlands, between May 2002 and May 2003. All patients were 
diagnosed with COPD [1]. Exclusion criteria were an acute exacerbation, recent (<6 months) 
participation in pulmonary rehabilitation program, primary comorbidity that may dominate 
health status, inability to speak or read Dutch, and inability to completely adhere to the  
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Table 1 Main domains and sub-domains of the Nijmegen Integral Assessment Framework  
 (NIAF) and their corresponding instruments, subscales. 
Main domain Sub-domain Instrument Subscale/ Measurement 
 
P
h
ys
io
lo
gi
ca
l F
u
n
ct
io
n
in
g 
Exercise Capacity VO2 maximum% predicted
a 
 Heart rate maximum% predicteda 
 TLCO% predicteda 
 BE deltaa 
Static Lung Volumes TLC% predictedb 
 RV% predictedb 
Airflow Post-bronchodilator FEV1% predicted
b 
 MEF50% predictedb 
 VE% predictedb 
Muscle Strength PE max% predicted
c 
 PI max % predicted
c 
 Quadriceps% predictedc 
Body Composition BMId 
 FFMId 
 
Sy
m
p
to
m
s 
Subjective Symptoms PARS-D Global Dyspnea Activity [22]  
 PARS-D Dyspnea Activity [22]  
 PARS-D Global Dyspnea Burden [22]  
 QoL-RIQ Breathing Problems [29]  
Dyspnea Emotions DEQ-Mood [22]  
 DEQ-Frustration [22] 
 DEQ-Anxiety [22]  
Expected Dyspnea PARS-D Expected Dyspnea [22] 
 
Fu
n
ct
io
n
al
 Im
p
ai
rm
e
n
t 
Actual Physical Activity Aktometer Mean [31,32]  
Behavioral Impairment SIP Home Management [30] 
SIP Ambulation [30]  
SIP Body Care & Movement [30]  
 SIP Mobility [30]  
Subjective Impairment QoL-RIQ General Activities [29]  
QoL-RIQ Social Activities [29]  
 Global impairment [22] 
 SIP Social Interaction [30]  
 SIP Burden [30]  
 
Q
u
al
it
y 
o
f 
Li
fe
 
General QoL BDI Primary Care [34]  
 SWLS-Total [35] 
 SCL Anxiety [33] 
HRQoL  Satisfaction Physical [22] 
 Satisfaction Future [22] 
Satisfaction Relations Satisfaction Spouse [22] 
 Satisfaction Social [22] 
Note: Instruments used: a=Vmax 29, Sensor Medics ; b=Masterscreen PFT spirometer / diffusion, Jaeger, c=Validyne CD23, d=W/H2, Bodystat. Abbreviations: %, percentage of 
predicted ; BDI, Beck Depression Inventory; BE,  Base Excess; BMI, Body Mass Index; DEQ, Dyspnea Emotions Questionnaire; FEV1, Forced Expiratory Volume in one second 
postbronchodilator value; FFMI, Fat Free Mass Index; MEF50, mid-expiratory Flow at 50% of forced vital capacity; PARS-D, Physical Activity Rating Scale –Dyspnea; PImax, maximal 
inspiratory mouth pressure; PEmax, maximal expiratory mouth pressure; QoL, Quality of Life; HrQoL, health related quality of life; QoL-RIQ, Quality of Life for Respiratory Illness 
Questionnaire; RV, Residual Volume; TLC, Total Lung Capacity; TLCO, transfer capacity (of lung) for carbon monoxide; SCL, Symptom Checklist; SIP, Sickness Impact Profile; SWLS, 
Satisfaction With Life Scale; VE, minute ventilation ;VO2max, maximal oxygen uptake.  
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research protocol. A detailed description of the recruitment procedure and the study sample 
can be found elsewhere [22]. Four years later patients were asked to participate in a follow-
up study. Patients gave informed consent and the local Ethics Committee approved both 
studies.  
 
Outcome variables 
Fatigue was measured by the Subjective Fatigue subscale of the Checklist Individual Strength 
(CIS) [23], a standardized and validated questionnaire that has been used in cohorts of 
healthy subjects [24,25], and in various patient populations [23,26,27]. The subscale consists 
of 8 items, scored on a seven point Likert-scale. Based on the total score, three subgroups 
can be defined: normal fatigue (≤26), mild fatigue (27-35) or severe fatigue (≥36). In this 
study we used two categories in the analyses: normal and abnormal fatigue. Abnormal 
fatigue was defined as either mild or severe fatigue. The minimally clinically important 
difference (MCID) is 10 points. 
Health status was measured by the Nijmegen Integral Assessment Framework (NIAF) 
[22], which covers four main domains: physiological functioning, symptoms, functional 
impairment, and QoL. These main domains were shown to be subdivided into 15 sub-
domains each representing a unique aspect of the patient’s health status. The NIAF 
organizes existing tests and instruments according to the sub-domains they measure (Table 
1). A sub-domain total score was calculated for each sub-domain.  
 
Statistical analysis  
Mann-Whitney U tests were performed to study the differences between patients with 
normal and patients with abnormal fatigue on the sub-domains of health status. Paired t-
tests were performed to test significant changes between the baseline and follow-up 
measurements. The p-value was set at <0.01. All analyses were performed using SPSS 14.0 
 
 
RESULTS 
 
Table 2 shows characteristics of the COPD patients at baseline.  
 
Abnormal fatigue and relationships between fatigue and health status 
At baseline, half of the 168 COPD patients experienced abnormal fatigue (mild plus severe), 
and a quarter experienced severe fatigue (Table 3). Significant relationships were found 
between fatigue and sub-domains of the main domains symptoms, functional impairment, 
and QoL (except actual physical activity). Patients with abnormal fatigue had significantly 
more problems on the sub-domains of the main domains symptoms, functional impairment 
and QoL (Table 4). The only exception was the actual physical activity sub-domain (as 
measured by an accelerometer), on which patients with or without abnormal fatigue 
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showed similar activity levels. On the main domain physiological functioning patients with 
abnormal fatigue scores only had significantly lower exercise capacity. 
 
 
 
Table 3 Mean (SD) and distribution of fatigue (CIS-Subjective Fatigue score) at baseline (N=168) 
 Mean  ±SD [95% CI] 
Group  27.3 ±11.4 [25.5-29.0] 
Fatigue, n (%)    
normal (≤ 26 points) 88 (52.4%)  
mild (≥ 27to ≤35 points) 39 (23.2%)  
severe (≥36 points) 41 (24.4%)  
 
 
 
Table 2 Characteristics of COPD patients at baseline (N=168) 
 Mean  ±SD [95% CI] 
Age  64.5  ±9.1 [63.1-65.9] 
FEV1% predicted 51.6  ±13.6 [49.5-53.6] 
FEV1 (Liter) 1.52  ±0.48 [1.44-1.59] 
FEV1/FVC% 43.6 ±11.3 [41.2-44.7] 
TLC% predicted 103.0 ±16.0 [100.6-105.5] 
RV% predicted 129.9 ±35.8 [124.4-135.3] 
TLCO% predicted 68.7 ±23.9 [65.1-72.3] 
BMI  25.6 ±4.1 [25.0-26.2] 
 n (%)  
Gender (male/female)  131/37 (78/22%)  
GOLD     
Stage 1 0 (0%)  
Stage 2 88 (52.4%)  
Stage 3 80 (47.6%)  
Stage 4 0 (0%)  
Education    
Low 85 (52.2%)  
Middle 48 (29.4%)  
High 30 (18.4%)  
Personal Situation    
Partner 137 (84.0%)  
Divorced 7 (4.3%)  
Widowhood 11 (6.7%)  
Single 8 (4.9%)  
Abbreviations: FEV1, Forced Expiratory Volume in one second postbronchodilator value; FEV1 %predicted, 
FEV1 postbronchodilator value as percentage of predicted value; FVC, Forced Vital Capacity; TLC, Total Lung 
Capacity; RV, Residual Volume; TLCO, transfer capacity (of lung) for carbon monoxide; BMI, Body Mass Index 
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Course of fatigue in COPD patients (N=77): baseline vs. four years later  
Forty-six percent of patients agreed to participate in the follow-up study after four years, 
reasons for non participation were diverse. No significant differences were found between 
patients who did not want to participate (91 patients) and patients who participated in the 
follow-up study (77 patients) with respect to age (mean 65.9 ±9.4 vs. 62.8 ±8.6; p=0.017), 
FEV1% of predicted (mean 50.4 ±13.4 vs. 52.9 ±13.8; p=0.293), severity of fatigue (mean 28.0 
±11.6 vs. 26.5 ±11.2; p=0.463), or any of the health status sub-domains measured at 
baseline. For patients who had both assessments, FEV1% predicted was not significantly 
different between baseline and after four years (p=0.200, Table 5).  
After 4 years, mean fatigue scores were significantly higher compared to baseline 
(Table 5). The percentage of patients with abnormal fatigue (mild plus severe) increased. 
Worsening of fatigue with the MCID was found in 33% of the patients, and 12% of the 
patients had better scores after 4 years. 
 
 
DISCUSSION & CONCLUSIONS 
 
In the present study, we measured the severity and natural course of fatigue with a 
standardized questionnaire that corrects for normal fatigue in patients with stable moderate 
Table 4 Correlations between fatigue and health statusa and differences between COPD patients 
with normal and patients with abnormal fatigue on health status at baseline 
 Pearson 
correlation 
with fatigue 
Normal Fatigue  
(N=88) 
Abnormal Fatigue 
(N=78) 
 
 Mean ±SD Mean ±SD p 
Physiological Functioning       
Exercise Capacity   0.30# 445.5 ±47.2 471.8 ±35.7 <0.001 
Static Lung Volumes -0.06 152.2 ±26.3 151.1 ±31.5 n.s. 
Airflow   0.07 782.5 ±37.7 790.8 ±35.9 n.s. 
Muscle Strength   0.17 203.7 ±30.3 213.4 ±37.1 n.s. 
Body Composition   0.04 864.9 ±26.5 871.2 ±30.3 n.s. 
Symptoms       
Subjective Symptoms   0.60# 34.5 ±12.4 50.7 ±14.9 <0.001 
Dyspnea Emotions   0.29# 13.7 ±4.5 15.6 ±4.8 0.003 
Expected Dyspnea   0.34# 1.8 ±0.8 2.7 ±1.0 <0.010 
Functional Impairment       
Actual Physical Activity   0.21 175.6 ±29.5 184.7 ±26.2 n.s. 
Behavioral Impairment   0.46# 18.9 ±14.0 30.8 ±16.2 <0.001 
Subjective Impairment   0.59# 44.2 ±16.1 64.6 ±18.5 <0.001 
Quality of Life       
General QoL   0.51# 51.7 ±9.5 63.6 ±12.5 <0.001 
HRQoL   0.55# 17.7 ±6.8 25.3 ±9.1 <0.001 
Satisfaction Relations   0.37# 7.8 ±7.6 12.3 ±9.2 0.001 
a For all sub-domains, the higher the score the more problematic; * p<0.01; n.s., non significant (p>0.01) 
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to severe COPD. At baseline, almost half of the patients showed abnormal fatigue: 23% mild 
and 24% severe fatigue. Patients with abnormal fatigue had significantly more limitations in 
many sub-domains of quality of life, symptoms, and functional impairment than patients 
with normal fatigue. With respect to physiological functioning patients with abnormal 
fatigue had lower exercise capacity as compared to patients with normal fatigue. After 4 
years, fatigue scores have become clinically relevant higher in one-third of patients, and 
clinically relevant lower in 12%. 
 
 
DISCUSSION 
 
Dyspnea is considered a key symptom in COPD [1,24,25]. As in earlier studies, we found 
moderate correlations between fatigue and dyspnea [5,15,17,18]. To our knowledge, this is 
the first study in which the relationship between fatigue and health status has been assessed 
in such detail. Fatigue was significantly related to almost all sub-domains of the main 
domains symptoms, functional impairment, and QoL. With respect to physiological 
functioning, fatigue was only related to the sub-domain exercise capacity but not to airflow, 
muscle strength, static lung volumes, or body composition. The significant (but low) 
correlation between fatigue and exercise capacity has not been reported earlier [16,19]. 
Fatigue was not significantly related to the sub-domain Airflow, which is consistent with 
Table 5 Characteristics and distribution of fatigue (CIS-Subjective Fatigue score) for patients who 
participated at baseline and after 4 years (N=77) 
 Baseline (n = 77) After 4 years (n=77) paired 
 Mean ±SD [95% CI] Mean ±SD [95% CI] t-test 
Gender (m/f),% (n) 83/17% (64/13)      
Age  62.7 ±8.6 [60.8-64.7] 66.8 ±8.7 [64.9-68.8]  
Characteristics        
FEV1% pred  52.9 ±13.8 [49.8-56.0] 54.3 ±16.9 [50.8-58.8] n.s. 
FEV1 (Liter) 1.61 ±0.48 [1.51-1.72] 1.59 ±0.54 [1.40-1.65] n.s. 
FEV1/FVC% 43.2 ±12.4 [40.4-46.0] 42.5 ±11.8 [39.7-45.2] n.s. 
TLC% predicted 103.4 ±16.0 [99.8-107.1] 98.9 ±14.4 [95.6-102.3] n.s. 
RV% predicted 127.4 ±36.9 [119.0-135.7] 115.4 ±30.3 [108.4-122.3] n.s. 
TLCO% predicted 70.1 ±25.8 [64.3-76.0] 60.4 ±23.9 [54.9-65.8] p<0.01 
BMI  25.7 ±3.6 [24.9-26.5] 26.0 ±4.0 [25.1-26.9] n.s. 
Fatigue        
Group  26.5  ±11.2 [23.9-29.0] 31.2  ±12.2 [28.4-33.9] p<0.01 
        
 % (n)  % (n)   
Normal fatigue 54.5% (42)  36.4% (28)   
Mild fatigue 24.7%  (19)  22.1% (17)   
Severe fatigue 20.8%  (16)  41.6% (32)   
Change in fatigue (MCID of 10 points) 
Fatigue improved      11.7%  (9)   
Fatigue same     54.5%  (42)   
Fatigue worsened     33.8%  (26)   
n.s.= non significant (p>0.01). Abbreviations: see Table 1; MCID, Minimally Clinically Important Difference 
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results found in other studies [15,16,19-21]. 
Some methodological comments have to be made. First, we only included patients 
with stable moderate to severe COPD without primary comorbidity. Although no significant 
correlations have been found between fatigue and airway obstruction in the present study 
and in other studies [15,16,19-21], results may be different for patients with mild or very 
severe COPD and for patients with primary comorbidity. Second, the sample size of the 
longitudinal data set was smaller than the baseline sample. However, no significant 
differences were found between participants and non-participants in the follow-up study on 
the characteristics measured at baseline. Nonetheless, we have to be cautious in 
generalizing these results due to the relatively small sample size.  
 
CONCLUSIONS 
 
Fatigue proved to be an important symptom in patients with moderate to severe COPD and 
appears to be related to many aspects of health status. Moreover, patients with abnormal 
fatigue have significantly more problems on many sub-domains of health status. In addition, 
our study also shows that after four years fatigue has relevantly increased in one third of 
patients. Hence, we will incorporate fatigue as a separate sub-domain in the NIAF.  
 
Practice implications 
We recommend that in the clinical management of patients with COPD assessment of 
fatigue is included as part of usual care, preferably by a standardized instrument (e.g. the 
Checklist Individual Strength) which corrects for normal fatigue. Future studies should be 
aimed at finding the causes of fatigue in COPD, since in most patients fatigue is getting 
worse over the years. This information is of importance for developing interventions aimed 
at improving fatigue. 
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ABSTRACT 
 
Objective 
To compose a battery of instruments that provides a detailed assessment of health status in 
COPD, but that is applicable and clinically meaningful in routine care. 
 
Methods  
In a previous study, we developed the Nijmegen Integral Assessment Framework (NIAF) that 
organizes existing tests and instruments by the sub-domains of health status they measure. 
Based on clinical and statistical criteria (correlation coefficients and Cronbach alpha’s) we 
selected for each sub-domain instruments from the NIAF. A COPD-study group was used to 
determine c-scores, and two control groups were used to determine the score ranges 
indicating normal functioning versus clinically relevant problems for each sub-domain. 
Existing questionnaire completion software (TestOrganiser) was adapted to enhance clinical 
applicability. 
 
Results  
The Nijmegen Clinical Screening Instrument measures eleven sub-domains of physiological 
functioning, symptoms, functional impairment, and quality of life. The TestOrganiser 
automatically processes the data and produces the graphical PatientProfileChart, which 
helps to easily interpret results. This envisages the problem areas and discrepancies 
between the different sub-domains.  
 
Conclusions  
The NCSI provides a valid and detailed picture of a patient’s health status within 15-25 min. 
In combination with the PatientProfileChart, the NCSI can be used perfectly in routine care 
as screening instrument and as a guide in patient-tailored treatment. 
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INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD) is a chronic, progressive, and incapacitating 
disease. Traditionally, treatment of COPD is focused on improving or maintaining 
physiological functioning of the patient. However, in the past decade, it is recognized that 
besides physiological functioning also symptoms, functional limitations and quality of life 
(QoL) are important domains of health status in these patients [1-2]. 
Studies have shown that symptoms, functional impairment, and QoL are relatively 
unrelated to physiological functioning [3-5]. In a previous study we also have shown that 
these four main domains of health status were shown to be subdivided into 15 relatively 
unrelated sub-domains [6]. An individual patient may experience clinically relevant problems 
in some of these sub-domains, but not in other sub-domains. As a consequence, to tailor 
treatment to the specific needs of the individual patient it is necessary to obtain an integral 
and detailed picture of health status of all sub-domains. 
In routine care, physiological functioning is measured by lung function tests. 
Although, many generic and disease specific questionnaires are available to measure 
symptoms, functional impairment and QoL [3,7], these three main domains commonly are 
not measured in routine care. A major reason for this is that current questionnaires are not 
suitable for application in routine care. This has several causes. First, questionnaires 
commonly consist of many items and are therefore time-consuming. Second, the scoring of 
questionnaires is often complex and has to be done by hand which is also time-consuming. 
Third, the clinical meaning of a particular score is often unclear due to the lack of adequate 
normative data. Normality cannot be defined by absence of for example symptoms. As 
patients with COPD are often elderly, the presence of an elevated score can also be the 
result of normal ageing instead of being the result of having COPD. Moreover, symptoms 
such as fatigue or shortness of breath may be experienced by healthy persons as well. 
Hence, it is important to know whether a score represents normal functioning or clinically 
relevant problems. Fourth, in a previous study, we found that existing questionnaires 
measure only one to three aspects of health status [6]. In addition, we have shown that 
there is considerable overlap between questionnaires with respect to the specific sub-
domains they measure. This implicates that, for an integral and detailed assessment of 
health status, a combination of several instruments is required in which overlap should be 
avoided. 
Consequently, the following criteria must be fulfilled to permit adequate assessment 
of health status suitable and useful in routine care: 1) a broad spectrum of aspects of health 
status has to be measured to obtain a comprehensive and detailed picture; 2) instruments 
should be as short as possible, but still have enough items to warrant adequate reliability; 3) 
overlap should be avoided; 4) scoring must be simple and results should be available 
immediately, preferably this should be automated; and 5) results should be easy to interpret 
and should indicate if a particular score indicates normal functioning or clinically relevant 
problems. Such an instrument would provide the clinician with a tool to identify patients 
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who need additional treatment and provides a detailed picture on the type and severity of 
problems in health status of an individual patient, and thereby can help the clinician in 
patient-tailored treatment. In addition,  it also could be used for outcome assessment, as 
part of an intervention, and for research studies. 
The aim of the present study was to compose a battery of existing questionnaires 
that fulfills all above-mentioned criteria for clinical applicability in a routine care outpatient 
setting. In this process we used the Nijmegen Integral Assessment Framework (NIAF) [6] as a 
guide for the selection of instruments. The NIAF is an evidence-based framework that 
organizes tests and questionnaires by indicating which sub-domains of health status actually 
are measured by specific (sub-)scales of various existing instruments. Data of matched 
control groups were used to determine cut-offs for each instrument to indicate normal 
functioning versus clinically relevant problems. In addition, existing software for 
computerized questionnaire completion was adapted specifically to facilitate clinical 
applicability of the test battery and easy interpretation of results. 
 
 
METHOD 
 
Subjects 
COPD- study group 
For the selection of instruments of the Nijmegen Clinical Screening Instrument (NCSI) we 
used the data from a sample of COPD patients that are representative for patients with 
stable COPD (GOLD II and III), with no primary co-morbidity, in routine care at outpatient 
clinics. This COPD-study group was recruited from three different pulmonary outpatient 
clinics in the Netherlands: University Lungcenter Dekkerswald of the Radboud University 
Nijmegen Medical Centre, Maas Hospital Boxmeer and Rijnstate Hospital Arnhem. Inclusion 
criteria were: diagnosis of GOLD II/III (FEV1% predicted between 30% and 80%), FEV1/FVC 
<70%, and reversibility of obstruction <12%. Exclusion criteria were: primary co-morbidity 
that may dominate health status, recent participation in a rehabilitation program (within 
previous six months), inability to speak or read Dutch, acute exacerbation of COPD, and 
inability to completely adhere to the research protocol. Screening the patient charts resulted 
into 361 eligible patients. A pulmonologist asked these patients for permission to be called 
by the investigator, and 316 (88%) agreed to be called for further information. One hundred-
sixty-eight patients (47%) participated in this study (see Table 1 for patient characteristics). 
Reasons for non-participation were diverse; predominantly being too busy, refusing cycle-
ergometry and travel problems. Patients gave informed consent and the local Ethics 
Committee approved this study. 
 
Control samples 
To determine the score range of the selected instruments that represents clinically relevant 
problems, we recruited patients with COPD included in a clinical multi-disciplinary 
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Table 1 Patient characteristics expressed in number (%) unless stated otherwise of the COPD 
outpatient study group (OP), patients included in pulmonary rehabilitation (PR), and healthy 
controls (HC)  
 OP  PR  HC  
N 168  131  69  
Male  131 (78.0%) 89  (67.9%) 48  (69.6%) 
Age (mean ±SD) 64.5 ±9.1 62.1   ±7.3 62.4  ±7.8 
range 43-80 
 
46 -78  41-76 
FEV1% pred (mean ±SD) 51.6 ±13.6 35.0  ±13.0 111.7  ±14.8 
GOLD        
Stage 1 0 (0%) 0 (0%) 0 (0%) 
Stage 2 88 (52.4%) 18   (13.7%) 0 (0%) 
Stage 3 80 (47.6%) 63   (48.1%) 0 (0%) 
Stage 4 0 (0%) 50  (38.2%) 0 (0%) 
BMI (mean (SD)) 25.6 (4.1) 24.4   (4.2) 26.4  (3.9) 
Education       
Low 85 (52.1%) 68 (51.9%) 20 (29.0%) 
Middle 48 (29.4%) 38 (29.0%) 18 (26.1%) 
High 30 (18.4%) 25 (19.1%) 21 (44.8%) 
Personal Situation       
Partner 137 (84.0%) 105 (80.1%) 52 (75.4%) 
Divorced 7 (4.3%) 6 (4.6%) 8 (11.6%) 
Widowhood 11 (6.7%) 9 (6.9%) 3 (4.3%) 
Single 8 (4.9%) 11 (8.4%) 6 (8.7%) 
 
Pulmonary rehabilitation program at the University Lungcenter Dekkerswald of the Radboud 
University Nijmegen Medical Centre. A key requirement for inclusion in this program is that 
patients have to experience clinically relevant problems in multiple areas of health status. 
The decision on this requirement was based on a 3-days intake procedure, in which 
elaborate assessments, physiological tests, and clinical interviews by seven disciplines 
(pulmonologist, psychotherapist, physiotherapist, nurse, dietitian, psychomotor therapist, 
social worker) took place. The results of these assessments and interviews are evaluated in a 
multi-disciplinary discussion. Inclusion criteria were: diagnosis of COPD [8] and clinically 
relevant problems in multiple areas of health status. Exclusion criteria: mild or isolated 
problems in health status and inability to speak or read Dutch. Subjects were matched to the 
COPD-study group by age and sex. See Table 1 for a description of this sample. 
 
To determine the score range of instruments indicating normal functioning, we recruited  
healthy controls by an advertisement in a regional newspaper. Exclusion criteria were: 
having asthma or COPD, being under regular treatment of any specialist and/or inability to 
speak or read Dutch. The subjects were screened for absence of chronic illnesses by one of 
the investigators (LD). Subsequently, lung function testing was performed. Based on all 
assessments a pulmonologist (JM) decided whether a person could be included or not. 
Subjects were matched on age and sex to the COPD-study group. See Table 1 for a 
description of this sample. 
38 | C H A P T E R  3  
 
Measurements 
In a previous study, we defined four domains of health status; Physiological Functioning, 
Symptoms, Functional Impairment, and QoL [6]. These four main domains of health status 
were found to be subdivided into 15 relatively unique sub-domains, which together 
constitute the NIAF for COPD. See Figure 1 for a general description of the development and 
validation of the NIAF. For a detailed description on the development and validation of the 
NIAF see elsewhere [6]. 
In a recent, yet, unpublished study, we found fatigue to be an important symptom in 
COPD that is relatively independent to the other sub-domains. For that reason, fatigue was 
included in the framework as a separate sub-domain of the main domain symptoms. Table 2 
shows the instruments that measure the sub-domains of health status. 
Questionnaire completion was performed by the TestOrganiser, which is a 
computerized questionnaire system developed by the Department of Medical Psychology 
and the Department of Instrumental Services of the Radboud University Nijmegen Medical 
Centre [6]. Questionnaires are presented in the same layout as paper-and-pencil versions, 
items cannot be skipped, and both scoring and data storage are automated. 
Construction of the Nijmegen Clinical Screening Instrument  
The NIAF organizes existing instruments by the sub-domains of health status they measure. 
Each sub-domain was measured by several tests or instruments or subscales of instruments 
(Table 2), and can be used interchangeably. Based on the following criteria we selected for 
each sub-domain one or two instruments for inclusion of the NCSI. 
 
A. Preliminary selection of instruments  
1. The scores on selected instruments should show a correlation of  >0.70 with the 
original NIAF-STS [9]. 
2. The selected instruments must be completed in as little time as possible (preferably 
<30 minutes), in other words a minimum number of items, but should show good 
reliability (Cronbach’s alpha >0.70). 
3. Although all instruments included in the NIAF are clinically relevant, in the selection 
process of instruments we also considered which instrument was most clinically relevant. 
These decisions were based on clinical experience of the pulmonologists (JM, YH, RD) and 
the clinical psychologist (JV). 
 
B. Statistical analysis on the preliminary selection 
1. For each sub-domain of health status, selected instruments were combined into a 
sub-domain total score (NCSI-STS) by adding scores of respective instruments. 
Spearman correlation coefficients between the original NIAF-STS and the new NCSI-
STS were calculated and had to be higher than 0.70, which is considered a criterion 
for instruments to measure the same concept [9,10]. 
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Figure 1 Main stages of the development of the Nijmegen Integral Assessment Framework (NIAF) for 
COPD (previous study) and the development of the Nijmegen Clinical Screening Instrument (NCSI) for 
COPD (present study)  
Previous 
study [6]: 
Step 1. Definition of conceptual models of the main domains and sub-domains 
of Health Status based on theoretical and clinical considerations 
 
Step 2. Selection of existing instruments (with documented evidence on validity, 
reliability, and sensitivity to change) for each sub-domain 
 
Step 3. Assessment of 168 COPD outpatients (OP) 
 
Step 4-7.Statistical analysis, in particular factor analysis to identify underlying 
concepts in the data 
 
Step 8. Weighting of variables to achieve similar scales of measurement within 
each factor 
 
Step 9. Calculation of Cronbach’s alpha reliability coefficients for each factor 
and variables that suppressed the alpha were excluded 
 
Step 10. Repeating of the factor analysis to retest the factor stability 
Development of the Nijmegen Integral Assessment Framework (NIAF) for COPD 
 
 
Present 
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Development of the Nijmegen Clinical Screening Instrument (NCSI) for COPD 
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Determining: 
 reference norms: c-scores (168 outpatients) 
 cut-offs indicating normal functioning (69 
healthy controls) 
 cut-offs indicating clinically relevant problems 
(131 patients included in pulmonary 
rehabilitation) 
Assessment of age & sex matched control groups  
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TestOrganizer 
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Table 2 Sub-domains of the Nijmegen Integral Assessment Framework (NIAF), their corresponding 
instruments, subscales/measurements. The preliminary selection of instruments for the Nijmegen 
Clinical Screening Instrument are indicated in bold type face 
  
Sub-domain 
 
Instrument 
 
Subscale/ Measurement 
correlation 
with 
NIAF-STS 
Number 
of items 
P
h
ys
io
lo
gi
ca
l F
u
n
ct
io
n
in
g 
Exercise Capacity Vmax 29, Sensor Medics VO2 maximum% predicted .79  
  Heart rate maximum% predicted .74  
  TLCO % predicted .73  
  BE delta .71  
Static Lung Volumes Masterscreen PFT 
spirometer/  
TLC % predicted .95  
 diffusion, Jaeger RV % predicted .95  
Airflow Masterscreen PFT 
spirometer/  
Post-bronchodilator FEV1% 
predicted 
-.91  
 diffusion, Jaeger MEF50 % predicted -.81  
  VE % predicted .72  
Gas Exchange  Vmax 29, Sensor Medics Delta (A-a)DO2 (kPa)   *  
  Delta PaCO2 (kPa)   *  
Muscle Strength Validyne CD23 PE max% predicted -.80  
  PI max % predicted -.75  
  Quadriceps % predicted -.72  
Body Composition W/H2 BMI -.95  
 Bodystat FFMI -.95  
Sy
m
p
to
m
s 
Subjective Symptoms PARS-D [6] Global Dyspnea Activity .89 1 
  Dyspnea Activity .89 14 
  Global Dyspnea Burden .85 1 
 QoL-RIQ [20]  Breathing Problems .76 9 
Dyspnea Emotions DEQ [6] DEQ-Mood .89 3 
  DEQ-Frustration  .84 3 
  DEQ-Anxiety .79 3 
Expected Dyspnea PARS-D [6] Expected Dyspnea  1.00 14 
Fatigue CIS [21]  Fatigue 1.00 8 
Fu
n
ct
io
n
al
 Im
p
ai
rm
e
n
t 
Actual Activity Aktometer [22]  Aktometer Mean 1.00 12 days 
Behavioral Impairment SIP [23,24]  SIP Home Management .82 10 
SIP Ambulation .81 12 
SIP Body Care & Movement .77 22 
  SIP Mobility .69 10 
Subjective Impairment QoL-RIQ [20]  QoL-RIQ General Activities  .90 4 
QoL-RIQ Social Activities .83 7 
 Global Impairment [6] Global impairment .78 1 
 SIP [23,24]  SIP Social Interaction .75 20 
  SIP Burden .71 5 
Q
u
al
it
y 
o
f 
Li
fe
 
General QoL BDI [25]  BDI Primary Care  .83 7 
 SWLS [26]  SWLS-Total  .81 5 
 SCL [27]  SCL Anxiety  .80 10 
HRQol  Satisfaction-Physical [6] Satisfaction Physical .88 1 
 Satisfaction-Future [6] Satisfaction Future .88 1 
Satisfaction Relations Satisfaction-Spouse [6] Satisfaction Spouse .84 1 
 Satisfaction-Social [6] Satisfaction Social  .84 1 
Abbreviations: %, percentage of predicted ; BDI, Beck Depression Inventory; BE,  Base Excess; BMI, Body Mass Index; CIS, Checklist Individual 
Strenght;  DEQ, Dyspnea Emotions Questionnaire; FEV1, Forced Expiratory Volume in one second postbronchodilator value; FFMI, Fat Free 
Mass Index; MEF50, mid-expiratory Flow at 50% of forced vital capacity; PARS-D, Physical Activity Rating Scale –Dyspnea; PImax, maximal 
inspiratory mouth pressure; PEmax, maximal expiratory mouth pressure; QoL, Quality of Life; HrQoL, health related quality of life; QoL-RIQ, 
Quality of Life for Respiratory Illness Questionnaire; RV, Residual Volume; TLC, Total Lung Capacity; TLCO, transfer capacity (of lung) for 
carbon monoxide; SCL, Symptom Checklist; SIP, Sickness Impact Profile; SWLS, Satisfaction With Life Scale; VE, minute ventilation ;VO2max, 
maximal oxygen uptake. *= non-linear variables  
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2. To test possible overlap between the sub-domains the inter-correlations between all 
NCSI-STS were calculated by spearman coefficients, and should be lower than 0.70. 
3. The Cronbach’s alpha reliability coefficients (internal consistency) of each NCSI-STS 
should be at least be moderate (>0.50) and preferably >0.70 [9]. 
 
Construction of normative data  
For each subscale, the total score range of the COPD study group was transformed to c-
scores. C-scores are similar to percentile scores, but differentiate more in the extremes of 
the score range and correct for skewed distributions. The score-range is 1-11, and the scores 
refer to the following percentiles respectively : 1.2-4.0-10.6-22.7-40.1-59.9-77.3-89.4-96.0-
98.8-100%. For each instrument the score belonging to the 80th percentile of the healthy 
controls was used as the maximal score of normal functioning (green colored score range), 
and the score belonging to the 20th percentile of the pulmonary rehabilitation patients was 
used as the minimum score representing clinically relevant problems (red colored score 
range). The area between green and red has been labeled ‘elevated’(yellow). 
 
New features of the TestOrganiser  
The TestOrganiser was originally developed for the purpose of data collection in research. In 
the past three years, the TestOrganiser has been implemented in our inpatient and 
outpatient clinic to develop and test clinical applicability and patient acceptability in routine 
care. The software of the TestOrganiser was revised in several aspects and new features 
were developed. These revisions particularly concerned automated data processing. The 
most important new feature is the graphical presentation of results on the level of an 
individual patient (the PatientProfileChart) to facilitate ease of interpretation of results for 
clinical purposes. 
 
 
RESULTS 
 
No significant differences were found between the COPD-study group and the two control 
groups with respect to age and sex (Table 1). 
 
Construction of the Nijmegen Clinical Screening Instrument 
A. Preliminary selection of instruments  
The preliminary selection of instruments for the NCSI is shown in Table 2. The instruments in 
bold were selected for the NCSI. The sub-domains exercise capacity, gas exchange and 
muscle strength require cycle-ergometry testing and muscle strength tests are too time-
consuming for use in a routine care outpatient setting and, therefore, were excluded. The 
sub-domains expected dyspnea (main domain symptoms) and actual physical activity (main 
domain functional impairment) were excluded because these tests also are too time-
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consuming: the PARS-Expected Dyspnea consist of 20 items and the accelerometer has to be 
worn for 12 days. 
With respect to the sub-domain dyspnea emotions (main domain symptoms) we 
included dyspnea related anxiety instead of dyspnea-related mood despite the higher 
correlation of the latter, because dyspnea-related anxiety is far more common in COPD than 
dyspnea-related depressed mood. With respect to the sub-domain subjective symptoms 
(main domain symptoms) we included the PARS-D Global Dyspnea Burden (1 item) instead 
of the PARS-D Dyspnea activity (14 items) for reasons of brevity. 
 
B. Statistical analysis on the preliminary selection 
The correlations between the sub-domain total scores of the NIAF (NIAF-STS) and the NCSI 
(NCSI-STS) all exceeded 0.70, which indicates that the NCSI-STS are conceptually similar to 
the NIAF-STS (Table 3). In addition, all Cronbach’s Alpha’s of the NCSI-STS were >0.70, except 
those of general QoL (0.61) and satisfaction relations (0.64) (Table 3).  
Tabel 3 Correlations between the sub-domains measured by the NCSI-sub-domain total scores 
(NCSI-STS) versus the NIAF-sub-domain total scores (NIAF-STS) (p<0.01) and Cronbach’s alpha 
reliability coefficients of all NCSI-STS 
D
o
m
ai
n
 Sub-domain Subscale/Measurement Correlation 
NCSI-STS vs.  
NIAF-STS 
Number  
of items 
Cronbach’s 
alpha 
P
h
ys
io
lo
gi
ca
l 
Fu
n
ct
io
n
in
g 
Static Lung Volumes TLC% predicted .99  -- 
 RV% predicted    
Airflow Post-bronchodilator FEV1 % pred. -.91  -- 
Body Composition BMI -.95  -- 
Sy
m
p
to
m
s 
Subjective Symptoms PARS-D Global Dyspnea Activity .93 2 .85 
 PARS-D Global Dyspnea Burden    
Dyspnea Emotions DEQ Frustration .96 6 .82 
 DEQ Anxiety    
Fatigue CIS fatigue 1.00 8 .83 
Fu
n
ct
io
n
al
 
Im
p
ai
rm
e
n
t Behavioral Impairment SIP Home Management .91 22 .72 
 SIP Ambulation 
Subjective Impairment QoL-RiQ General Activities .90 4 .88 
Q
u
al
it
y 
o
f 
Li
fe
 
General QoL Satisfaction With Life Scale  .94 12 .61 
 BDI Primary Care     
HRQoL  Satisfaction Physical 1.00 2 .71 
 Satisfaction Future    
Satisfaction Relations Satisfaction Spouse 1.00 2 .64 
 Satisfaction Social Relations    
Abbreviations: see table 2 
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In general, there was none or at best moderate overlap between the sub-domains of the 
NCSI-STS as expressed by non-significant to at best moderate inter-correlations (Table 4). 
Additional items were added to measure smoking-status (yes/no) and willingness to 
quit smoking (yes/no). 
 
Construction of normative data  
Characteristics of the sub-domains included in the NCSI for all study groups are presented in 
Table 5. As expected, in healthy controls there was a strong floor effect on disease-related 
domains: symptoms (except fatigue) and functional impairment. In general, there were no 
evident problems related to floor and ceiling effects in both COPD groups. As expected, the 
pulmonary rehabilitation control group showed the highest scores on all sub-domains and 
healthy controls the lowest.  
Table 4 Intercorrelations between the Nijmegen Clinical Screening Instrument sub-domain total 
scores (NCSI-STS) 
Main domain 
Physiological 
Functioning Symptoms 
Functional 
Impairment Quality of Life 
 Sub-domain S
ta
ti
c 
Lu
n
g 
V
o
lu
m
es
 
O
b
st
ru
ct
io
n
 
B
o
d
y 
C
o
m
p
o
si
ti
o
n
 
Su
b
je
ct
iv
e 
Sy
m
p
to
m
s 
D
ys
p
n
ea
 E
m
o
ti
o
n
s 
Fa
ti
gu
e 
B
eh
av
io
ra
l I
m
p
ai
rm
en
t 
Su
b
je
ct
iv
e 
Im
p
ai
rm
en
t 
G
en
er
al
 Q
O
L 
H
R
Q
o
L 
Sa
ti
sf
ac
ti
o
n
 R
el
at
io
n
s 
P
h
ys
io
lo
gi
ca
l 
Fu
n
ct
io
n
in
g 
Static Lung Volumes 1.00           
Obstruction - 1.00          
Body Composition - 0.28 1.00         
Sy
m
p
to
m
s 
Subjective Symptoms - 
-
0.28 
- 1.00        
Dyspnea Emotions - - - 0.27 1.00       
Fatigue - - - 0.52 0.30 1.00      
Fu
n
ct
io
n
al
 
Im
p
ai
rm
e
n
t Behavioral Impairment - - - 0.48 0.25 0.43 1.00     
Subjective Impairment - - - 0.65 0.42 0.60 0.54 1.00    
Q
u
al
it
y 
O
f 
lif
e General QOL - - - 0.45 0.41 0.44 0.44 0.59 1.00   
HRQoL - - - 0.46 0.40 0.55 0.49 0.62 0.63 1.00  
Satisfaction Relations - - - 0.29 0.35 0.39 0.30 0.48 0.49 0.54 1.00 
Only correlations with p<0.01 are printed 
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New features of the TestOrganiser  
To enable patients with no prior computer experience to complete the questionnaires easily, 
a simple response-board was developed with a minimum of (large) buttons. A network 
function was integrated that enables immediate access to the results after test completion 
on every computer in the hospital. The most important new feature is the automatic 
production of graphical representations of the results: the PatientProfileChart (see Figure 2). 
The PatientProfileChart (PPC) provides a graphical presentation of the scores of an 
individual patient. Each column represents a specific instrument within a sub-domain. All 
score ranges are based on the reference sample (COPD-study group) and are expressed as c-
scores. The x represents the score of the individual patient. First, the x indicates how a 
patient scores in relation to the general COPD population. For example, the patient in Figure 
2 had a raw score on Depression of 3 which falls in the 7th C-score of the COPD reference 
sample. This means that 77,3% of the reference sample had a lower score. Second, the score 
range of each instrument is divided into coloured ranges, which allow absolute 
interpretations. The green score range indicates ‘normal functioning’, the yellow score range 
indicates ‘mild problems’, and the red score range indicates ‘clinically relevant problems’. 
The patient in Figure 2 scored in the yellow area (‘mild problems’). Thus, although this 
patient had a higher score than 77% of the COPD reference sample (7th C-score), still this 
score did not indicate clinically relevant problems. 
 
 
DISCUSSION 
 
In the present study, we developed the Nijmegen Clinical Screening Instrument (NCSI), that 
is short enough to be completed in routine care, but stills provides much detail on a patient’s 
health status. In addition, the TestOrganiser was adapted to further improve clinical 
applicability of the NCSI in routine care. To facilitate interpretation of a patient’s scores, we 
developed the PatientProfileChart that presents results graphically. In addition, we 
determined cut-offs based on reference groups indicating whether a particular score 
indicates normal functioning or clinically relevant problems. 
Guidelines for treatment of COPD emphasize the importance of maintaining and 
optimizing health status  [8;11-12], and describe for every COPD severity stage (based on the 
degree of airway obstruction; I-IV) what type of treatment is indicated. Pulmonary 
rehabilitation, for example, is indicated for GOLD stages III-IV. However, health status 
consists of four main domains: physiological functioning, symptoms, functional impairment, 
and quality of life [1,2,6,13], divided into at least 15 unique sub-domains [6]. Given the 
findings of many studies showing that FEV1 is poorly related to symptoms, functional 
impairment, and quality of life [3-5;14] it is impossible to determine the status of other sub-
domains of health status on the basis of FEV1 alone. Thus, FEV1 gives no information on any 
aspect of health status other than airway obstruction, and as such is a poor indicator for  
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Nijmegen Clinical Screening Instrument (NCSI) 
 
 Patient characteristics  28-03-2008 
Name  
Date of birth  
Sex  
PatiëntNumber  
ResearchNummer 
Notes 
 
                
                       
              
University Lungcenter Dekkerswald @2007 
 
Figure 2 The PatientProfileChart; a graphical representations of the patients’ results  
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specific interventions such as pulmonary rehabilitation. Consequently, tailoring treatment to 
the needs of the individual patient requires an integral and detailed picture of the individual 
patient’s health status by measuring of all four main domains and their many sub-domains. 
Many generic and disease-specific instruments have been developed to measure 
health status in COPD patients [3,7]. However, most of these instruments are rather lengthy, 
scoring is time-consuming, commonly measure only few aspects of health status, and in 
many cases it is unclear whether a score represents normal functioning or clinically relevant 
problems, due to the lack of normative data. In addition, as existing instruments measure 
only few aspects of health status, the need for a detailed assessment of health status to 
enable patient-tailored treatment requires the combination of multiple instruments. 
However, such a battery of instruments would diminish clinical applicability even further as 
this would increase problems with regard to the length of instruments, time-consuming 
scoring procedures, as well as the overlap found between instruments [6]. 
The need for short questionnaires that allow measurement of symptoms, functional 
impairment, and quality of life in routine care has been acknowledged by other researchers. 
Several instruments have been developed for this purpose; the Clinical COPD Questionnaire 
(CCQ) [15], the Respiratory Illness Questionnaire–monitoring 10 (RIQ-MON10) [16], and the 
EuroQoL (EQ-5D) [17]. These instruments are short (six to ten items), and have shown good 
validity and reliability. However, the CCQ measures only three sub-domains of health status, 
the RIQ-MON10 measures only two sub-domains, and the EQ-5D measures only three sub-
domains. Although, these instruments are short and easy to score, these do not provide a 
detailed picture of the patient’s health status, and lack normative data indicating normal 
functioning versus clinically relevant problems. Hence, these instruments still do not satisfy 
all requirements for clinical applicability as pointed out in the introduction. 
We did not develop a new instrument, as we did not want to add to the abundance 
of instruments already available, but we set out for a new approach which would render 
existing instruments suitable for use in routine care. We composed a battery of existing 
instruments with a minimum number of items, but with a maximum of detail of health 
status, a minimum of overlap between instruments, and good reliability and validity. 
Although clinical considerations did play a role in the selection process of instruments, 
decisions were not based on personal preferences of the researchers, or on how frequent a 
particular instrument is used in COPD research. The selection of instruments from the 
empirically validated integral assessment framework of health status in COPD [6], the NIAF, 
was primarily guided by statistical analyses. The NIAF contains 16 sub-domains of health 
status covering the main domains physiological functioning, symptoms, functional 
impairment, and quality of life. In addition, this framework provides additional validity 
information on many existing instruments: it indicates what sub-domain(s) of health status 
specific instruments measure and it indicates which instruments measure the same sub-
domains of health status. 
Although the NCSI enables a quick (15-25 minutes) and detailed assessment of health 
status, typical questionnaire problems such as complex scoring procedures and the problem 
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of interpretability of results remained. To provide a solution for these problems the software 
of the TestOrganiser was adapted. This involved automatic scoring, a network facility, and 
the development of a special response-board. After instructions, additional questions of 
patients predominantly were related to the content of the questionnaire items, and rarely 
with regard to computer operating.  
The most important new feature of the TestOrganiser is the PatientProfileChart. 
Immediately after completion of the NCSI, the PatientProfileChart is generated by the 
TestOrganiser, is available on every authorized computer in the clinic, and can immediately 
be discussed with the patient. The interpretation of the PatientProfileChart is very easy: for 
the clinician, but also for the patient. A short training is sufficient to learn clinicians how to 
interpret the PatientProfileChart. The colored areas of the score range of each instrument 
indicate whether a patient shows normal functioning in a particular sub-domain of health 
status or clinically relevant problems.  
Psychometric properties of the NCSI are good. The correlations between the NCSI-STS 
and the corresponding NIAF-STS were high and well above the criterion for conceptual 
similarity. Within the NCSI there was little overlap between the NCSI-STS as expressed by 
non-significant to at best moderate inter-correlations. This also indicates that each sub-
domain of the NCSI represents a unique aspect of a patient’s health status. The internal 
consistency of the NCSI-sub-domain total scores in general were good, except the general 
Qol and satisfaction relations. 
Some methodological issues need to be addressed. First, in the present study the 
test-retest reliability and the responsiveness-to-change of the instruments used to measure 
the sub-domains of health status were not tested. However, inclusion of instruments with 
adequate psychometric properties was one of the selection criteria for the NIAF. For most of 
the included instruments test-retest reliability and responsiveness-to-change were found 
adequate in other studies [18,19,21,24]. Second, not all sub-domains of health status are 
measured by the NCSI. Some sub-domains required measurements that are too time-
consuming for use in routine care at an outpatient clinic (e.g. cycle-ergometry testing, 
accelerometry). Future studies are needed to find alternatives that can be used for 
measuring those sub-domains in routine care. Nevertheless, the decision on what specific 
measurements are too time-consuming also may depend on specific settings. The final issue 
refers to the use of control groups and the need for cut-offs. Normal functioning cannot be 
defined by absence of symptoms or functional impairment, for example, due to effects of 
normal ageing. This means that the upper part of the score range in healthy subjects 
indicates abnormal functioning. Therefore, we used the 80th percentile of healthy controls 
as the upper limit of normal functioning. Similarly, ‘clinically relevant problems’ cannot be 
defined by the mere presence of such problems. For example, healthy subjects may 
experience fatigue or shortness of breath as well. In addition, even patients with multiple 
and severe problems in health status (the inpatient pulmonary rehabilitation controls) may 
not have problems in all sub-domains. So, we assumed that for each sub-domain the lower 
part of the score range of the rehabilitation patients overlaps with the score range of normal 
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functioning or mild problems. Therefore, we chose the 20th percentile of the pulmonary 
rehabilitation patients as the cut-offs for clinically relevant problems. Although the method 
we used to calculate cut-off scores indicating normal functioning versus clinically relevant 
problems is an accepted approach [25], to a certain degree these cut-offs remain arbitrary. 
However, decisions on, for example, which patients do need additional treatment versus 
those who do not, never depend on one single sub-domain, but on the profile on all sub-
domains. Most important criteria in this respect are the number of sub-domains showing 
clinically relevant problems and discrepancies between the severity of physiological sub-
domains versus the sub-domains measuring symptoms, functional impairment, or quality of 
life. This may render the arbitrariness of cut-offs less problematic. In addition, the clinical 
relevance of the cut-offs (i.e. the profiles) were clinically tested during 3 years in different 
settings, and proved to be quite accurate. 
The NCSI can be used for several clinical purposes. Screening and monitoring. In our 
centre, every year the patient completes the NCSI during a regular visit. In this way, 
problems in all four domains of health status are revealed in an early stage.  
Decision making. The profile of the PatientProfileChart indicates which type of 
intervention would be required for this individual patient (e.g. pulmonary nurse, an 
outpatient or multi-disciplinary pulmonary rehabilitation program). As pointed out above 
such decisions are based on the profile of all sub-domains. Additionally, the discussion of the 
PatientProfileChart with patient and partner elucidates the mechanisms underlying the 
problems in health status. This provides additional information on which type of intervention 
is best suited.  
Motivational intervention. The NCSI and PatientProfileChart can be used as an 
intervention to increase the patient’s motivation to adopt adequate health behaviors (e.g. 
stop smoking, regular exercise) or to enroll in additional treatment (e.g. rehabilitation 
program). This is simply done by discussing the PatientProfileChart with the patient and his 
partner. The motivational effect is achieved by several psychological mechanisms ‘hidden’ in 
this procedure. The most important are firstly, results are presented graphically, which has 
much greater impact than words, and thereby powerfully increases awareness of the 
severity of his problems. Secondly, the profile is the resultant of responses of the patient 
himself and does not reflect the opinion of the clinician. This increases commitment and 
avoids conflicting opinions. The NCSI can also be used for outcome assessment and research 
purposes. 
In conclusion, in this study we composed a battery of instruments that enables the 
clinician to obtain a valid, reliable, and detailed picture of a patient’s health status by 
measuring multiple sub-domains covering all four main domains. In combination with the 
TestOrganiser and the PatientProfileChart, the NCSI can easily be used in routine care as a 
guide in patient-tailored treatment. 
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ABSTRACT  
 
Background  
Improving patients’ health status is one of the major goals in COPD treatment. 
Questionnaires could facilitate the guidance of patient-tailored disease management by 
exploring which aspects of health status are problematic, and which aspects are not. Health 
status consists of four main domains (physiological functioning, symptoms, functional 
impairment, and quality of life), and at least sixteen sub-domains. A prerequisite for patient-
tailored treatment is a detailed assessment of all these sub-domains. Most questionnaires 
developed to measure health status consist of one or a few subscales and measure merely 
some aspects of health status. The question then rises which aspects of health status are 
measured by these instruments, and which aspects are not covered. As it is one of the most 
frequently used questionnaires in COPD, we evaluated which aspects of health status are 
measured and which aspects are not measured by the St George’s Respiratory Questionnaire 
(SGRQ).  
 
Methods  
One hundred and forty-six outpatients with COPD participated. Correlations were calculated 
between the three sections of the SGRQ and ten sub-domains of the Nijmegen Integral 
Assessment Framework, covering Symptoms, Functional Impairment, and Quality of Life. As 
the SGRQ was not expected to measure physiological functioning, we did not include this 
main domain in the statistical analyses. Pearson’s r ≥0.70 was used as criterion for 
conceptual similarity.  
 
Results  
The SGRQ sections Symptoms and Total showed conceptual similarity with the sub-domain 
Subjective Symptoms (main domain Symptoms). The sections Activity, Impacts and Total 
were conceptual similar to Subjective Impairment (main domain Functional Impairment). 
The SGRQ sections were not conceptual similar to other sub-domains of Symptoms, 
Functional Impairment, nor to any sub-domain of Quality of Life. 
 
Conclusions  
The SGRQ could facilitate the guidance of disease management in COPD only partially. The 
SGRQ is appropriate only for measuring problems in the sub-domains Subjective Symptoms 
and Subjective Impairment, and not for measuring problems in other sub-domains of health 
status, such as Quality of Life. 
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BACKGROUND 
 
COPD is a chronic and debilitating disease and a leading cause of morbidity and mortality 
worldwide [1]. According to the latest estimates of the World Health Organization (WHO), 
210 million people have COPD and 3 million people died of COPD in 2005 [2]. Improving 
patients’ health status is one of the major goals in COPD treatment [3].  
 Quality of life has become an important endpoint in medical care, but still there is no 
consensus on the definition of these concepts [4]. Smith and colleagues (1999) consider 
quality of life and health status to be separate constructs, in which quality of life is more 
related to mental health, whereas health status is more related to physical functioning [4]. 
The WHO uses a broader definition of health status, by defining health status as ‘a state of 
complete physical, mental and social well-being, and not merely the absence of disease or 
infirmity’. Similarly, others [5,6] define health status as an overall concept covering 
physiological functioning, symptoms, functional impairment, quality of life, and social 
functioning as important main domains. These main domains were empirically found to be 
further divided into sixteen sub-domains [7,8], each sub-domain representing a unique 
aspect of health status. Despite differences in definitions found in the literature it has 
become clear that a patient’s functioning consists of many conceptually distinct sub-
domains. Patient-tailored treatment then requires assessment of all these sub-domains. 
 Questionnaires could facilitate the guidance of patient-tailored disease management 
by exploring which aspects of health status are problematic and which aspects are not. The 
past decade many questionnaires have been developed to measure health status. However, 
most of these instruments consists of only one or a few subscales and thus measure merely 
some aspects of health status. The question then rises which aspects of health status are 
measured by these instruments, and which aspects are not covered. 
 The St George’s Respiratory Questionnaire (SGRQ), for instance, is one of the most 
frequently used and translated disease specific health status instruments in COPD [9-11]. A 
recent Pubmed search gave 555 hits (date 06/03/2010; terms SGRQ and St George’s 
Respiratory Questionnaire). The SGRQ has been developed to allow comparative 
measurement of health between patient populations and to quantify changes in health 
following therapy [12]. The SGRQ consists of three sections and a total score: Symptoms, 
measuring the frequency and severity of respiratory symptoms; Activity, measuring 
limitation of activities by breathlessness and activities that cause breathlessness; Impacts, 
measuring disturbances in social and psychological functioning due to airway disease; Total 
score summarizes the impact of the disease on overall health status [12-14]. The SGRQ thus 
measures maximally three of the sixteen aspects of health status. It is not clear which 
aspects of health status are measured, and which aspects of health status are not measured 
by the SGRQ. This question is all the important to unravel, because the SGRQ, as many other 
questionnaires, is subject to conceptual confusion. The SGRQ initially was conceived as a 
standardized self-completed questionnaire for measuring health and perceived well-being 
(‘QoL’) in airways diseases [12]. In the literature, however, the SGRQ is interchangeably 
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referred to as a measure of quality of life [15], health-related quality of life [16], health 
status [17], a measure for impaired health [18], or a measure of overall impact of the disease 
[19]. Different terms are used for the concept(s) the SGRQ measures. Additionally, since the 
SGRQ is often used as a criterion in validity testing of other instruments [20,21], it is 
essential to clarify which aspects of health status the SGRQ measures. 
 In the present study, we tested which aspects of health status are measured by the 
SGRQ in COPD, by comparing the SGRQ sections Symptoms, Activity and Impact with 
multiple aspects of the health status domains symptoms, functional impairment and Quality 
of Life. 
 
 
MATERIAL AND METHODS 
 
Subjects 
The 146 subjects took part on a longitudinal study on health status in COPD. Patients were 
recruited from three different outpatient centres in the Netherlands: Radboud University 
Nijmegen Medical Centre, Maas Hospital Boxmeer, and Rijnstate Hospital Arnhem. Patients 
had to fulfil the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria of a 
post-bronchodilator FEV1% predicted between 30 and 80 percent with a reversibility of 
obstruction of less than 12% [1]. Patients suffering from primary co-morbidity or co-
morbidity that prevented full adherence to the research protocol were excluded, as well as 
patients with an acute exacerbation, recent (<6 months) participation in a rehabilitation 
program, or who were not able to speak or read Dutch. One-hundred-and-sixty-eight 
patients participated in this study. After one year, the assessments were repeated in 146 
patients (87% of included patients in first part). Reasons for dropout were diverse: passed 
away (N=5), co-morbidity (N=3), participation in a rehabilitation programme between the 
first and second assessments (N=2), being too busy (N=4), found participation too exhausting 
(N=3), or no transportation (N=2). For three patients the reasons for dropout were unknown. 
Data of these 146 patients were used in the present study. The inclusion procedure is 
described in detail elsewhere [7]. The study was approved by the Medical Ethics Committee 
CMO region Arnhem-Nijmegen (P02.1411L; CMO-nr 2002/047). Subjects gave informed 
consent.  
 
Procedures 
Subjects visited the Department of Pulmonary Diseases twice. Physiological assessments 
were performed and subjects received the Aktometer (accelerometer measuring actual 
physical activity) [22]. Two weeks later subjects completed questionnaires by the 
TestOrganiser, a computer program developed by the Department of Medical Psychology 
and the Department of Instrumental Services of the Radboud University Nijmegen Medical 
Centre [7]. Questionnaires were presented in the same layout as the paper-and-pencil 
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versions, and a simple response board enabled subjects with no prior computer experience 
to operate the TestOrganiser easily. 
 
Measurements 
Demographic data were recorded. Pulmonary function tests were performed, including 
transfer capacity for carbon monoxide using the Jaeger masterlab-spirometer according to 
ERS-criteria [23], and indices of body composition (BodyStat 1997). 
 
St George’s Respiratory Questionnaire (SGRQ) 
The SGRQ consists of 50 items with weighted responses divided in three sections - 
Symptoms, Activity, and Impacts - and a Total score [12-14]. Scores are expressed as 
percentages of the maximally possible sum of weights. A score of zero represents no health 
impairment, a score of 100 means maximal health impairment.  
 
Health status main domains symptoms, functional impairment, and Quality of Life  
Health status was measured by the Nijmegen Integral Assessment Framework (NIAF) [7]. The 
NIAF provides a detailed and empirical definition of health status and covers the domains 
physiological functioning, symptoms, functional impairment, and Quality of Life. These four 
main domains were found to be subdivided into 15 distinct sub-domains [7,8]. In another 
study [8], we found that fatigue was an additional sub-domain. Factor analyses were used to 
identify underlying concepts in the data. Social functioning did not emerge as a separate 
factor, aspects of social functioning were part of the main domains Quality of Life and 
functional impairment. The sub-domains are measured by different existing instruments, 
and for each sub-domain a Sub-domain Total Score (STS) was calculated. As the SGRQ was 
not expected to measure physiological functioning, in this study we only evaluated the ten 
sub-domains of the main domains symptoms, functional impairment, and Quality of Life. See 
Table 1 for definitions of the sub-domains and corresponding instruments.  
 
Statistical analyses 
The relationships between the sections of the SGRQ and the sub-domains of the NIAF, as 
well as the intercorrelations of the SGRQ sections, were analyzed by Pearson correlation 
coefficients. To avoid Type I error due to multiple testing P was set at 0.01. A Pearson’s r ≥ 
0.70 was used as criterion for conceptual similarity between the sections of the SGRQ and 
the sub-domains of the NIAF [24]. 
 
 
RESULTS 
 
Subjects  
The study sample could be characterized as predominantly male, low educated, and living 
with a partner (Table 2). Most subjects were GOLD II/III patients. Some subjects were  
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Table 1 Main domains Symptoms, Functional Impairment and Quality of Life of the Nijmegen 
Integral Assessment Framework 
Domain/Sub-domain Definition Instrument (subscales) 
Symptoms   
Subjective Symptoms 
 
The patient’s overall burden of 
pulmonary symptoms 
PARS-D: Global Dyspnea Activity,  
Global Dyspnea Burden,  
Dyspnea Activity [7];  
QoLRiQ: Breathing Problems [33] 
Dyspnea Emotions The level of frustration, depressive 
feelings, and anxiety a patient 
experiences when dyspnoeic 
DEQ: Frustration, Mood, Anxiety [7] 
Expected Dyspnea The level of dyspnea that a patients 
expect to experience during specific 
activities no longer performed 
PARS-D: Expected Dyspnea [7] 
Fatigue The level of experienced fatigue CIS: Subjective fatigue [34] 
Functional Impairment   
Actual Physical Activity 
 
 
The actual physical activity a patient 
performs during two weeks 
Aktometer (electronic 
accelerometer) [22] 
 
Behavioral Impairment The extent to which a person cannot 
perform specific and concrete 
activities as a result of having the 
disease 
SIP: Body Care & Movement, Home 
Management, Mobility, Ambulation  
[35] 
Subjective Impairment The experienced degree of 
impairment in general, and in social 
functioning 
QoLRiQ: General Activities, Social 
Activities [33]; Global Impairment 
[7]; SIP: Social Interaction, Burden  
[35] 
Quality of Life   
General QoL 
 
Mood, anxiety, and the satisfaction 
of a person with his/her life as a 
whole 
Satisfaction With Life Scale [36] 
Symptom Check List: Anxiety [37] 
BDI: Primary Care [38] 
HRQoL 
 
Satisfaction related to physiological 
functioning and the future 
 
Satisfaction Physiological 
Functioning, Satisfaction Future [7] 
 
Satisfaction Relations Satisfaction with the (absent) 
relationships with spouse and others 
Satisfaction Spouse, Satisfaction 
Social [7] 
PARS-D, Physical Activity Rating Scale -Dyspnea; QoLRiQ, Quality of Life for Respiratory Illness Questionnaire; 
DEQ, Dyspnea Emotions Questionnaire; CIS, Checklist Individual Strength; SIP,: Sickness Impact Profile; QoL, 
Quality of Life; HRQoL, Health Related Quality of Life;  BDI, Beck Depression Inventory 
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classified in GOLD I or IV, due to normal variation in FEV1 between the time of the first 
assessment and second assessment one year later. 
 
Conceptual similarity between sections of the SGRQ and sub-domains of the NIAF  
The SGRQ sections were significantly correlated to many health status aspects, however 
conceptual similarity (r ≥ 0.70) was only reached for two sub-domains of the NIAF (Table 3). 
 
The SGRQ sections Symptoms and Total were conceptual similar to the NIAF sub-domain 
subjective symptoms (main domain symptoms). The SGRQ sections Activity, Impacts, and 
Total were conceptually similar to the NIAF sub-domain subjective impairment (main domain 
functional impairment). 
 
 
Table 2 Demographic, clinical characteristics, and data of the St George’s Respiratory 
Questionnaire of participating COPD patients 
Variable  Mean ±SD 
Male sex %  76.7 
Age (years)  65.8 ±9.0 
Education % Low 
Middle 
High 
48.6 
29.5 
19.9 
Personal situation % Partner 
Divorced 
Widowhood 
Single 
77.8 
6.3 
8.3 
7.6 
Cigarette smoking % Current 
Former 
Never 
41.8 
45.9 
11.0 
BMI (kg/m2) 
FEV1 (L) 
FEV1 % predicted 
FEV1/FVC %  
TLC % predicted 
RV % predicted 
TLCO % predicted 
 25.9 ±4.1 
1.6 ±0.5 
53.6 ±13.9 
44.0 ±11.4 
103.7±14.6 
128.3 ±30.3 
62.3 ±21.5 
GOLD % I 
II 
III 
IV  
2.1 
58.9 
34.2 
4.8 
SGRQ section Symptoms 
Activity 
Impacts 
Total 
40.9 ±24.8 
40.9 ±21.8 
20.2 ±13.5 
30.2 ±15.4 
Data are presented as mean ±SD unless otherwise indicated. Percentages may not add up to 100 due to 
missing data (three patients with no specified education, two patients with no specified smoking habits). 
BMI, body mass index; FEV1, forced expiratory volume in one second; % predicted, as percentage predicted; 
FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; TLCO, transfer capacity (of lung) for 
carbon monoxide; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SGRQ, St George’s 
Respiratory Questionnaire.  
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Intercorrelations of the SGRQ sections  
Intercorrelations between the SGRQ sections were moderate to high (Table 4). The SGRQ 
section Total exceeded the criterion of conceptual similarity with all SGRQ sections (r ≥ 0.70, 
p<0.01). The correlation between the sections Impacts and Activity almost reached the 
criterion of conceptual similarity (r = 0.69, p<0.01). 
 
 
DISCUSSION  
 
The present study evaluated which aspects of health status are measured by the sections of 
the SGRQ, and which aspects of health status are not covered by the SGRQ. The sections of 
the SGRQ correlated significantly with most sub-domains of the NIAF, indicating that the 
SGRQ was related to many health status aspects. However, most correlations were low to 
moderate and well below 0.70, indicating that shared variance was too low to conclude that 
sections of the SGRQ were conceptually similar to these sub-domains.  
Table 3 Correlations between the St George’s Respiratory Questionnaire and the Nijmegen Integral 
Assessment Framework# 
  Sections of the St George’s Respiratory Questionnaire 
  Symptoms Activity Impacts Total 
M
ai
n
 d
o
m
ai
n
s 
o
f 
th
e 
N
ijm
eg
en
 In
te
gr
al
l 
A
ss
es
sm
en
t 
Fr
am
ew
o
rk
 
Symptoms 
      Subjective Symptoms 
      Dyspnea Emotions 
      Expected Dyspnea  
      Fatigue 
 
 
0.70¶  
0.25 
0.43 
0.47 
 
0.64 
0.31 
0.59 
0.57 
 
0.60 
0.32 
0.43 
0.60 
 
0.74¶ 
0.35 
0.57 
0.65 
Functional Impairment 
      Actual Physical Activity 
      Behavioral Impairment 
      Subjective Impairment 
 
 
--- 
0.28 
0.67 
 
0.42 
0.65 
0.70¶ 
 
0.31 
0.54 
0.71¶ 
 
0.34 
0.61 
0.81¶ 
Quality of Life 
      General QoL 
      HRQoL  
      Satisfaction Relations 
 
0.50 
0.43 
0.24 
 
0.46 
0.42 
--- 
 
0.52 
0.46 
--- 
 
0.57 
0.51 
0.21 
#only significant correlations (p<0.01) are shown; ¶Pearson’s r≥0.70 (criterion for conceptual similarity) 
Table 4 Intercorrelations between sections of the St George’s Respiratory Questionnaire# 
St George’s Respiratory Questionnaire 
 Symptoms Activity Impacts Total 
Symptoms 1.00 -- -- -- 
Activity  0.50 1.00 -- -- 
Impacts 0.54 0.69 1.00 -- 
Total 0.73¶ 0.88¶ 0.91¶ 1.00 
#only significant correlations (p<0.01) are shown; ¶Pearson’s r≥0.70 (criterion for conceptual similarity) 
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 Applying the criterion of conceptual similarity, the SGRQ measured two of the ten 
evaluated sub-domains of health status. The SGRQ sections Symptoms and Total showed 
conceptual similarity with the sub-domain subjective symptoms (main domain symptoms), 
the SGRQ sections Activity, Impacts, and Total showed conceptual similarity with the sub-
domain subjective impairment (main domain functional impairment). 
 In a previous study [7] we found a high correlation between the sub-domains 
subjective impairment and subjective symptoms. The instruments included in these sub-
domains were different with respect to the content of the items, but had in common that 
the item-and-response format required highly subjective and general interpretations by the 
patient. It was argued that both sub-domains measured highly subjective notions of ‘being 
ill’, also referred to as illness perceptions [25]. As the SGRQ reached the criterion for 
conceptual similarity with these two sub-domains, this would imply that the SGRQ in fact 
measures illness perceptions, related to symptoms (section Symptoms and Total) and 
functional impairment (sections Activity and Impacts). This conclusion is underlined by the 
high intercorrelations between the SGRQ sections, some correlations even exceeding the 
criterion for conceptual similarity.  
 Although illness perceptions related to symptoms and functional impairment are very 
relevant concepts, many other important aspects of health status are not covered by the 
SGRQ. With respect to the SGRQ as a measure of aspects of symptoms, these are restricted 
to the subjectively experienced severity of pulmonary symptoms. Other important aspects of 
symptoms, such as dyspnea-related emotions, are not measured specifically. With respect to 
functional impairment, only the subjectively experienced impairments are measured by the 
SGRQ. Impairment on the behavioral level or actual physical activity level is not measured by 
the SGRQ sections. Furthermore, the present study showed that the SGRQ does not measure 
any of the three sub-domains of quality of life evaluated in this study (general Quality of Life, 
health-related Quality of Life, and satisfaction relations). Finally, since the SGRQ measures 
merely two sub-domains of the ten evaluated sub-domains, the SGRQ does not provide a 
detailed measurement of health status. Similarly, present data show that the SGRQ should 
be considered a valid measure of impaired health in COPD, as the SGRQ originally was 
conceived. However, the SGRQ measures only two aspects of impaired health (subjective 
symptoms and subjective impairment). To measure all aspects of impaired health, and 
thereby allowing patient-tailored treatment, other instruments need to be included as well. 
 Some methodological issues need to be addressed. First, the NIAF is not the definite 
answer to the problem of conceptual confusion in current health status instruments. Other 
aspects of health status not included in the framework may be relevant to COPD patients. 
This needs to be addressed in future studies, in which patient feedback should be 
incorporated. Nevertheless, this framework does provide a much more detailed definition of 
health status, as expressed by the many sub-domains, and is much more formulated in terms 
of empirical observations than found in the literature. Each sub-domain represents a 
(conceptually) unique health status aspect. At least 16 sub-domains are measured to provide 
a detailed picture of the health status of a COPD patient.   
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 Second, using the criterion of conceptual similarity (r ≥ 0.70) as a standard for validity 
seems a very strict criterion. However, considering the conceptual confusion in health status, 
one must be carefully interpreting results of earlier validity studies. Often, much lower 
correlations are accepted as evidence for the validity of the instrument under scrutiny. For 
example, a correlation between two instruments of 0.40 may be statistically significant, but 
it indicates only 16% of shared variance. Unambiguous conclusions concerning conceptual 
similarity between two instruments can only be drawn from the results using a strict 
approach.  
 The present study focuses on the relationships between the SGRQ sections and the 
main domains symptoms, functional impairment, and Quality of Life. Therefore, the 
conclusions of the present study are not applicable with respect to physiological functioning. 
However, from a theoretical point of view it is unlikely that a questionnaire will provide a 
direct measure of physiological processes. For example, studies to date [26,27] often show a 
relationship between FEV1 and the SGRQ. However, these correlations are low to moderate 
and do not exceed the criterion of conceptual similarity.  
 With respect to generalizability of the present study, we believe that the present 
sample may be an adequate reflection of a the Dutch population of patients with COPD seen 
in an outpatient clinic. This sample may however not be representative for subgroups of 
COPD such as patients in pulmonary rehabilitation or patients with primary co-morbidity, 
which were two major exclusion criteria.  
 An important clinical implication of the present study is that the SGRQ could facilitate 
the guidance of disease management only partially. The SGRQ can only be used 
appropriately for exploring problems in the sub-domains subjective symptoms and 
subjective impairment, and not for exploring problems in other sub-domains of health 
status, such as aspects of quality of life. 
 Most instruments claiming to measure specific aspects of health status contain only 
two to five subscales. Thus, at best only some aspects of health status are measured by a 
specific instrument. This not only has implications for clinical practice, but also for research 
purposes. In pharmacological trials, the drug under study may have beneficial effects on 
some aspects of health status, but not on other aspects. If the instruments used measure 
only few aspects of health status beneficial effects may be missed. With respect to the use of 
instruments in clinical practice, the present results indicate that one single instrument 
cannot provide sufficient information on a patient’s health status to effectively tailor 
treatment to the needs of the individual patient, since measuring all aspects of health status 
is a prerequisite for patient-tailored treatment. This requires combining different 
instruments into a battery of instruments measuring multiple aspects of health status. 
However, implementing instruments in daily practice to facilitate disease management 
requires that instruments are not too time consuming. The past decade a few short 
instruments have been developed specifically to allow measurement of health status aspects 
in routine care, such as the Clinical COPD Questionnaire [28], the Respiratory Illness 
Questionnaire-monitoring 10 [29], and the EuroQoL [30]. None of these instruments provide 
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a detailed picture of a patient’s health status. Recently, we developed the Nijmegen Clinical 
Screening Instrument (NCSI), an instrument which can be used in routine care [31]. The NCSI 
is based on the NIAF and measures eleven sub-domains of physiological functioning, 
symptoms, functional impairment, and quality of life. The NCSI thus enables a quick (15-25 
minutes) and detailed assessment of health status. Also, the COPD Assessment Test (CAT) 
was developed [31], ‘a validated short and simple instrument for assessing the impact of 
COPD on health status’. The CAT is constructed as a uni-dimensional instrument, i.e. 
measuring one single concept, as expressed in a single score. In addition, the correlation 
between the CAT and the SGRQ-C was well above the criterion for conceptual similarity 
(r=0.80) [30]. Taken together, it is very likely that the CAT, like the SGRQ, measures illness 
perceptions. How important illness perceptions may be, patient-tailored treatment requires 
a detailed assessment of many aspects of health status. Therefore, the CAT also will have 
limited value in patient-tailored treatment. 
 
CONCLUSIONS 
 
Detailed measurement of health status in patients with COPD is a prerequisite for patient-
tailored treatment. However, carefulness should be noted when selecting instruments to 
measure health status, because most instruments measure only a few aspects of health 
status. The SGRQ can only be used appropriately for measuring problems in the sub-domains 
Subjective Symptoms and Subjective Impairment, and not for measuring problems in other 
sub-domains of health status, such as aspects of Quality of Life. Different instruments should 
be combined to provide a detailed picture of a patient’s health status.    
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ABSTRACT  
 
Background  
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease. Not only the 
(extra-)pulmonary manifestations, but also the impact on health status differs between 
patients. Some patients experience more symptoms, functional impairment, and lower 
quality of life (QoL) than would be expected based on the physiological disease severity. In 
other patients, these domains of health status are better balanced. Adaptation to the 
disease, reached by adequate self-management behaviour, plays a role in this. The primary 
aim of this study was to identify clinical phenotypes based on health status and examine 
whether these are an expression of level of adaptation. The secondary aim was to examine 
whether these clinical phenotypes show a different response in health status in usual care 
and in an inpatient pulmonary rehabilitation program (PR). 
 
Methods  
A cluster analysis was performed on baseline data of health status in 160 outpatients. Based 
on a discriminant analysis PR patients were assigned to one of the identified clusters. With 
paired t-tests the effect of usual care (n=143) and effect of PR (n= 459) on health status in 
the clusters was examined.  
 
Results  
Three phenotypes were identified that were based on the balance or imbalance between 
symptoms, impairments and QoL versus physiological disease severity. Two types were 
adapted: phenotype 1 ‘moderate COPD - low impact on health status’ and phenotype 3 
‘severe COPD - moderate impact on health status’. One type was not-adapted: phenotype 2 
‘moderate COPD - high impact on health status’. In usual care the health status of the 
patients remained unchanged over a one year period. At the end of inpatient pulmonary 
rehabilitation program (PR) significant improvements were found on four (phenotype 1) to 
ten (phenotype 2) of eleven sub-domains of health status. These improvements resulted in a 
better balance between the four domains of health status, indicating better adaptation.  
 
Conclusions  
Three clinical phenotypes were identified based on health status, that differed in the level of 
adaptation and response to treatment. Knowing to which clinical phenotype a patient 
belongs can help to optimize patient-tailored treatment.  
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BACKGROUND  
 
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable 
disease characterized by persistent airflow limitation that is usually progressive and 
associated with enhanced chronic inflammatory response in the airways and the lung to 
noxious particles or gases [1]. The various pulmonary and extra-pulmonary manifestations of 
COPD make it a complex and heterogeneous disorder [2]. In the past years, the 
acknowledgement of the heterogeneity of COPD has led to an increasing number of studies 
attempting to identify homogeneous subgroups. The hypothesis of these studies is that each 
subgroup responds differently to (pharmacological) treatment and has a different course in 
time. Identification of phenotypes would enhance patient tailored treatment and improve 
outcome [3-5].  
To date, most studies focused on identification of phenotypes based mainly, and 
sometimes exclusively, on the (patho)physiological disease characteristics of COPD [6-10]. 
However, patients with COPD not only have physiological disturbances, but also may 
experience symptoms, functional impairments, and a lowered quality of life. From this 
perspective health status can be defined as comprising of four main domains: physiological 
functioning, symptoms, functional impairments, and quality of life [11]. These main domains 
have been shown to be subdivided into many more concrete sub-domains, each 
representing unique information of a patient’s health status [12]. The main domains 
symptoms, functional impairments, and quality of life have been shown to be poorly related 
to pathophysiological aspects and the physiological functioning [2, 12, 13]. This can be 
observed in clinical practice where some patients report more severe symptoms, functional 
impairments, or lower quality of life than is expected based on physiological test results, and 
vice versa. 
 Symptoms, functional impairments, and quality of life are not solely determined by 
physiological functioning, but also by the degree to which the patient succeeds to adapt to 
the illness through adequate self-management behaviours [14-16]. Examples of self-
management strategies are: adherence to medication regimes, exacerbation management, 
adopting a healthy life style (stop smoking, regular exercising), energy saving strategies, 
breathing regulation, and stress management. Adopting self-management strategies by the 
patient will result in better adaptation to the disease and subsequently the patient will 
experience less impact on health status. However, adequate adaptation requires behaviour 
change by the patient [14, 15]. Not all patients succeed to change behaviour and as a result 
may suffer from more severe symptoms, functional impairments, and lower quality of life 
than would be expected based on physiological functioning. Identification of clinical 
phenotypes reflecting the degree of adaptation to the disease could be of added value in 
addition to pathophysiological phenotypes in guiding patient-tailored treatment.  
In the present study we investigated whether clinical phenotypes can be identified 
that reflect the level of adaptation to the disease using cluster analysis based on all four 
domains of health status. We hypothesized that adaptation to the disease is reflected by the 
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relative balance between disease severity (i.e. physiological functioning) on the one hand 
and the severity of symptoms, functional impairments and reduced quality of life on the 
other. In patients who are adapted the four domains of health status are in balance, in 
patients who are not adapted these four domains are not in balance. Although this 
balance/imbalance can be observed in clinical practice, such profiles have not yet been 
identified through empirical studies. Burgel et al. [4] already found that their clinical 
phenotypes were not based on airflow limitation and showed marked differences in quality 
of life and symptoms. In the present study we included also parameter measuring functional 
impairment. The secondary aim was to explore if these clinical phenotypes respond 
differently to usual care and to a multidisciplinary pulmonary rehabilitation program, which 
includes an intensive array of interventions aimed at improving adaptation to the disease by 
teaching the patient adequate self-management strategies in addition to exercise training. 
 
 
METHODS 
 
We used two different datasets in the present study. For the identification of the clinical 
phenotypes we used a dataset of stable COPD outpatients receiving usual care at an 
outpatient clinic (OP group). We expected that in this sample two groups of patients could 
be identified, those who are adapted to the disease and those patients who are not. In this 
sample we also investigated the course in time of these phenotypes, over a one-year period. 
To investigate response to treatment in the identified phenotypes a sample of 
patients enrolled in a multidisciplinary pulmonary rehabilitation program was used (PR 
group). This pulmonary rehabilitation program aims at improving integral health status (i.e. 
physiological functioning, symptoms, functional impairments, and quality of life) and 
contains interventions to improve physiological functioning (e.g. exercise training), but also a 
wide array of interventions to improve the adaptation to the disease by teaching the patient 
self-management behaviors (e.g. education and specific cognitive behavioral interventions). 
This program is in line with the recent ATS/ERS statement on pulmonary rehabilitation [17]. 
We expected that the majority of the patients in this sample could be labelled as non-
adapted at the start of the program and would benefit most from the pulmonary 
rehabilitation program.  
 
Subjects  
Outpatients (OP group) 
Outpatients with stable COPD were recruited between 2002 and 2005 as part of a 
longitudinal study on health status in COPD [12] at the University Lung Centre Dekkerswald 
of the Radboud University Medical Centre, Maas Hospital Boxmeer, and Rijnstate Hospital 
Arnhem. During one year all patient charts were screened by a pulmonologist, which 
resulted in 361 eligible patients, of whom 168 (47%) eventually participated. Complete 
datasets at baseline were present of 160 outpatients. COPD was diagnosed by the presence 
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of a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity 
(FVC) ratio of <70% according to the GOLD guidelines [1]. In the present study only patients 
with an FEV1% of predicted between 30% and 80% were included. Exclusion criteria were: co 
morbidity dominating health status, an acute exacerbation, recent participation in 
pulmonary rehabilitation program (within past 6 months), and inability to completely adhere 
to the research protocol. A detailed description of the recruitment procedure, the study 
sample and measurements can be found elsewhere [12]. The study was approved by the 
local Ethics committee (P02.1411L; CMO-nr2002/047) and informed consent was obtained 
from all participants. 
 
Pulmonary rehabilitation sample (PR group) 
Complete datasets were collected of 459 patients with COPD who completed a 12-week 
inpatient multidisciplinary pulmonary rehabilitation program at the University Lung Centre 
Dekkerswald of the Radboud University Medical Centre, between July 2002 and July 2013 as 
part of usual care. Based on extensive assessments and clinical interviews by seven 
disciplines (pulmonologist, psychologist, physiotherapist, nurse, dietician, psychomotor 
therapist, social worker) for each individual patient goals were set for the pulmonary 
rehabilitation program. During twelve weeks the patients followed a multidisciplinary and 
individualized treatment program, consisting of a training program, education sessions, 
group therapy and individual therapy. Every three weeks the treatment progress was 
evaluated by the seven disciplines and with the patient. If necessary the treatment program 
was adapted. Exclusion criteria for the present study: inability to speak or read Dutch and/or 
an incomplete dataset. Data collection was part of usual care and anonimised before 
analyses. 
 
Data collection 
Baseline assessments for both sample were performed during two days in the OP-sample 
and during three days in the PR-sample. During the first visit a pulmonary function tests, 
bioelectrical impedance, and maximal incremental cycle ergometry testing were performed. 
During the second visit data were collected on demographics, tobacco smoking, self-
reported co morbidities and health status was measured by the Nijmegen Clinical Screening 
Instrument (NCSI) [18]. The NCSI is a battery of existing instruments that was empirically 
composed such that overlap between instruments was avoided and that a wide variety of 
aspects of integral health status can be measured. The NCSI measures eleven sub-domains 
of integral health status (See Table 1). For all scores, the higher the score on a sub-domain 
the more problematic. In the PR-sample, on the second and third day interviews by seven 
disciplines also took place.  
All assessments (except incremental cycle ergometry) were repeated after one year 
in the OP group (complete datasets of 143 patients) and at the end of the rehabilitation in 
the PR group (459 complete datasets). 
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Table 1 Health status sub-domains and their definition and included instruments of the Nijmegen 
Clinical Screening Instrument (NCSI) 
sub-domain Definition Instruments/measurement No of 
items 
Physiological functioning    
Airflow  Post bronchodilator FEV1% of 
predicted 
 
Body Composition  Body Mass Index  
Exercise Capacity  VO2 max % of predicted  
Symptoms    
Subjective Symptoms The patient’s overall burden of 
pulmonary symptoms 
PARS-D Global Dyspnea Activity [12] 
PARS-D Global Dyspnea Burden [12] 
2 
Dyspnoea Emotions The level of frustration and 
anxiety a person experiences 
when dyspnoeic 
DEQ Frustration [12] 
DEQ Anxiety [12] 
6 
Fatigue  The level of experienced 
fatigue 
CIS Subjective fatigue [20] 8 
Functional Impairment    
Subjective Impairment The experienced degree of 
impairment in general 
QoLRiQ General Activities [21] 4 
Behavioral Impairment The extent to which a person 
cannot perform specific and 
concrete activities as a result 
of having the disease 
SIP Home Management [22] 
SIP Ambulation [22] 
22 
Quality of Life    
General Quality of Life Mood and the satisfaction of a 
person with his/her life as a 
whole 
BDI Primary Care [23] 
Satisfaction With Life Scale[24] 
12 
Health-related Quality 
 of Life 
Satisfaction related to physical 
functioning and the future 
Satisfaction physiological functioning 
[12] Satisfaction future [12] 
2 
 
Satisfaction Relations Satisfaction with the (absent) 
relationships with spouse and 
others 
Satisfaction spouse [12] 
Satisfaction social [12] 
2 
 
FEV1: Forced expiratory volume in 1 seconde; VO2max : maximal oxygen uptake; PARS-D: Physical Activity 
Rating Scale-Dyspnea; DEQ: Dyspnea Emotions Questionnaire; CIS: Checklist Individual Strength; SIP: Sickness 
Impact  
 
Statistical methods 
 
Primary aim: Identification of clinical phenotypes in the OP group 
To identify clinical phenotypes the hierarchical cluster analysis using Ward’s method (with 
squared Euclidean distance) [4, 19] was performed. Ward’s cluster analysis is applied when 
there is no prior knowledge about the number of clusters or how the clusters may be 
characterized. In this analysis grouping is based such that subjects in the same cluster are 
more similar to each other than to subjects in other clusters. The following 11 parameters 
were included in the Ward’s cluster analysis; FEV1% of predicted, body composition (BMI 
kg·m-2), exercise capacity (VO2 max% of predicted), subjective symptoms, dyspnea emotions, 
fatigue, subjective impairment, behavioral impairment, general quality of life, health related 
quality of life, and satisfaction relations. Based on the dendogram the optimal number of 
clusters can be identified.  
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Second, a one-way ANOVA and Tukey’s post hoc test were performed to determine 
whether all included variables are significantly different between the clusters.  
Third, a (stepwise) discriminant function analysis was performed to determine which 
parameters are most discriminatory between the clusters. The discriminant cluster analysis 
also creates an equation, which allows assigning new cases to the clusters. This equation was 
used to assign each of the 459 patients of the PR group into a cluster.  
 
Secondary aim: Examination of change in health status over time in usual care (OP group) 
and treatment response (PR group). 
To analyse change over time in health status sub-domains in usual care, paired t-tests were 
performed for each sub-domain in outpatients who completed the assessment one year 
later (N=143, 89.4%). For each sub-domain the score at baseline was compared to the score 
after one year (except for exercise capacity, because the maximal ergometry test was not 
performed during the second assessment). These analyses were performed on the whole OP 
group and for each cluster separately. 
Paired t-tests were performed to examine response to treatment (i.e. improvement 
in health status) in 459 patients of the PR group. The scores on the 11 outcome measures 
before rehabilitation were compared to the scores at the end of rehabilitation for the whole 
group PR group and for each of the clusters separately. 
 
All statistics are presented as mean ± standard deviation (SD) or percentage (number of 
patients, n). Differences between clusters on sex, GOLD-grade, nutritional status, tobacco 
use, and education were tested with Pearson chi square test and differences between 
clusters on age, Tiffeneau index, and number of self-reported co morbidities were analysed 
with Oneway ANOVA. Z-scores were calculated for allowing comparisons of the different 
sub-domains and to illustrate the relative distance from the total group mean (Z-score = 0). 
Z-scores were calculated as: (phenotype mean score - baseline mean score of OP group) / 
baseline standard deviation of OP group. Differences in usual care and response to 
treatment were tested with Paired t-tests. To avoid Type I error due to multiple testing P 
was set at 0.01. All statistics were performed by using SPSS16.0 (SPSS Inc, Chicago, IL.). 
 
 
RESULTS 
 
Outpatient study sample (OP group) 
The baseline characteristics of the OP group are presented in Table 2. Most patients were 
male, overweight, former smoker, low educated, and 76% reported having one or more co 
morbidities Due to normal variation in FEV1 some patients were classified as GOLD grade 1 
or GOLD grade 4 (8%). 
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Table 2 Baseline characteristics of outpatients (N=160); for total group and for each identified 
phenotype 
 Total 
group 
Phenotype 1 
(n=53) 
Phenotype 2 
(n=34) 
Phenotype 3 
(n=73) 
p-value 
Male  77  (123) 77.4  (41) 70.6  (24) 79.5  (58) 0.06 
Age (mean ±sd)  64.2 ±9.1 65.1 ±9.3 64.5 ±8.4 63.4 ±9.2 0.56 
Tiffeneau (FEV1/FVC) 42.9 ±11.4 46.9 ±9.2 46.2 ±13.0 38.6 ±10.6  
GOLD grade      <0.01 
grade 1 (mild) 2.5  (4) 5.7  (3) 3.0  (1) -  
grade 2 (moderate) 50.3  (80) 73.6  (39) 51.5  (17) 32.9  (24)  
grade 3 (severe) 42.1  (67) 20.8  (11) 42.4  (14) 57.5  (42)  
grade 4 (very severe) 5.0  (8) - 3.0  (1) 9.6  (7)  
Nutritional status       <0.01 
Underweight (BMI <21) 11.9  (19) 7.5  (4) 14.7  (5) 13.7  (10)  
Normal weight (>21 BMI <25) 35.0  (56) 54.7  (29) 11.8  (17) 31.5  (23)  
Overweight (>25 BMI <30) 37.5  (60) 30.2  (16) 50.0  (17) 37.0  (27)  
Obese (BMI >30) 15.6  (25) 7.5  (4) 23.5  (8) 17.8  (13)  
Tobacco use      <0.01 
Smoker 26.3  (42) 22.6  (12) 20.6  (7) 31.5  (23)  
Former smoker 60.0  (96) 50.9  (27) 61.8  (21) 65.8  (48)  
Never smoked 13.8  (22) 26.4  (14) 17.6  (6) 2.7  (2)  
Education      0.63 
Low 51.6  (82) 50.0  (26) 53.0  (18) 52.0  (38)  
Middle  30.2  (48) 28.58  (15) 23.5  (8) 34.3  (25)  
High  18.2  (29) 21.1  (11) 23.5  (8) 13.7  (10)  
Co morbidities (self-reported)  1.34 ± 1.25 1.25 ±1.00 2.41 ±1.46 0.92 ±1.02 <0.01 
None  28.1  (45) 24.5  (13) 5.9  (2) 41.1  (30)  
Fatigue  30.0  (48) 22.6  (12) 70.6  (24) 16.4  (12)  
Back pain 30.6  (49) 32.1  (17) 38.2  (13) 26.0  (19)  
Rheumatoid arthritis 24.4  (39) 15.1  (8) 61.8  (21) 13.7  (10)  
Psychological problems 6.3  (10) - 26.5  (9) 1  (1)  
Diabetes mellitus 5.0  (8) 7.5  (4) 2.9  (1) 4.1  (3)  
Cancer  3.1  (5) 3.8  (2) 2.9  (1) 2.7  (2)  
Cardiac disease  7.5  (12) 5.7  (3) 14.7  (5) 5.5  (4)  
Other 27.5  (44) 37.7  (20) 23.5  (8) 21.9  (16)  
Data are expressed as % (N) or mean ± SD; FEV1%: Forced expiratory volume in 1 second; FVC: Forced Vital 
Capacity; GOLD: global initiative for chronic obstructive lung disease; BMI: body mass index 
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Figure 1 Dendogram showing the results of the Ward’s cluster analysis in 160 outpatients with COPD. 
Note: Each line at the vertical axis represents a patient. Patients who are more similar to each other 
than to other patients are grouped together. The length of the horizontal lines represents the degree 
of similarity between the patients in the groups.  
 
Identification of clinical phenotypes in the OP group 
The hierarchical cluster analysis using Ward’s method on data of 160 patients of the OP 
group produced three clusters (Figure 1). Significant differences were found on baseline 
characteristics between the three clusters in BMI categories, tobacco use, and number of 
self-reported co morbidities (Table 2). The One-way ANOVA Tukey’s post hoc test showed 
that the three clusters were significantly different on all included sub-domains, except for 
body composition (BMI, Table 3). 
The first cluster (phenotype 1) was characterized by having moderate COPD, normal 
weight, high performance on exercise capacity, and mild impact on symptoms, functional 
impairments, and quality of life (Table 2, Table 3 and Figure 2). Cluster 2 (phenotype 2) 
patients were characterized by moderate COPD, overweight, moderate performance on 
exercise capacity, and with high impact on symptoms, impairment, and quality of life. Cluster 
3 (phenotype 3) patients were characterized by severe COPD, overweight, moderate 
performance on exercise capacity, and mild impact on symptoms, impairment, and quality of 
life.  
Although comparable on FEV1% predicted and BMI with phenotype 1, phenotype 2 
patients had significantly higher scores on all sub-domains of symptoms, functional 
impairment, and quality of life compared to phenotype 1 (Table 3 and Figure 2). 
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Figure 2 Mean z-scores on the sub-domains for each phenotype.  
Note: All scores the higher the more problematic, for this figure the FEV1% of predicted and VO2 % 
max of predicted were mirrored. 1= ‘moderate COPD –mild impact on health status’; 2= ‘moderate 
COPD - high impact on health status’; 3= ‘severe COPD - mild impact on health status’ 
 
Phenotype 3 patients had significantly poorer FEV1% predicted than phenotype 2, but 
reported significantly lower impact on symptoms, functional impairment and quality of life 
when compared to phenotype 2. Remarkably, phenotype 3 had more severe COPD than 
phenotype 1, but had similar mild impairment in five out of six sub-domains of the main 
domains symptoms and quality of life (p >0.01). 
 Discriminant analysis showed that 95% of the OP group could correctly be classified 
by the following five variables: VO2% predicted, FEV1% predicted, general quality of life, 
behavioral impairments, and fatigue.  
 
Pulmonary rehabilitation study sample (PR group) 
Baseline characteristics of the 459 COPD patients of the PR group are presented in table 4. 
Almost half was female, most had moderate to very severe COPD, were former smoker, low 
educated, and 72% reported having one or more co morbidities. Based on the equation from 
the discriminant analysis the patients of the PR group were assigned into one of the three 
phenotypes. Whereas patients of the OP group primarily were identified as phenotype 1  
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Table 4 Baseline characteristics of patients who completed pulmonary rehabilitation; for total 
group and each phenotype 
 total group 
(N=459) 
Phenotype 1 
(n=27) 
moderate COPD - 
mild impact 
health status 
Phenotype 2 
(n=271) 
moderate COPD 
- high impact 
health status 
Phenotype 3 
(n=161) 
severe COPD 
- mild impact 
health status 
Male  53.5  (243) 50.0  (13) 46.5  (125) 66.0  (105) 
Age  60.5 ±8.8 58.4 ±9.2 60.5 ±8.8 60.8 ±8.8 
Tiffeneau (FEV1/FVC)  36.7 ±12.1 46.8 ±10.9 38.9 ±12.2 31.3 ±9.8 
GOLD grades      
grade 1 (mild) 3.8  (17) 12.0  (3) 4.9  (13) 0.6  (1) 
grade 2 (moderate) 22.3  (100) 56.0  (14) 26.6  (71) 9.6  (15) 
grade 3 (severe) 47.0 (211) 28.0  (7) 48.3  (129) 47.8  (75) 
grade 4 (very severe) 26.9  (121) 4.0  (1) 20.2  (54) 42.0  (66) 
Nutritional status       
Underweight (BMI <21) 14.7  (67) 18.5  (5) 14.1  (38) 14.9  (24) 
Normal weight (>21 BMI <25) 34.6  (158) 40.7  (11) 32.7  (88) 36.6  (59) 
Overweight (>25 BMI <30) 32.2  (147) 37.0  (10) 27.5  (74) 39.1  (63) 
Obese (BMI >30) 18.6  (85) 3.7  (1) 25.7  (69) 9.3  (15) 
Tobacco use      
Smoker 10.8  (49) 3.8  (1) 13.0  (35) 8.2  (13) 
Former smoker 84.6  (384) 76.9  (20) 83.3  (224) 88.1  (140) 
Never smoked 4.6   (21) 19.2  (5) 3.7  (10) 3.8  (6) 
Education      
Low 51.9  (235) 34.6  (9) 54.9  (147) 49.7  (79) 
Middle  34.6  (157) 50.0  (13) 33.2  (89) 34.6  (55) 
High  13.5  (61) 15.4  (4) 11.9  (32) 15.7  (25) 
Co morbidities (self-reported)  1.53 ±1.27 0.88 ±0.82 1.85 ±1.30 1.09 ±1.12 
None  24.0  (109) 38.5  (10) 14.1  (38) 38.4  (61) 
Fatigue  44.1  (200) 38.5  (10) 53.9  (145) 28.3  (45) 
Back pain 24.4  (111) 7.7  (2) 30.0  (81) 17.6  (28) 
Rheumatoid arthritis 20.9  (95) 11.5  (3) 26.4  (71) 13.2  (21) 
Psychological problems 16.3  (74) 3.8  (1) 22.7  (61) 7.5  (12) 
Diabetes mellitus 9.9  (45) 3.8  (1) 11.9  (32) 7.5  (12) 
Cancer  1.3  (6) - 1.9  (5) 0.6  (1) 
Cardiac disease  15.9  (72) 11.5  (3) 17.1  (46) 14.5  (23) 
Other 20.3  (92) 11.5  (3) 21.2  (57) 20.1  (32) 
Data are expressed as % (N) or mean ± SD; FEV1%: Forced expiratory volume in 1 second; FVC: Forced Vital 
Capacity; GOLD: global initiative for chronic obstructive lung disease; BMI: body mass index 
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‘moderate COPD with mild impact on health status’ or phenotype 3 ‘severe COPD with mild 
impact on health status’ (33% and 46%, respectively), patients in the PR group primarily 
were identified as phenotype 2 ‘moderate COPD with high impact on health status’ (59% vs 
21% in the outpatient sample) and only 6% was identified as phenotype 1 ‘moderate COPD 
with mild impact on health status’.  
 
Differences in change in health status between phenotypes in usual care (OP group) and in 
treatment response (PR group) 
Of the 160 outpatients, 143 patients (89.4%) also participated one year later. Reasons for 
non-adherence were diverse, but no significant differences were found on the eleven 
outcome variables nor on the baseline characteristics between the responders and non-
responders (data not shown). On a group level only significant change was found on fatigue 
between baseline and follow-up (p < 0.01, Table 5). Between phenotypes only very few 
significant differences were found over the one-year period in usual care. Phenotype 1 
patients had significantly higher scores (more problems) in fatigue and health-related quality 
of life, and phenotype 3 patients had significant better FEV1% predicted (p < 0.01, Table 5). 
 
Significant improvements were found in 10 of 11 sub-domains in the total PR group 
when post-rehabilitation scores were compared to pre-rehabilitation scores (Table 6). Major 
differences were found between the three phenotypes in the number of significantly 
improved sub-domains at end of rehabilitation, varying from four (phenotype 1) to ten 
significantly improved sub-domains (phenotype 2) (Table 6). The different patterns of 
improvement between the three phenotypes for each sub-domain are presented in Figure 3. 
 
 
DISCUSSION 
 
In the present study we identified three clinical phenotypes based on a wide variety of 
parameters measuring aspects of physiological functioning, symptoms, functional 
impairment, and quality of life in a group of outpatients with stable COPD GOLD 2-3. The 
main differences between phenotypes were based on the relative balance between 
physiological disease severity on the one hand and the severity of symptoms, functional 
impairment, and quality of life on the other, which is assumed to be a reflection of the 
degree of adaptation to the disease. There was no change in almost any of the health status 
sub-domains in the usual care group over a one-year period, but there were significant 
improvements in almost all of the health status sub-domains in patients who were included 
in the pulmonary rehabilitation program.  
Phenotype 1 (‘moderate COPD – low impact’) was characterized by moderate COPD 
and mild problems in the domains symptoms, functional impairment, and quality of life, 
which were in balance with disease severity. Clearly, this phenotype can be labelled as 
‘adapted’. Phenotype 2 (’moderate COPD - high impact’) experienced severe problems in 
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health status despite moderate disease severity. In these patients there is a clear imbalance 
between disease severity and impact on symptoms, functional impairment, and quality of 
life. Therefore this phenotype was labelled as ‘non-adapted’. Phenotype 3 (‘severe COPD – 
low impact’) is more difficult to interpret. In fact, similar to phenotype 2, an imbalance was 
observed between disease severity on the one hand and severity of symptoms, functional 
impairment, and quality of life, but in reversed direction. Phenotype 3 patients showed 
much lower impact on symptoms, functional impairment, and quality of life than would be 
expected based on their severe COPD. Does this particular imbalance in phenotype 3 
indicate extremely well adapted patients? Or does this imbalance indicate non-adapted 
patients. In clinical practice patients who report mild or no symptoms, functional 
impairment, and good quality of life despite severe COPD are well recognized.  In some of 
these patients this may be a reflection of very adequate adaptation to the disease. But other 
patients with this profile tend to ignore and trivialize their symptoms, or simple are not 
sensitive to bodily symptoms, which eventually may lead to an escalation of problems in 
health status. These patients in clearly are not well adapted. This subgroup of patient may 
be labelled ‘at risk’. Future research and clinical testing is needed to shed more light on this 
particular phenotype.  
In searching for more homogeneous COPD subgroups, this is the first study that 
includes such a large set of parameters measuring symptoms, functional impairment, and 
quality of life, in addition to parameters measuring physiological functioning. In line with 
other studies performing cluster analysis [3, 4] we confirmed that airflow limitation was not 
the only characteristic in the identified clinical phenotypes. Burgel et al [4] found marked 
differences between phenotypes in reported symptoms and quality of life regardless of 
COPD severity. We observed the same phenomenon in the present study, but also 
incorporated functional impairment as a domain and examined the role of adaptation in the 
identified clusters. The discriminant analysis revealed that all four main domains of health 
status are relevant in this respect, as shown by the fact that of each main domain one or two 
sub-domains were necessary to assign new patients to one of the identified clinical 
phenotypes. 
Studies to date using cluster analysis recommend to evaluate treatment response [3, 
5, 20-23]. Although such studies have been performed evaluating the effect of 
pharmacological treatment in diverse phenotypes [24, 25], similar studies with respect to 
non-pharmacological treatments are lacking. In the usual care group over one year only 
significant changes were found in fatigue. The pulmonary rehabilitation program, with its 
strong emphasis on teaching the patient self-management strategies in order to improve 
adaptation to the disease did show major improvements in health status. Especially in the 
non-adapted phenotype 2 the improvements in experienced symptoms, impairment and 
quality of life were most pronounced.  
With respect to the change in health status over a one-year period in the usual care 
sample (OP group), on a group level significant changes were found only in fatigue.  
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Figure 3 Mean scores on each sub-domain at start and end of pulmonary rehabilitation for each 
phenotype Note: the vertical axis displays the minimal and maximal score for that specific sub-
domain. Higher scores mean more impact on the sub-domain, except for FEV1% of predicted and VO2 
max% predicted where 100% represent the ideal score. 
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In contrast, in the PR group statistically significant and clinically relevant improvements were 
found in all sub-domains except for airflow limitation. Moreover, the three clinical 
phenotypes showed a different pattern of change in the sub-domains of health status with 
respect to response to treatment.  
 
Limitations 
In the present study we included a group of patients with stable GOLD moderate to severe  
COPD (II-III) and we excluded co-morbidities dominating health status to identify clinical 
phenotypes. This selection of patients may limit generalizability of the results. Ideally, the 
cluster analysis should be replicated in a group of COPD patients with the complete 
spectrum of GOLD I-IV to examine whether all possible clinical phenotypes based on health 
status were identified. 
We included a limited set of systemic effects of COPD (FEV1, BMI, RV and TLC). 
Theoretically, other systemic effects such as muscle strength may/could be responsible for 
the observed discrepancies. Future studies should examine the role of systemic effects of 
COPD in these clusters, especially in phenotype 2. 
Although, low numbers of non-adapted patients (phenotype 2) were found in the OP 
group, we found similar profiles in the PR group with respect to the balance/imbalance 
between the domains in phenotype 2. Due to the low number of patients in phenotype 1 
‘moderate COPD-mild impact on health status’, in the PR group, the effect of rehabilitation 
in phenotype 1 patients should be interpreted with caution.  
In this study the timeframes to examine the effect of usual care and the inpatient 
pulmonary rehabilitation on health status were different. This could lead in favour of the 
effects of pulmonary rehabilitation on health status. Ideally, data from one year after 
completion of the inpatient pulmonary rehabilitation program would be compared to the 
data before the pulmonary rehabilitation to examine whether the PR effects remain stable 
over a one-year follow-up, and in particular if patients remain more adapted than compared 
to start of rehabilitation.  
 
Implications  
The findings of the present study and other studies that performed cluster analysis have 
important implications for future studies and clinical practice. These studies have shown that 
COPD patients represent a very heterogeneous group of persons. Using cluster analyses it is 
possible to identify more homogeneous sub-groups that respond differently to 
pharmacological and non-pharmacological treatment. The present study showed that, 
besides phenotypes based on different pathophysiological mechanisms, also phenotypes 
exists that are more determined by behavioral aspects (i.e. adapting to the disease by self-
management behaviours).  
Knowing which type of patients will benefit from specific interventions, will help in 
guiding patient tailored treatment and improve outcome and cost-effectiveness of both 
pharmacological and non-pharmacological treatment. Eventually, this could lead to different 
sets of custom made interventions that are effective for a specific phenotype. 
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Usual care generally has a focus on physiological assessment and pharmacological 
treatment. The fact that in the usual care group (OP group) 20% of patients was classified as 
non-adapters calls for the need of regular screening for the degree of adaptation to the 
disease as part of usual care. In addition, in the usual care group non-adapted patients did 
not show any improvement in health status, whereas non-adapted patients showed major 
improvements in health status in the pulmonary rehabilitation group. Clearly, non-adapted 
patients profit from interventions aimed at improving self-management behaviour, which is 
one of the key components of the pulmonary rehabilitation program as stated by the 
American Thoracic Society and European Respiratory Society (ATS/ERS) [17]. In adapted 
patients probably a limited selection of treatment modalities may be sufficient. Future 
studies are necessary to identify the minimal treatment components for each clinical 
phenotype to optimize physiological functioning and adaptation to the disease in a patient. 
Phenotype 3 ‘severe COPD and mild impaired health status’ patients, are a group of 
patients that need special attention. Although some of these patients may be well adapted 
to the disease, others may be at risk for poor adaptation by ignoring symptoms and 
impairments. Moreover, these patients have severe COPD. Regular check-ups of these 
patients are warranted. 
 
Conclusions 
Studies to date identified phenotypes that are mainly based on different underlying 
pathophysiological mechanisms. In the present study we have identified phenotypes that are 
based more on behavioral aspects. Whereas, pathophysiological phenotypes may help 
guiding pharmacological treatment, the phenotypes identified in the present study may help 
to improve (cost-)effectiveness of non-pharmacological treatments, such as self-
management programs and pulmonary rehabilitation programs.   
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ABSTRACT 
 
Background  
Patients with severe asthma experience problems in different areas of their health status. 
Identification of these areas will provide insight in the patients needs and perhaps what 
determines the burden of disease. The Nijmegen Clinical Screening Instrument (NCSI) was 
recently developed for use in clinical practice in patients with COPD and provides a detailed 
picture of the patients’ physiological functioning, symptoms, functional impairment, and 
Quality of Life. Main purpose of this study is to evaluate the use of the NCSI to measure 
health status as compared to the Asthma Control Questionnaire (ACQ) and Asthma Quality 
of Life Questionnaire (AQLQ) in patients with severe asthma. 
 
Methods  
The NCSI, AQLQ, and ACQ were measured in 167 patients with severe asthma. Pearson 
correlations were calculated between NCSI sub-domains and the AQLQ domains and the 
ACQ. 
 
Results  
The NCSI measures more aspects of health status as compared to the ACQ and AQLQ in 
patients with severe asthma. Beside symptoms, subjective impairment, and emotions the 
NCSI also measures general Quality of Life, health related Quality of Life, satisfaction with 
relations, fatigue, and behavioral impairment. On all NCSI sub-domains proportions of 
patients with normal, mild, and severe problems were found. Heterogeneity was found on 
the number and on the combination of sub-domains on which patients reported severe 
problems.  
 
Conclusions  
The NCSI provides a more detailed picture of the individual patient with severe asthma than 
the ACQ and AQLQ. The use of the NCSI might allow quick identification of the problem 
areas and possible factors that impair health status. 
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INTRODUCTION 
 
Patients with severe asthma suffer from serious problems in health status, such as 
symptoms during day- and nighttime [1], impairments in daily life activities [2], and lower 
quality of life (QoL)[3-6]. For adequate assessment and management of patients with severe 
asthma a detailed evaluation of patients’ needs would be helpful to identify the factors that 
influence their health status. An instrument that provides a detailed picture of the different 
aspects of the patient’s health status would be very useful. This information would guide 
treatment, help to open up the communication with the patient, and to improve the 
patient’s self-management. 
Many disease specific and generic questionnaires exist that measure aspects of 
health status. In asthma the Asthma control Questionnaire (ACQ) and Astma Quality of Life 
Questionnaire (AQLQ) and to a lesser extend the, St George Respiratory Questionnaire 
(SGRQ) and Quality of Life for Respiratory Illness Questionnaire (QoL-RiQ) are used for this 
purpose [7-10]. These instruments, especially the AQLQ and ACQ, are widely used in 
research, have proven to be valid, reliable, and are able to measure change, to describe 
groups and effects of interventions. However, on the level of the individual patient and in 
clinical care these instruments seem less appropriate. The ACQ only indicates whether the 
asthma is controlled or uncontrolled in a patient and provides no information on health 
status. The AQLQ measures only four domains, and lacks normative data,  which means  that  
the clinical relevance of particular scores on the level of the individual patient is unclear.  
The Nijmegen Clinical Screening Instrument (NCSI) was specifically developed for use 
in clinical care of patients with COPD,  to detect the problems in health status on individual 
patient base [11]. The NCSI measures eleven sub-domains of health status covering aspects 
of physiological functioning, symptoms, functional impairment and Quality of life with a 
battery of subscales from disease specific and generic questionnaires, as well as the results 
of lung function test. For each sub-domain of the NCSI normative data indicating normal 
functioning, mild problems and severe problems were collected. Immediately after the 
patient has completed the questionnaire part on the computer, are the results presented on 
the graphical PatientProfileChart (Figure 1)[11]. 
Although developed and validated in patients with COPD [11], have previous studies 
shown that all NCSI sub-domains are relevant in other diseases as well, including Q-fever[12, 
13], and cardiac diseases (submitted). We hypothesized that the NCSI can be used also in 
patients with asthma. Astma and COPD have overlapping clinical characteristics and both 
patient groups report similar problems in health status. Moreover, patients with severe 
asthma are known to experience severe symptoms, functional impairment, and lower QoL 
[1-6]. Therefore, a group of patients with severe asthma would be most suitable to examine 
whether the NCSI can identify  problems in health status in patients with severe asthma.   
The main purpose of this study is to evaluate the NCSI in measuring the unmet needs 
in patients with severe asthma. The primary aim is to evaluate the internal consistency of 
the NCSI, and to investigate the relationships between the sub-domains of the NCSI, the ACQ  
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 Figure 1 The PatientProfileChart a graphical representation of the patient’s scores on the diverse 
aspects of health status as measured by the NCSI. Note: in this figure we plotted the mean score of 
the study group (blue dots) on that particular aspect instead of the individual score which is normally 
plotted in the graphs. The green area represents normal functioning, yellow area mild problems, and 
red area severe problems 
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total, and the AQLQ domains in patients with severe asthma. The secondary aim is to 
evaluate to what extent the NCSI measures other sub-domains of health status as compared 
to the disease specific AQLQ and ACQ, and whether these sub-domains are relevant in 
patients with severe asthma. 
 
 
MATERIALS AND METHODS 
 
Study design 
This cross-sectional study was conducted in patients with severe asthma who were referred 
to the Dutch Asthma Centre in Davos for high altitude treatment. On admission, all patients 
were assessed according to a systematic protocol. The study was approved by the Medical 
Ethical Committee of the Amsterdam Medical Centre and the approval was adopted by the 
Asthma Centre Davos. Written informed consent was obtained from all patients participating 
in the study. All data was collected in usual care, shortly after admission, and anonymized 
before analysis. 
 
Study population 
Adult patient (18-75 years) with a diagnosis of severe asthma who were referred to the 
Dutch Asthma Centre Davos, Switzerland, between January 2008 and January 2010 were 
asked to participate in the study. Severe asthma was defined according to the international 
criteria [14]. Dutch lung physicians send patients with severe asthma to the high altitude 
clinic in Davos, when optimal treatment, according to the GINA guidelines at sea level is not 
enough to reach control of asthma [15].  All patients were prescribed high doses of inhaled 
corticosteroids (≥ 1000µg·day of fluticasone or equivalent) or oral corticosteroids, combined 
with long-acting bronchodilators for at least 1 year, in accordance to the GINA Guidelines 
stages 4-6 [15]. Most patients also used additional asthma medications (e.g. antihistamines, 
montelukast. Theaphylline etc). Patients with a smoking history >15 years, had to show 
reversibility in FEV1 to short-acting beta agonist >12 % predicted in order to exclude patients 
with smoking related COPD. All patients were symptomatic and had experienced at least one 
severe exacerbation during the past year requiring a course of oral corticosteroids. Before 
referral to the high altitude clinic, inhalation technique and adherence with treatment was 
checked by the referring pulmonologist.  
 
Questionnaires 
AQLQ. The Asthma Quality of Life Questionnaire standardized version (AQLQ-S) [1, 8] 
measures four domains: symptoms, activity limitation, emotional function, and 
environmental stimuli. Score range from 1 to 7, lower scores indicate more problems. 
ACQ. The Asthma Control Questionnaire (ACQ) [7, 16] consists of six items which are 
scored from 0 ( totally controlled) to 6 ( severely uncontrolled) covering day and nighttime 
symptoms, activity limitations and rescue bronchodilator use. 
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Table 1 Domains, sub-domains, definitions, instruments and number of included  items from the 
instrument of the questionnaire part of the Nijmegen Clinical Screening Instrument (NCSI). 
Domain/ sub-domain Definition Instruments/measurement Number 
of items 
Physiological functioning    
Airflow  Post bronchodilator  
FEV1%  predicted 
 
 
Body Composition  Body Mass Index 
 
 
Symptoms    
Subjective Symptoms The patient’s overall burden of 
pulmonary symptoms 
PARS-D Global Dyspnea 
Activity [20] 
PARS-D Global Dyspnea 
Burden [20] 
2 
Dyspnea Emotions The level of frustration and anxiety a 
person experiences when dyspnoeic 
DEQ Frustration [20] 
DEQ Anxiety [20] 
6 
Fatigue  The level of experienced fatigue CIS Subjective fatigue [21] 8 
Functional Impairment    
Behavioral Impairment The extent to which a person cannot 
perform specific and concrete 
activities as a result of having the 
disease 
SIP Home Management [22] 
SIP Ambulation [22] 
22 
Subjective Impairment The experienced degree of 
impairment in general 
QoLRiQ General Activities 
[10] 
4 
Quality of life    
General Quality of Life Mood and the satisfaction of a 
person with his/her life as a whole 
BDI Primary Care [17] 
Satisfaction With Life Scale 
[19] 
12 
Health-related Quality  
of Life 
Satisfaction related to physical 
functioning and the future 
Satisfaction physiological 
functioning [20] 
Satisfaction future [20] 
2 
 
Satisfaction Relations Satisfaction with the (absent) 
relationships with spouse and others 
Satisfaction spouse [20] 
Satisfaction social [20] 
2 
 
PARS-D: Physical Activity Rating Scale-Dyspnea; DEQ: Dyspnea Emotions Questionnaire; CIS: Checklist 
Individual Strength; SIP: Sickness Impact Profile; QoLRiQ: Quality of Life for Respiratory Illness Questionnaire; 
BDI, Beck Depression Inventory 
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The cut-off point for well controlled asthma is lower than 1.5 [7]. 
NCSI. The Nijmegen Clinical Screening Instrument (NCSI)[11] is a battery of existing 
tests and disease specific and generic instruments that provide a detailed assessment of 
health status. The NCSI covers four main domains: physiological functioning, symptoms, 
functional impairment, and quality of life. These main domains are subdivided into eleven 
sub-domains that measure: airflow, body composition, static lung volumes (excluded in the 
present study), subjective symptoms, dyspnea emotions, fatigue, behavioral impairment, 
subjective impairment, general QoL, health related QoL, and satisfaction relations. See Table 
1 [10, 17-22 ] for the definitions of the sub-domains and the included tests and instruments 
by which these sub-domains are measured. Completion of the questionnaire part of the NCSI 
is computerized [22] and scoring is automated. Normative data for each subscale were 
collected in healthy subjects and different samples of patients with COPD to identify cut-offs 
scores indicating normal functioning, mild problems or severe problems [11]. For each 
patient a personal profile can be made visible on the PatientProfileChart, see figure 1. For all 
sub-domains: the higher the score the more problematic. 
 
Measures 
Lung function parameters. Forced expiratory volume in 1 second (FEV1) was assessed after 
maintenance medication and inhalation of 400 µg salbutamol. Exhaled nitric oxide 
measurements were performed by standardized method [23] using the NIOX.  
Sensitisation to specific IgE was assessed with a panel of common aero-allergens (house dust 
mite, mixed grass and birch pollen, cat and dog dander and Aspergillus) by UniCap and 
expressed in kU/L. Patients were classified as allergic sensitized if IgE to one or more 
allergens was > 0.35 kU/l. 
 
Statistics 
Data are presented as mean ± standard deviation (SD), unless stated otherwise. Cronbach’s 
Alpha reliability coefficients were calculated to study the internal consistency reliability of 
the items of each sub-domain/subscale of the NCSI, ACQ and AQLQ, an α > 0.70 is 
considered reliable. Pearson correlation coefficients were calculated to study the 
relationships between the sub-domains of the NCSI, the ACQ total, and the subscales of the 
AQLQ. Conceptual similarity was defined by a correlation of 0.70 or higher. To avoid Type I 
error due to multiple testing P was set at 0.01. All statistics were performed by using SPSS 
16.0 (SPSS Inc, Chicago, IL.). 
 
 
RESULTS 
 
Subject characteristics 
One hundred and eighty patients were admitted to the high altitude clinic between January 
2008 and January 2010, of which 167 agreed to participate in the study. Thirteen patients 
96 | C H A P T E R  6  
 
 
were not able to fill the questionnaires adequately because of illiteracy or did not agree to 
participate for personal reasons. The baseline characteristics of the 167 patients with severe 
asthma included in this study are presented in Table 2. Uncontrolled asthma was found in 
91% (ACQ >1.5) of the patients in this study.  
 
NCSI-scores in severe asthma patients 
Overall, high percentages of severe problems were found in the sub-domains of symptoms, 
functional impairment, and QoL (Fig 2.). The most prevalent sub-domains with severe 
impairment were subjective symptoms (82.0%), fatigue (90.4%), subjective impairment 
(86.8%), and general QoL (81.4%). Furthermore, 31.7% of the patients had clinically relevant 
 
Figure 2 Percentages of patients with asthma with normal functioning, mild problems and severe 
problems for each sub-domain of the NCSI 
Table 2 Patient characteristics (N = 167) Data are presented as N (%), mean ± SD or median 
(range), unless otherwise stated. 
  
Age (yrs) 44.5 ± 15 
Sex (male) N (%) 58 (35%) 
Asthma duration (yrs) 30 (1-66) 
Sensitized to allergens 112 (67%) 
BMI 28.1 ( range 16.8-54.5) 
Ex-smokers 57 (34%) 
FEV1% pred. 87.7 ± 24.5 
FeNO ppb 20.7 (4-233) 
ACQ score 3.2 ± 1.1 
ICS µg/day 0-8000 
Daily OCS N (%) 82 (49%) 
BMI: body mass index; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FeNO: exhaled nitric 
oxide fraction; ACQ: Asthma Control Questionnaire score, 0-6, where 0 = well controlled; ICS: inhalation 
corticosteroids; OCS: oral corticosteroids. 
H E A L T H  S T A T U S  M E A S U R E M E N T  I N  A S T H M A  | 97 
 
 
Figure 3 Distribution of percentages of patients with severe asthma with severe problems on n 
number of sub-domains of the NCSI 
 
depressive symptoms (subscale within sub-domain general QoL, not shown). 
Diversity between patients was found in the number of sub-domains with severe 
problems (Figure 3). Nineteen percent of patients were severely impaired in all eight sub-
domains of the NCSI, and 80% of patients had five or more severely impaired sub-domains.  
 
Inter correlations of the questionnaires 
With respect to the AQLQ, the domain activity reached conceptual similarity with the 
domain symptoms and environmental stimuli, although the latter two domains were only 
moderately related (Table 3).  
Correlations between most of the NCSI sub-domains were moderate to absent, as 
shown in Table 4. Only the sub-domains subjective symptoms and subjective impairment 
reached the criterion for conceptual similarity (r > 0.70), indicating that these two sub-
domains measure highly related concepts.  
 
Table 3 Correlations between the subscales of the Asthma Control Questionnaire (ACQ) and 
domains of the Asthma Quality of Life Questionnaire (AQLQ). 
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ACQ total   1.00      
AQLQ symptoms -0.83 1.00     
AQLQ activity limitation -0.67 0.85 1.00    
AQLQ emotional stimuli -0.35 0.54 0.39 1.00   
AQLQ environmental stimuli -0.35 0.48 0.69 0.34 1.00  
AQLQ total -0.74 0.90 0.91 0.64 0.73 1.00 
Note. N = 167.  Correlations > 0.70 in bold. 
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Table 4 Correlations between the sub-domains of the Nijmegen Clinical Screening Instrument (NCSI). 
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Physiological  FEV1% of predicted -0.23   -0.13 
ns 0.04 ns -0.19ns -0.19 ns -0.05ns -0.07 ns -0.14ns 
functioning FeNO 0.09 ns 0.18 ns -0.15 ns 0.06 ns -0.09 ns 0.14 ns 0.04 ns -0.01ns 
 BMI 0.23 0.05 ns 0.01 ns 0.23 0.23 ns 0.03 ns 0.17 ns 0.01ns 
Symptoms subjective symptoms 1.00        
 dyspnea emotions 0.35 1.00       
 fatigue 0.37 0.09 ns 1.00      
Functional  subjective impairment 0.71 0.25 0.46 1.00     
impairment behavioral impairment# 0.34 ns 0.18 ns 0.32 ns 0.34 1.00    
Quality of Life general QoL 0.24 0.67 0.20 ns 0.23 0.34 ns 1.00   
 health related QoL 0.47 0.43 0.41 0.54 0.43 0.67 1.00  
 satisfaction relations 0.17 ns 0.29 0.09 ns 0.20 ns 0.26 ns 0.52 0.45 1.00 
Note.  N=167 except for behavioral impairment due to a technical error (N=53).  
Table 5 Cronbach’s reliability coefficient (α), score range, mean ±SD and 95% confidence interval of 
the three questionnaires, the Asthma Control Questionnaire (ACQ), the Asthma Quality of Life 
Questionnaire (AQLQ) and the Nijmegen Clinical Screening Instrument (NCSI)  in patients with 
severe asthma (N = 167). 
  Cronbach’s 
Alpha 
Score 
range 
Mean ± SD [95% CI] 
ACQ total 0.87 0-6 3.2 ± 1.1 [2.9 - 3.3] 
AQLQ symptoms 0.88 1-7* 3.9 ± 1.1 [3.7 – 4.1] 
 activity limitation 0.88 1-7* 3.5 ± 1.2 [3.3 – 3.6] 
 emotional function 0.84 1-7* 4.9 ± 1.3 [4.7 – 5.1] 
 environmental stimuli  0.77 1-7* 4.2 ± 1.5 [4.0 – 4.5] 
 total  1-7* 4.0 ± 1.0 [3.8 – 4.1] 
NCSI-Symptoms subjective symptoms 0.89 2-20 14.1 ± 4.2 [13.5 – 14.8] 
 dyspnea emotions 0.83 6-24 12.0 ± 4.0 [11.4 – 12.6] 
 fatigue 0.82 8-56 47.1 ±8.7 [45.8 – 48.5] 
NCSI-Functional impairment behavioral impairment # 0.79 0-99.2 26.2 ± 20.5 [20.5 – 31.8] 
 subjective impairment 0.89 4-28 17.7 ± 5.4 [16.9 – 18.5] 
NCSI- Quality of life general QoL 0.54 1-101.6 28.0 ± 17.8 [25.3 – 30.7] 
 health related QoL 0.47 2-10 6.1 ± 1.7 [5.8 – 6.3] 
 satisfaction relations 0.62 2-10 4.1 ± 2.0 [3.8 – 4.4] 
Note. Pearson correlations between the sub-domains of the NCSI , the ACQ, and  the AQLQ for patients with 
asthma at start of rehabilitation. N = 167 except for behavioral impairment due to technical error (N = 53). * 
Lower scores indicate more problems 
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Table 6 Correlations between the sub-domains of the Nijmegen Clinical Screening Instrument 
(NCSI), the Asthma Control Questionnaire (ACQ), and the Asthma Quality of Life Questionnaire 
(AQLQ)  to examine conceptual similarity. 
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Physiological functioning       
FEV1% predicted -0.26    0.16 
ns 0.09 ns 0.20 ns 0.01 ns 0.14 ns 
FeNO 0.12 ns -0.07 ns 0.05 ns -0.12 ns 0.19 ns 0.01 ns 
BMI 0.18 ns -0.12 ns -0.16 ns -0.07 ns -0.02 ns -0.13 ns 
NCSI symptoms       
subjective symptoms 0.66 -0.67 -0.58 -0.40 -0.29 -0.64 
dyspnea emotions 0.21 -0.30 -0.16 ns -0.69 -0.16 ns -0.36 
fatigue 0.44 -0.47 -0.43 -0.16 ns -0.19 ns -0.43 
NCSI functional impairment       
behavioral impairment# 0.49 -0.53 -0.59 -0.41 -0.39 -0.60 
subjective impairment 0.77 -0.70 -0.65 -0.37 -0.30 -0.68 
NCSI Quality of Life       
general QoL 0.18 ns -0.29 -0.21 -0.54 -0.23 -0.36 
health related QoL 0.40 -0.46 -0.42 -0.50 -0.24 -0.50 
satisfaction relations 0.15 ns -0.18 ns -0.25 -0.31 -0.23 -0.27 
Note. Pearson correlations between the sub-domains NCSI, ACQ, AQLQ for patients with difficult to control 
asthma at start of rehabilitation. N = 167 except for behavioral impairment due to technical error (N = 53). 
Correlations > 0.70 in bold. Correlations in ‘bold-italic’ nearly reach conceptual similarity.ns = not significant. 
 
Reliability of the questionnaires 
For all sub-domains the internal consistency was good, irrespective of the questionnaire 
used, except for the NCSI sub-domains of QoL see Table 5. However, the Cronbach’s alpha of 
the two separate subscales that together measure general QoL was good (Satisfaction With 
Life Scale (SWLS) 0.88 and Beck’s Depression Inventory (BDI) 0.83, respectively. 
 
Conceptual similarity between the questionnaires 
The ACQ-total score reached conceptual similarity with AQLQ-symptoms and nearly with 
AQLQ-activity limitations (Table 6). The ACQ-total showed conceptual similarity only with 
NCSI subjective impairment, and nearly with NCSI subjective symptoms. 
The AQLQ-symptoms showed conceptual similarity with NCSI subjective impairment, 
and nearly with NCSI subjective symptoms. AQLQ-activity limitations nearly reached 
conceptual similarity with NCSI subjective impairment. AQLQ-emotional functioning reached 
conceptual similarity with NCSI dyspnea emotions. AQLQ-environmental stimuli did not 
reach conceptual similarity with any NCSI sub-domain. 
Nor the ACQ or domains of the AQLQ did show conceptual similarity with the NCSI 
sub-domains fatigue, behavioral impairment, general QoL, health-related Qol, and 
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satisfaction with relations. The NCSI, ACQ, and AQOLQ were not significantly related to FEV1, 
FeNO, BMI. 
 
 
DISCUSSION 
 
The present study shows that the Nijmegen Clinical Screening Instrument (NCSI) measures 
more aspects of health status than the Asthma Control Questionnaire (ACQ) and the Asthma 
Quality of Life Questionnaire (AQLQ-S) in patients with severe asthma. All sub-domains of 
the NCSI proved to be relevant in this patient group.  
The main aim of this study was to evaluate the added value of the NCSI to measure 
aspects of health status above the frequently used disease specific instruments AQLQ and 
ACQ. The AQLQ and the ACQ are used in numerous studies to evaluate interventions [24-27], 
and to describe groups of patients with asthma [28]. These studies have provided important 
information about the experienced symptoms, activity limitations, emotional functioning, 
and impact of environmental stimuli on these patients. However, health status most 
certainly comprises of more sub-domains than the four subscales covered by the AQLQ and 
the one subscale of the ACQ. We expected that the ten sub-domains of the NCSI probably 
measures the same, but certainly even more, aspects of health status than the AQLQ.  
Both the AQLQ and the NCSI measure the subjective symptoms, subjective 
impairment, and emotions. However, the NCSI measures also airflow, body composition and 
items that measure the experienced fatigue, satisfaction with life in general, mood, 
satisfaction with relationships and future, and sickness-related behavioral impairment that 
are not covered by the AQLQ and ACQ. On all eight NCSI sub-domains,  measured by the 
questionnaire part, high proportions of patients with serious problems were found. In 
addition, all eight sub-domains were shown to represent conceptusally distinct aspects of 
the patients health status, as evidenced by the low intercorrelations. Only the sub-domains 
subjective symptoms and subjective impairment showed conceptual similarity. The domain 
AQLQ activity limitation showed high inter correlations with the domains symptoms and 
environmental stimuli indicating that they measure similar concepts. However, the 
moderate correlation between symptoms and environmental stimuli indicate that these two 
domains measure separate concepts, thus both share different parts with the domain 
activity limitation. This is not surprising since the items of activity limitation measure activity 
limitation due to environmental stimuli and due to their asthma symptoms. Thus, the NCSI 
questionnaire part measures seven aspects of health status whereas the AQLQ measures 
three distinct aspects of health status. This suggests that, in patients with severe asthma, the 
NCSI is capable of providing a more complete picture of the patient’s problems and needs on 
health status as compared to the ACQ and AQLQ.  
The present study shows that all NCSI subscales represent highly relevant sub-
domains of health status in patients with severe asthma. In addition, heterogeneity was 
found between patients with respect to the number of sub-domains and in the combination 
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of sub-domains on  which patients experienced severe problems. Low to absent correlations 
were not only found between the non-physiological sub-domains of the NCSI, but also 
between physiological functioning and symptoms, behavioral impairment, and QoL.  This is 
not a new phenomena, Haldar etal [29] also found that symptom perception is not always in 
concordance with eosinophilic airway inflammation, and concluded that both, symptoms 
and physiologic parameters, have to be measured to get a complete picture.  
Several limitations of the present study should be kept in mind with respect to the 
generalizability of the results. In this study we included a select group of patients, more 
specifically patients with severe asthma referred to a high-altitude inpatient pulmonary 
clinic. Even in this highly selected group of patients with severe asthma, marked 
heterogeneity was found. Which makes it feasible that this might even be more pronounced 
in a more general sample of patients with asthma. The moderate internal consistencies of 
the sub-domains of QoL are another limitation. In COPD the same problem exist, a possible 
explanation is that the included subscales measure different concepts, however further 
refinement will be necessary. One might question the adequacy of the cut-off scores for 
normal functioning on the sub-domains of the NCSI. Since, these cut-offs were based on a 
group of healthy persons matched by age and sex to a COPD study group [11]. This could 
lead to an underestimation of problems in patients with asthma, because asthma patients 
are generally somewhat younger. Morroy et al [13], found no significant differences 
between patients with Q-fever older and patients with Q-fever younger than 50 years on 
seven of eight NCSI sub-domains, patients younger than 50 years had significant higher 
scores on dyspnea emotions. 
 The reason for this study was the need for an instrument that would enable a 
detailed evaluation of the needs of patients with severe asthma and that could help to 
identify the factors that aggravate, complicate, or influence disease perception. The NCSI 
provides a detailed assessment of health status, and includes normative data, which render 
the patient’s scores on each sub-domain clinically meaningful [11]. The powerful mechanism 
is not the NCSI as instrument per sé, but by discussing the PatientProfileChart with the 
patient. The PatientProfileChart visualizes on which sub-domain a patient functions normally 
and on which sub-domain a patient experience severe problems. The PatientProfileChart 
allows the doctor and other healthcare providers to quickly identify the factors leading to 
disease burden by discussing the results [30]. Moreover, the discussion with the patient also 
facilitates shared-decision making, which has proven to be important in promoting 
adherence [31]. Moreover, the complexity of the balance between health status and the 
underlying problems and self-management capacities, may  become visible in the discussion. 
This information may help in guiding non-pharmacological treatment since pharmacological 
treatment alone seems to be insufficient in patients with severe asthma [31]. In COPD this 
approach have been implemented in usual care since several years and has proven its clinical 
relevance. The next step would be to implement the NCSI in treatment of patients with 
severe asthma, and examine its sensitivity to change.  
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CONCLUSIONS 
The present study showed that the NCSI, ACQ and AQLQ measure highly relevant 
aspects of health status in patients with severe asthma.  However, the NCSI measures more 
aspects of health status that are not covered by the ACQ and AQLQ. The NCSI in combination 
with the PatientProfileChart might help to identify the impact on daily life, symptoms, QoL, 
and impairments in the individual patient with severe asthma. 
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ABSTRACT 
 
Background  
Q fever is a zoonosis caused by the obligate intracellular bacterium Coxiella burnetii. The two 
long term complications, after primary infection, are chronic Q fever in ~1% of patients, and 
a chronic fatigue syndrome in 10-20%. However, the existence of a protracted decreased 
health status after Q fever remains controversial.  
 
Aim  
To determine the health status of the patients of the Q fever outbreak in The Netherlands in 
2007, 1 year after primary infection. 
 
Design  
Cross-sectional case-control study. 
 
Methods  
Health status of the patients from the 2007 Dutch Q fever outbreak was compared to age-, 
sex- and geographically matched and Q fever seronegative controls. Health status of both 
patients and controls was assessed with the Nijmegen Clinical Screening Instrument (NCSI). 
 
Results  
Fifty-four Q fever patients provided 34 years of age- and sex-matched controls from the 
same neighbourhood. Eleven controls had positive Q fever serology and were excluded. Q 
fever patients had significantly more problems on the sub-domains of symptoms and 
functional impairment. Overall quality of life was decreased in both patients and controls, 
59% vs. 39%, respectively, ns. Severe fatigue levels were present in 52% of patients vs. 26% 
in controls (p< 0.05).  
 
Conclusion  
These data support a sustained decrease in many aspects of health status in Q fever patients 
in The Netherlands, 1 year after primary infection. 
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INTRODUCTION 
 
Q fever is a zoonosis caused by the obligate intracellular bacterium Coxiella burnetii [1]. In its 
acute form, Q fever generally presents as a mild flu-like syndrome, atypical pneumonia or 
hepatitis [1, 2]. After primary infection, ~1% of patients develop chronic Q fever, mainly as 
endocarditis in patients with pre-existing cardiac valvulopathies [1, 3].  
In recent years, research groups have drawn attention to another, less known, 
chronic sequel to primary Q fever, which takes the form of a debilitating chronic fatigue 
syndrome lasting >6 months in up to circa 20% of patients [4-9]. However, despite these 
reports on post Q fever fatigue, the existence of a ‘post Q fever fatigue syndrome’ or QFS as 
a distinct clinicopathological entity remains controversial, especially in France and the US [1, 
10]. 
 In 2007, a goat farming-related Q fever outbreak of 73 cases was identified in the 
rural town of Herpen, The Netherlands [11]. Since then, an ongoing Q fever endemic has 
produced the Dutch province of North-Brabant as the currently most hyperendemic region 
in the world with more than 3000 acute Q fever cases in 2008 and 2009 [12, 13].  
No data exist on the impact on the long-term impact on health status after acute Q 
fever in The Netherlands. The aim of the present study was to determine the health status of 
the patients of the Q fever outbreak in The Netherlands in 2007, 1 year after primary Q fever 
infection. 
 
 
METHODS 
 
Patients 
All patients from the Q fever outbreak cluster in Herpen (n=73) were asked to participate. A 
case of acute Q fever was defined as any inhabitant of the outbreak cluster area who 
presented with compatible clinical symptoms and a positive serology defined by 
immunofluorescence assay (IFA) (Focus diagnostics). Positive serology was defined as both 
anti-phase II IgM and anti-phase II IgG antibodies with a 1:64 or greater dilution or a 
seroconversion consisting of a 4-fold increase of anti-Phase II IgG titer during follow-up. All Q 
fever patients were followed up serologically for a period of 1 year for antibodies against 
both Phase I and Phase II antigens, to exclude progression to chronic infection. As controls, 
Q fever patients were asked to bring along an age- and sex matched control subject from 
their neighbourhood, without a history of Q fever. Control subjects had to be age (±10 years) 
and sex matched to the patient. Control subjects were serologically tested for C. burnetii 
antibodies using IFA. Positive serological findings of Q fever excluded controls from the 
primary analysis. Documentation on actual significant comorbidity was available for all 
participants. All patients provided written informed consent. The study was approved by the 
local Ethical Board for Human Research. (Commissie Mensgebonden Onderzoek file-nr.: 
2008/192, ABR nr.: NL24404.091.08). 
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Study design 
The health status of the patients from the 2007 Q fever outbreak was compared to age-, sex- 
and geographically matched controls. Health status of both patients and controls was 
assessed with the Nijmegen Clinical Screening Instrument (NCSI) 1 year after the initial Q 
fever infection.  
 
The Nijmegen Clinical Screening Instrument (NCSI) 
In the literature, health status is defined as covering physiological functioning, symptoms, 
functional impairment in daily life, and quality of life (QoL) as main domains [14, 15]. These 
domains were shown empirically to be subdivided into many independent sub-domains [16]. 
The NCSI is an empirically composed battery of well validated instruments, that enable a 
detailed measurement of these sub-domains of health status [17]. See Table 1 for the tests 
and instruments by which the sub-domains of health status were measured. In the present 
study, the NCSI covers eight sub-domains of the main domains ‘symptoms’, ‘functional 
impairment’ and ‘quality of life’. The clinical meaning of these main domains is given 
hereafter. 
 
Table 1 Main domains and sub-domains of the NCSI, their corresponding instruments and 
subscales  
Main domain Sub-domain Instrument subscale 
Symptoms Subjective symptoms PARS-D Global dyspnea activity 
  PARS-D Global dyspnea burden 
 Dyspnea emotions DEQ-frustration 
  DEQ-anxiety 
 Fatigue Checklist Individual Strength 
Functional impairment Behavioral impairment SIP home management 
  SIP ambulation 
 Subjective impairment QOL-RIQ general activities 
Quality of Life General QoL BDI primary care 
  SWLS-total 
 HRQoL Satisfaction physical 
  Satisfaction future 
 Satisfaction relations Satisfaction spouse 
  Satisfaction social 
 
Main domain subjective symptoms 
The sub-domain subjective symptoms represent the patient’s overall burden of dyspnea and 
experienced dyspnea during activities. The sub-domain dyspnea emotions embodies the 
level of frustration and anxiety a person experiences when dyspnoeic. 
 
Main domain functional impairment 
The sub-domain behavioral impairment represents the extent to which a person cannot 
perform specific and concrete activities, with respect to ambulation and activities at home, 
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as a result of having the disease. The sub-domain subjective impairment represents the 
experienced degree of impairment. 
 
Main domain QoL 
The sub-domain general QoL covers mood and satisfaction with  life as a whole. The sub-
domain HRQoL represents satisfaction with physical functioning and confidence in the 
future. The sub-domain satisfaction relations represents the satisfaction with (or absence of) 
the relationships with spouse and others.  
 
The NCSI provides normative data for each sub-domain; increasing scores indicating normal 
functioning, mild problems or severe problems. 
 
Statistical analysis 
All quantitative data are presented as mean ± SD if normally distributed, otherwise median 
values (with range) are reported. Testing for differences between patients and controls was 
performed by Pearson’s χ2 or Mann-Whitney test when appropriate. Statistical significance is 
set at a P< 0.05. Data were analyzed with SPSS 14. 
 
 
RESULTS 
 
A total of 54 of the 73 (74%) Q fever patients from the 2007 Herpen outbreak agreed to 
participate. Thirty-four of these patients provided an age- and sex-matched control from the 
same neighbourhood. Eleven of these controls had positive Q fever serology and were 
excluded, leaving 23 seronegative controls for comparison. Characteristics of the study and 
seronegative control subjects are given in Table 2. Patients and controls proved to be well 
matched for age, sex and pre-existing comorbidity and smoking status.  
 
Table 2 Patient characteristics expressed in number (%) unless stated otherwise of the patient 
group, and control group 
 Patient Control p-value 
N 54 23  
Male 33 (61.1%) 10 (42.3%) p >0.05* 
Age, mean ±SD 53.1 ±14.2 53.6 ±9.7 p >0.05$ 
Range 20-81 38-73  
Comorbidity 22 (40.7%) 9 (39.1%) p >0.05* 
Smoking status   p >0.05* 
Current 24 (44.4%) 6 (26.1%)  
Former 19 (35.2%) 8 (34.8%)  
Never 11 (20.4%) 9 (39.1%)  
*Pearson chi-square $Mann-Whitney test 
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Results on the sub-domains of the NCSI on a group level are provided in Table 3. Q 
fever patients had significantly higher scores on all sub-domains of ‘symptoms’ (subjective 
pulmonary symptoms, dyspnea emotions, fatigue), ‘functional impairment’ (subjective 
impairment, behavioral impairment) and ‘satisfaction with relations’. With respect to the 
main domain ‘quality of life’, there was a non-significant trend towards more problematic 
(i.e. higher) scores on the sub-domains ‘general quality of life’ (P= 0.09) and ‘health related 
quality of life’ (P= 0.073).  
 
In Figure 1, results are presented on an individual level by the percentages of 
patients and controls scoring in the range of normal, mild, or severe problems. Fatigue 
scores of Q fever patients were abnormal (score: mild or severe) in 74% vs 48% in controls.  
 
Figure 1 Percentages of normal, mild, and severe problems for each sub-domain of the NCSI for the 
patient and control group (*P<0.05). 
Table 3 NCSI scores on all sub-domains (the higher the score, the more problematic)  
Main domain Sub-domain Min-max Patient  
Mean ±SD 
Control 
Mean ±SD 
p-value 
Symptoms Subjective Symptoms 2-20 7.26 ±4.85 4.57 ±4.92 0.002 
 Dyspnea Emotions 6-24 9.85 ±4.36 7.39 ±3.16 0.005 
 Fatigue 8-56 34.35 ±13.78 23.87 ±14.08 0.004 
Functional Impairment Behavioral Impairment 0-135.5 8.21 ±11.65 3.13 ±6.37 0.050 
 Subjective Impairment 4-28 9.70 ±5.55 6.00 ±3.49 <0.001 
Quality of Life General QoL 1-101.6 19.52 ±17.84 11.96 ±9.98 ns 
 HRQoL 2-10 4.26 ±2.04 3.35 ±1.40 ns 
 Satisfaction Relations 2-10 3.72 ±2.08 2.70 ±1.29 0.015 
Mann-Whitney test , ns= not significant. 
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Figure 2 Frequency distribution of numbers of sub-domains with severe problems in patients and 
controls 
 
Severe fatigue levels were present in 52% of patients vs. 26% in controls. Overall QoL 
was decreased in a substantial number of patients and controls, but not significantly 
different between the two groups (Q fever patients 59% vs. controls 39%, ns).  
 
In Figure 2, the percentage of patients and controls (y-axis) is given as a function of 
the number of sub-domains in which these patients and controls experience severe 
problems (x-axis) . In addition to the primary data analysis, we compared NCSI scores of the 
excluded seropositive controls (n=11) with the scores of seronegative control subjects 
(n=23). The NCSI scores of seropositive- and seronegative controls were not statistically 
different in all eigth measured sub-domains of health status (P> 0.05 for all sub-domains).  
 
 
DISCUSSION 
 
One year after primary infection, Q fever patients from the 2007 Herpen outbreak had a 
significantly lower health status in many sub-domains of the main domains ‘symptoms’ and 
‘functional impairment’, when compared to age-, sex- and geographically matched controls. 
Overall QoL and health-related QoL were significantly decreased in both patients and 
controls. Furthermore, on an individual level, patients had severe problems in more sub-
domains than controls. Our findings lend support to the notion of a protracted 
reconvalescence phase after Q fever associated with decreased health status in many 
aspects. 
We found remarkably high clinically relevant (=severe) fatigue levels in roughly half 
(52%) of the Q fever patients 1 year after infection. In two separate case control studies 
published as letters the editor in the Lancet in 1996, Marmion et al. [4] and Ayres et al. [5] 
reported a syndrome of protracted fatigue and debility in Q fever patients for >5 years after 
primary infection with similar fatigue levels [67% (n=39) and 66% (n=71) respectively]. Five- 
and 10-year follow-up of the large Q fever outbreak in the West Midlands, UK, also showed 
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similar levels of chronic fatigue [6, 7]. Dubbed the post Q fever fatigue syndrome (QFS), this 
protracted fatigue state shares common features with the chronic fatigue syndromes 
following other (viral) pathogens such as Epstein-Barr virus and Ross River virus [9].  
Although there was a significantly higher fatigue level in Q fever patients, the 
abnormally high-fatigue level and low overall QoL and health-related QoL of the control 
group is striking. We postulate two explanations for this. First, the level of co-morbidity in 
this study is ~40%, which could partly account for the overall high scores on the NCSI sub-
domains. Second, the original normal values for NCSI sub-domain scores were derived from 
healthy control subjects with normal pulmonary function tests. As these test were not 
available in the present study and given the significant smoking history equally present in 
patients and controls, undocumented pre-existing pulmonary morbidity may also have 
increased NCSI sub-domain scores in both groups. 
Remarkably, NCSI scores from controls without a clinical history of Q fever but with 
serological evidence of exposure to C. burnetii (and thus excluded from the primary 
analysis), were not statistically different from seronegative controls, suggesting that clinical 
expression of acute Q fever infection is an essential factor in the subsequent sustained 
decrease in health status. Severity of initial illness previously indeed has been shown to be 
the best predictor of subsequent development of a post-infective fatigue syndrome in both 
viral and non-viral pathogens, including Q fever [9]. Moreover, the same genetic 
polymorphisms in cytokine genes with critical roles in the inflammatory reponse to infection, 
underpin both the severity of the acute sickness and the average time to recovery across 
varied infections, including Q fever [19]. 
There are obvious difficulties with the credibility of QFS as a distinct clinico-
pathological entity, as confounding factors such as financial compensation or insurance 
benefits following the acute sickness can be held responsible for the symptomatology and 
associated reduced QoL. However, both the West Midlands outbreak mentioned earlier and 
the currently described Dutch outbreak were non-occupational and no litigation for financial 
compensation was pursued. A QFS diagnosis relies solely on the patient’s own account of 
symptoms. In clinical practice, QFS patients remain indistinguishable from patients with a 
complete recovery after primary infection with C. burnetii, as they do not meet the criteria 
for chronic Q fever infection: anti-phase I IgG titers are less than 800 and appropriate 
cultures of the patients blood or tissues show no viable bacteria. Recently, an elegant new 
paradigm of persistence of Coxiella antigenic non-viable cell residues after primary infection 
in interaction with immunogenetic polymorphisms in the host has been put forward to 
better explain the chronic sequelae of acute Q fever, including QFS [20]. The importance of 
genetic host factors in QFS is supported by research done by Kerr et al. [21, 22] in the UK. 
They found significant differences in expression of 88 human genes, notably with a high 
proportion of genes involved in the immune response and infection, between patients with 
idiopathic chronic fatigue syndrome and normal controls. Remarkably, QFS patients were 
found to have similar patterns of gene expression to patients with idiopathic chronic fatigue 
syndrome. 
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Although our data support a decrease in many aspects of health status in many Q 
fever patients, some considerations have to be taken into account. First of all, patient 
numbers are small. However, Q fever patients were optimally matched, including serological 
testing in the controls. Furthermore, despite the small numbers, a statistically significant 
difference was found in six of the eight tested sub-domains of the NCSI, supporting the 
notion of a rather large difference in health status between patients and controls. Second, 
the NCSI has proved to be a useful tool in assessing health status for use in research and 
care, but has mostly been applied in COPD patients. We used the NCSI in the setting of post-
infectious health status assessment for the first time. Nevertheless, the various (parts of) 
questionnaires used to compile the NCSI function in their original and unaltered form. These 
generic questionnaires are not specified to assess only pulmonary disease and assess the 
different sub-domains of health status in the exact same way these instruments were 
originally designed and validated for.  Moreover, the NCSI can be used by the clinician as an 
excellent tool to identify and monitor health status in its various sub-domains and can even 
guide therapeutic (psychological) interventions.  
In conclusion, these data support a sustained decrease in health status in Q fever 
patients in The Netherlands, one year after primary infection. With more than 3000 new Q 
fever patients in the last 2 years in the setting of the ongoing Dutch Q fever epidemic, these 
are the first clinical data indicating a major long-term burden of the disease in the years to 
come.  
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Several questionnaires have been developed to measure impaired health and well-being in 
patients with COPD. Although research using these questionnaires has provided important 
information about patients with COPD, it has also raised new questions. While the choice of 
questionnaire is often based on which questionnaires are commonly used, it is not always 
clear what questionnaires actually measure. The conceptual confusion regarding terms such 
as health status, quality of life, health-related quality of life, etcetera has played a major role 
in this. This is illustrated by the fact that questionnaires that are assumed to measure 
different concepts show overlap, and that questionnaires said to measure the same concept 
yield different results [1]. Moreover, the same questionnaire is used in one study to measure 
quality of life and in another study to measure health status or health-related quality of life, 
depending on what is ‘hot’ at that moment. By using different terms for the same 
questionnaire it is unclear which concept is being evaluated. In research, but especially in 
clinical care, it is important to know what is measured and what the results imply. If these 
questions cannot be answered, then it is questionable whether the use of these instruments 
is of added value to the individual patient.  
Already in 1997, a round table conference concluded that it would be better to 
improve existing questionnaires rather than develop new ones [1]. The authors 
recommended comparison of existing instruments to identify the best instrument, 
standardization of terminology, and improvement of the validity and interpretability of the 
instruments, with a view to improving and standardizing the measurement of health status 
in research and in clinical practice. However, since then several instruments have been 
developed for COPD, such as the COPD Assessment Test (CAT) to measure COPD health 
status [2] and the Clinical COPD Questionnaire (CCQ) to measure symptoms and functional 
state [3], and the conceptual confusion remains.  
Questionnaire validation is a difficult process. The traditional validation approach for 
a new questionnaire is to correlate questionnaire data with those of an existing 
questionnaire assumed to measure a particular concept. However, there are several 
problems to this approach in the case of health status and quality of life. First, there are 
multiple definitions of health status and quality of life. Second, no gold standard exists for 
highly subjective concepts such as quality of life, and so the validity of the questionnaire that 
is used as a reference in this process is also unclear. Our research group used a different 
approach when developing the Nijmegen Integral Assessment Framework (NIAF) [4]. 
Questionnaires and tests were selected on the basis of theoretical models found in the 
literature and were used to collect data from a group of outpatients with COPD. These data 
were analyzed, by factor analysis, to establish what the questionnaire measured, instead of 
making assumptions about what it measures. This enabled tests and questionnaires that 
measured the same concept to be grouped together, with subscales of questionnaires that 
measure different aspects of integral health status being classified in different sub-domains. 
This resulted in the NIAF, which provides an overview by organizing tests and questionnaires 
according to what aspects, physiological functioning, symptoms, functional impairment, or 
quality of life, they actually measure [4]. This framework brings greater clarity to the 
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measurement of integral health status in several ways. For instance, the NIAF can be used as 
standard to examine what a questionnaire measures, by comparing it with included 
questionnaires, and it provides an overview of what sub-domains are measured by the 
included tests and questionnaires. It can also be used as guide to select tests and 
questionnaires to measure certain sub-domains of integral health status.  
Using the NIAF, we could show that integral health status covers at least sixteen 
relatively unrelated sub-domains that cannot be measured with currently available 
individual instruments. This makes it necessary to use a combination of instruments to 
measure a patient’s integral health status. The Nijmegen Clinical Screening Instrument (NCSI) 
was developed with this in mind (chapter 3), by combining subscales from existing 
questionnaires for each sub-domain of the NIAF. In this way, various aspects of integral 
health status are covered with as little overlap as possible. For use in clinical care, it was 
necessary to remove five of the sixteen sub-domains as these took too much time to 
complete. Even so, the NCSI measures more aspects of integral health status than most 
other frequently used (disease-specific) questionnaires. By using the NIAF as golden 
standard for the selection of items to measure health status, no question about what is 
actually measured by the NCSI exists, and it is also apparent what is not measured by the 
NCSI. 
In research, the St George Respiratory Questionnaire (SGRQ) [5], the Asthma Control 
Questionnaire (ACQ) [6, 7], and the Asthma Quality of Life Questionnaire (AQLQ) [8] are 
disease-specific questionnaires that are used the most often to measure quality of life or 
health-related quality of life in patients with COPD and asthma. The SGRQ is sometimes also 
used to measure health status. Comparison of the SGRQ with the NIAF (chapter 4) and the 
ACQ and AQLQ with the NCSI (chapter 6) showed that these instruments have relatively little 
conceptual similarity with the NCSI sub-domains. The SGRQ, ACQ, and AQLQ showed 
conceptual similarity with the NCSI sub-domains subjective symptoms and subjective 
impairment, and the AQLQ additionally with dyspnea emotions. Moreover, the three 
questionnaires definitely do not measure any aspect of quality of life, as defined in this 
thesis (chapter 1). The recently developed CAT and CCQ have been shown to be conceptually 
similar to each other and to the SGRQ (correlations between 0.64-0.77) [9-11], thus 
presumably these instruments also only measure two aspects of functional impairment and 
symptoms. Regardless of how important these sub-domains are, health status encompasses 
more sub-domains than those measured by the ACQ, AQLQ, and SGRQ. Hence integral 
health status cannot be measured with these instruments alone.  
Another shortcoming of many questionnaires is the interpretability of the scores. In 
general, the higher (or lower) the score, the more problems on that aspect exist. However, 
normality cannot be defined by the absence of symptoms of impairment. For example, 
healthy people also experience fatigue (Chapter 2). For this reason, we collected reference 
data for each sub-domain of the NCSI, to improve the interpretability of findings, both in 
research and clinical settings. Instead of only providing mean scores, information is also 
available about, for example, how many patients experience severe problems on specific 
G E N E R A L  D I S C U S S I O N  | 119 
 
sub-domains. Moreover, it can be seen on which sub-domains of integral health status the 
patient functions normally or has problems. Results are visualized for patients and clinicians 
in the PatientProfileChart, using different colors (green, yellow, and red) for greater clarity. 
In this way, patients are given verbal and visual feedback of information, which minimizes 
the chance that there are misunderstandings and facilitates discussion. Also possible 
discrepancies between sub-domains are visible and subject for discussion.  Discussing results 
and potential treatments with patients improves their commitment and treatment 
adherence and can lead to better results with patient-tailored treatment.  
One of the goals of patient-tailored treatment in COPD is to optimize and/or maintain 
the patient’s integral health status [12, 13]. Many treatment modalities aim at teaching 
patients adequate self-management strategies, such as adherence to medication regimens, 
exacerbation management, stopping smoking, taking regular exercise, energy-saving 
strategies, breathing regulation, stress management, and so on. All these self-management 
strategies need to be adopted in daily life and most important require behavioral change 
[14, 15]. However, some patients report more symptoms, functional impairments, and 
quality of life issues than one would expect on the basis of their disease severity, and it is 
these patients who tend not to implement self-management strategies in daily life. This may 
be for several reasons. Patients need to acknowledge that COPD is a chronic and progressive 
disease, which requires changes in daily life, but if patients do not think that this will be 
beneficial, then they tend not to make behavioral changes. In turn, clinicians need to be able 
to recognize which patients do not adequately adapt to the disease. Awareness of the 
necessity and motivation to change behavior are necessary ingredients for adaptation. It is 
important to establish whether certain patients can be helped to adapt to their disease, 
which would improve their integral health status. The first step is to identify the patient’s 
level of adaptation to COPD.  
It is difficult to define adaptation to disease and how to assess it. For example, while 
physical activity should be discouraged in some patients, it should be encouraged in others. 
We took a different approach to assessing adaptation, on the assumption that patients who 
are not adequately adapted to their disease experience more symptoms, functional 
impairment, and lower quality of life than would be expected on the basis of their disease 
severity. In patients who have adapted to their disease, the four domains of health status 
are in balance, but not in other patients. If these differences exist, then it might be possible 
to identify different groups of patients with COPD by cluster analyses (chapter 5). Indeed, 
two clinical phenotypes were found in which physiological functioning, symptoms, functional 
impairments, and quality of life were in balance, and one clinical phenotype was found with 
more reported symptoms, greater functional impairment, and poorer quality of life, all of 
which were not consistent with the FEV1% predicted. We then investigated whether these 
profiles really reflected the level of adaptation, by examining the effect of pulmonary 
rehabilitation on the three clinical phenotypes. One of the goals of pulmonary rehabilitation 
is to stimulate adaptation to the disease by promoting self-efficacy and behavior change 
[16]. We expected that rehabilitation would be most effective in patients with the ‘not 
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adapted’ clinical phenotype and perhaps less effective in patients with the ‘adapted’ clinical 
phenotype, especially because the latter reported no or lower levels of symptoms, 
functional impairment, and quality of life. As expected, pulmonary rehabilitation had the 
greatest effect in the ‘not adapted’ patients expressed by  a better balance between the four 
domains of integral health status at the end of rehabilitation.  Understanding what type of 
treatment works and what type does not in specific clinical groups of patients will help 
clinicians to choose potentially effective treatments for specific patients. It is important to 
appreciate that identifying a patient’s clinical phenotype is not a substitute for identifying 
the patient’s individual profile, but is an aid to facilitate appropriate tailored treatment. 
In this thesis, the definition of integral health status was based on theoretical models, 
such as the model of Wilson and Cleary [17], which has also been shown to fit other diseases 
such as HIV [18], Hodgkin’s lymphoma [19], and Parkinson’s disease [20]. Independent of the 
type of disease, integral health status minimally covers the domains physiological 
functioning, symptoms, functional impairment, and quality of life. How these domains are 
measured depends partly on the characteristics of a given disease. For example, the lung 
function test provides important information about the severity of COPD, but has no added 
value in many other diseases. However, beside disease-specific aspects, integral health 
status also encompasses generic aspects, such as general quality of life. The NCSI 
incorporates disease-specific and generic instruments that, in theory, should be applicable to 
other patient groups with respiratory symptoms. If this hypothesis is correct, it would make 
it possible to compare different disease groups. In addition, the PatientProfileChart with cut-
off scores could help guide treatment choices in other diseases. The studies involving 
patients with asthma (chapter 6) and patients with Q-fever (chapter 7) showed that the 
various sub-domains of the NCSI are also relevant in these patient groups. For all sub-
domains, a certain proportion of patients were found to have normal or raised levels or 
clinically relevant problems. These groups shared some characteristics but differed in others. 
For example, in both groups fatigue and poor general quality of life were clinically relevant 
problems, but whereas a large proportion of patients with asthma experienced subjective 
impairments and subjective symptoms, this was not the case for patients with Q-fever. Thus 
while the generic part of the NCSI can probably be used for other diseases, it might be 
necessary to make adaptations with regard to the level of symptoms and physiological 
measures.  
 
Future research 
The aim of the studies described in this thesis was to clarify the assessment of integral health 
status in individual chronically ill patients – what should be measured and how it should be 
measured. While some questions were answered, new ones arose.  
Fatigue was not originally incorporated in the NIAF (chapter 2), and it is possible that 
other sub-domains of physiological functioning, symptoms, functional impairment, or quality 
of life also merit inclusion in the NIAF and the NCSI. Open semi-structured interviews with 
patients might provide new important information about topics that are currently not 
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assessed. It is then a question of collecting and analyzing data and establishing reference 
data. This is also true if the NIAF and NCSI are to be used for other diseases.  
The NCSI was developed for use in both research and clinical settings, to gain a 
detailed picture of a patient’s integral health status, to identify problems early. While it was 
originally intended to repeat this screening every year, results (chapter 5) showed that in 
most patients there are no clinically relevant changes in a year. Since the NCSI takes 20 
minutes to complete, it might be more of a burden than a benefit to patients. More research 
is needed to find the appropriate time frame for screening, bearing in mind that the optimal 
timing of screening may vary between patients depending on the specific problems they 
experience. Another point that needs attention is the relevance of screening. It is intended 
to help clinicians make treatment choices, but this has yet to be confirmed in daily practice.  
The identification of the three clinical phenotypes that each responded differently to 
treatment seem to be an important addition to the NCSI, but needs to be validated in clinical 
practice, as existing datasets were used in the study described in chapter 5. Future research 
should investigate whether knowing how well a patient is adapted to his or her disease 
influences the choice of treatment to optimize that patient’s integral health status. In 
addition, more needs to learned about whether other types of treatment beside pulmonary 
rehabilitation influence the integral health status of the three clinical phenotypes. 
Understanding what type of treatment works and what type does not in specific clinical 
phenotypes will help clinicians select effective treatments for each clinical phenotype.  
At the moment, the NCSI has proven useful in research studies involving patients 
with Q-fever [21-24](chapter 7), asthma (chapter 6), and cardiac diseases (submitted). The 
next step is to implement the NCSI with the PatientProfileChart in clinical practice for these 
diseases. It would be interesting to examine whether comparable clinical phenotypes can be 
identified in these patient groups, since adaptation to disease is not exclusive to COPD.  
 
Clinical implications 
Concepts are often used in research and clinical practice without there being a clear 
understanding of what these concepts entail – not everyone uses the same definitions for 
concepts. What is quality of life to one person, is health status to another. Thus to avoid 
conceptual confusion, concepts should be defined when they are used.  
The NCSI was developed for both research purposes and clinical use. One advantage 
of using a standardized instrument in daily practice is that in a short time many questions 
are answered and the same information is available for each patient. Time constraints, and 
the burden and benefit to patients are factors that influence what it is reasonable to assess 
in clinical care. The NCSI takes about 20 minutes to complete and provides a detailed picture 
of a patient’s integral health status (PatientProfileChart). This profile provides information 
about problem areas and makes discrepancies visible to both physician and patient. 
Discussion of the PatientProfileChart with the patient has proven very effective – problems 
were detected early, before they exacerbated, so that treatment could be started in a timely 
fashion. Ideally, this method should be implemented for screening and monitoring in all 
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centers dealing with patients with COPD. However, standard assessment with the NCSI 
might be too time consuming and some patients experience no problems. For these reasons, 
a short screening instrument with the simple outcome ‘yes, more assessment is needed’ or 
‘no, more assessment is not needed’ was developed, based on the NCSI. This screening 
instrument identifies patients who experience problems in their integral health status and 
who need detailed assessment. In this way, many patients can be easily screened in daily 
clinical practice.  
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In this thesis, we focused on the assessment of integral health status in patients with chronic 
lung diseases. On the basis of theoretical models and clinical considerations, we defined 
concepts, selected tests and instruments, and empirically tested these in a group of patients 
with Chronic Obstructive Pulmonary Disease (COPD). Factor analysis revealed that integral 
health status encompasses at least four domains: physiological functioning, symptoms, 
functional impairment, and quality of life. These four domains can be subdivided into several 
sub-domains, all of which are relatively unrelated to each other, so that each sub-domain 
reflects a unique aspect of integral health status. This means that these different aspects all 
need to be measured in order to get a complete picture of a patient’s integral health status. 
The development of an instrument that measures the integral health status of patients with 
COPD, its use in daily clinical practice, and its usefulness in other chronic diseases were the 
three main subjects of this thesis.  
 
 
Chapter 2 
Given that patients with COPD report fatigue as the second most important symptom after 
dyspnea, it is remarkable that fatigue has not gained much attention in COPD research and 
especially not in clinical practice. In the study reported in Chapter 2, the prevalence and 
natural course of ‘normal’ and ‘abnormal’ fatigue and the relationship between fatigue and 
the many sub-domains of integral health status were investigated in patients with COPD. 
Results showed that more than half of the patients reported abnormal fatigue, and after 
four years a clinically relevant increase in fatigue was observed in one third of the patients. 
Patients with abnormal fatigue had a significantly lower exercise capacity and had more 
symptoms, a greater functional impairment (except actual daily activity), and a poorer 
quality of life than patients with normal levels of fatigue. Analysis showed that fatigue and 
dyspnea are conceptually distinct and that both measure a unique aspect of integral health 
status. Therefore fatigue has to be measured in order to get a complete picture of a patient’s 
integral health status. Accordingly, fatigue was incorporated as an additional sub-domain in 
the Nijmegen Integral Assessment Framework (NIAF), within the main domain symptoms. 
 
 
Chapter 3 
Since treatment goals have expanded from merely optimizing physiological functioning to 
optimizing patients’ integral health status, there is a need for an instrument that measures 
the integral health status of patients. This instrument should be suitable for use in both 
research and clinical settings. For use in daily clinical practice, it is essential that this 
instrument is short and easy to complete and score, and that results are easy to interpret. In 
particular, results should be clinically meaningful with respect to the individual patient. In 
the study described in Chapter 3, a battery was developed of existing questionnaires that 
fulfill the above-mentioned criteria: the Nijmegen Clinical Screening Instrument (NCSI). The 
comprehensive Nijmegen Integral Assessment Framework (NIAF) was used as ‘gold standard’ 
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for the selection of subscales for the sub-domains. Cut-off scores for normal functioning and 
severe problems in the sub-domains were established using data for age and sex-matched 
healthy controls and patients who were enrolled in an inpatient pulmonary rehabilitation 
program. To enhance the clinical applicability of this instrument, computer software was 
developed to present results in a graph, the PatientProfileChart, immediately after 
assessment. The PatientProfileChart provides a visual presentation of the results in green-
yellow-red ‘traffic light’ bars (see figure 1, chapter 3). The software makes it also possible to 
complete the questionnaire at home and avoids missing values by not allowing to skip items. 
The NCSI in combination with the PatientProfileChart provides a detailed picture of a 
patient’s integral health status and indicates problem areas and discrepancies between the 
diverse sub-domains.  
 
 
Chapter 4 
The St. George Respiratory Questionnaire (SGRQ) is one of the most frequently used 
questionnaires in COPD research. The SGRQ is variously assumed to measure health-related 
quality of life, quality of life, or health status. Although these terms and definitions are used 
interchangeably in the literature, the different terms refer to different concepts, as pointed 
out in the Introduction. In order to interpret data, it is important to know what exactly is 
measured with the sections Symptoms, Activity, and Impact of the SGRQ. This was addressed 
in the study reported in Chapter 4. Comparison of the SGRQ with eleven non-physiological 
sub-domains of the NIAF revealed that the SGRQ sections measure only subjective 
impairment and subjective symptoms, especially dyspnea. Thus, the SGRQ measures only 
two aspects of integral health status and therefore does not provide a complete picture. 
Most importantly, we found that the SGRQ does not measure quality of life or health-related 
quality of life. 
 
 
Chapter 5  
In recent years, several phenotypes of COPD have been identified, based on physiological 
and pathological parameters that respond differently to pharmacological treatment. Not 
only pulmonary and extra-pulmonary manifestations of COPD, but also their impact on 
health status differ between patients. In clinical practice, some patients report more 
symptoms, functional impairments, and lower quality of life than would be expected on the 
basis of the results of physiological tests, and vice versa. Adaptation to the disease is 
assumed to play an important role in this observed discrepancy. In the study reported in this 
chapter, we identified three clinical phenotypes, based on a variety of parameters measuring 
aspects of integral health status, which reflected the level of adaptation to COPD. A 
secondary aim was to examine whether these clinical phenotypes respond differently to care 
as usual and to an inpatient pulmonary rehabilitation program, which has a strong focus on 
improving adaptation to disease. Health status did not improve in any of the three 
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phenotype groups after one year of care as usual; however, there were intergroup 
differences after the inpatient pulmonary rehabilitation program. Whereas the ‘adapted’ 
phenotypes showed significant improvements in four to six sub-domains, the ‘non-adapted’ 
phenotype showed significant improvements in ten of eleven sub-domains of integral health 
status. These improvements resulted in a better balance between the four domains of 
health status, indicating better adaptation. Thus knowing a patient’s clinical phenotype will 
help clinicians to optimize patient-tailored treatment.  
 
 
Chapter 6  
The NCSI was developed on the basis of data from patients with COPD. As the NCSI includes 
both generic and disease-specific instruments to measure the integral health status, it is 
plausible that the instrument can also be used for other diseases with respiratory symptoms. 
The relevance of the NCSI was evaluated in a group of patients with severe asthma, by 
comparing it with the internationally most frequently used asthma questionnaires, the 
Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ). All 
sub-domains of the NCSI identified a substantial proportion of patients with severe 
problems, indicating that all sub-domains are relevant in patients with asthma. The NCSI 
sub-domains subjective symptoms, fatigue, subjective impairment, and general quality of life 
identified the highest proportion of patients with severe problems. There was also 
heterogeneity in the number of sub-domains in which patients had severe problems. The 
ACQ showed conceptual similarity with two of eight sub-domains of the NCSI, namely, 
subjective symptoms and subjective impairment. The AQLQ showed conceptual similarity 
with three of eight sub-domains of the NCSI, namely, subjective symptoms, subjective 
impairment, and dyspnea emotion. In contrast to the other subscales of the AQLQ, the 
subscale environmental stimuli measured an aspect of integral health status not measured 
with the NCSI. However, neither the ACQ nor the AQLQ measured any aspect of quality of 
life. On the basis of these results, it can be concluded that the NCSI measures more sub-
domains of integral health status that are relevant to patients with severe asthma. In 
particular, some highly relevant aspects, such as fatigue and general quality of life, are not 
covered by the ACQ and AQLQ. 
 
 
Chapter 7 
In 2007 there was an outbreak of Q-fever in the Netherlands. The study described in Chapter 
7 evaluated the integral health status of patients with Q-fever one year after the outbreak in 
comparison with age- and sex-matched controls not affected by Q-fever. In both groups, a 
proportion of the participants had normal, mild, or severe problems on all sub-domains of 
the NCSI. However, patients who had positive Q-fever serology reported more problems in 
the domains symptoms and functional impairment than did the control participants. Fatigue 
was especially a prominent symptom in the patients with Q-fever. Unexpectedly, the control 
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participants also experienced a poor general quality of life, health-related quality of life, and 
fatigue. Many patients still had an impaired integral health status one year after the 
infection. It is important to monitor the integral health status of patients with Q-fever in 
order to tailor healthcare interventions with a view to limiting or preventing long-term 
consequences. 
 
 
Chapter 8 
The various studies of this thesis were discussed and new research questions and clinical 
implications were formulated in this chapter. Central to this thesis was the question why and 
how integral health status should be measured in individual patients. Chronic disease affects 
the whole person, not just the physiological system involved. This justifies the measurement 
of more than only physiological parameters. The studies showed that integral health status 
encompasses many relatively independent sub-domains of physiological functioning, 
symptoms, functional impairment, and quality of life, which all have to be measured to 
provide a complete picture of a patient’s integral health status. This was possible with the 
NCSI. Moreover, although the NCSI was developed for patients with COPD, it proved useful 
for patients with other chronic (lung) diseases. The presentation of the results of the NCSI in 
a PatientProfileChart makes it easier to discuss findings with patients and helps guide 
patient-tailored treatment. It is essential to determine to what extent patients adapt to their 
disease, as this proved to be an important determinant of integral health status.  
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In dit proefschrift ligt de focus op het meten van de integrale gezondheidstoestand van 
patiënten met een chronische longziekte. Gebaseerd op theoretische modellen en klinische 
overwegingen zijn concepten gedefinieerd, werden testen en instrumenten geselecteerd en 
empirisch getoetst in een groep patiënten met Chronic Obstructive Pulmonary Disease 
(COPD). Factor analyses lieten zien dat de integrale gezondheidstoestand op zijn minst vier 
domeinen bevat: fysiologisch functioneren, symptomen, functionele beperkingen en 
kwaliteit van leven. Deze vier domeinen kunnen elk onderverdeeld worden in verschillende 
subdomeinen die allemaal relatief ongerelateerd zijn.  Dat wil zeggen dat elk subdomein een 
uniek aspect van de integrale gezondheidstoestand reflecteert. Deze bevinding duidt de 
noodzaak tot het meten van alle aspecten aan, om zo tot een compleet beeld van de 
integrale gezondheidstoestand van de patiënt te komen. De ontwikkeling van een 
instrument dat de integrale gezondheidstoestand van patiënten met COPD meet, de 
toepassing in de dagelijkse praktijk en de bruikbaarheid bij andere chronische ziekten zijn de 
drie hoofd onderwerpen van dit proefschrift. 
 
 
Hoofdstuk 2 
Gegeven dat patiënten met COPD moeheid rapporteren als het tweede belangrijke 
symptoom na benauwdheid, is het opvallend dat moeheid weinig belangstelling heeft gehad 
in COPD onderzoek en in de klinische praktijk. In de studie beschreven in hoofdstuk 2 zijn de 
prevalentie en het natuurlijk beloop van ‘normale’ en ‘abnormale’ moeheid en de relatie 
tussen moeheid en veel subdomeinen van de integrale gezondheidstoestand onderzocht in 
patiënten met COPD. De resultaten lieten zien dat meer dan de helft van de patiënten 
abnormale moeheid rapporteerde, en na vier jaar een klinisch relevante toename in 
moeheid kon worden geobserveerd in meer dan een derde van de patiënten. Patiënten met 
abnormale moeheid hadden een significant lager inspanningsvermogen en rapporteerden 
meer symptomen, meer functionele beperkingen (m.u.v. de gemeten dagelijkse activiteit) en 
slechtere kwaliteit van leven in vergelijking met patiënten met een normaal 
moeheidsniveau. Analyses lieten zien dat moeheid en benauwdheid conceptueel 
verschillend zijn en beide unieke aspecten van de integrale gezondheidstoestand meten. Om 
een compleet beeld van de patiënt zijn/haar integrale gezondheidstoestand te krijgen moet 
moeheid ook gemeten worden. Zodoende is moeheid geïmplementeerd als een aanvullend 
subdomein in het Nijmegen Integral Assessment Framework (NIAF), binnen het 
hoofddomein symptomen. 
 
 
Hoofdstuk 3 
Doordat de behandeldoelen verbreed zijn van het optimaliseren van voornamelijk 
fysiologisch functioneren naar het optimaliseren van de patiënt’s integrale 
gezondheidstoestand ontstond de noodzaak voor een instrument dat de problemen in de 
patiënt’s integrale gezondheidstoestand meet. Dit instrument moet zowel gebruikt kunnen 
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worden voor onderzoeksdoeleinden als ook in de dagelijkse zorg. Voor het gebruik in de 
dagelijkse praktijk is het essentieel dat het instrument kort, makkelijk in te vullen en scoren 
is en dat de resultaten makkelijk te interpreteren zijn. Het belangrijkste is dat de resultaten 
klinische waarde hebben op het niveau van de individuele patiënt. In de studie beschreven in 
hoofdstuk 3 werd een batterij van bestaande vragenlijsten samengesteld dat voldoet aan 
alle bovenstaande criteria samengesteld: het Nijmegen Clinical Screening Instrument (NCSI). 
Het uitgebreide Nijmegen Integral Assessment Framework (NIAF) is als ‘gouden standaard ’ 
gebruikt voor de selectie van subschalen van de subdomeinen. Cut-off scores voor normaal 
functioneren en ernstige problemen werden verzameld in een op leeftijd en geslacht ge-
matchte groep van gezonde controles en een groep patiënten die een klinisch 
longrevalidatie programma volgden. Om de klinische toepasbaarheid te vergroten werd 
computer software ontwikkeld om zo de beschikbaarheid van de resultaten in een 
PatiëntenProfielKaart (PPK) meteen na afname van de vragenlijst mogelijk te maken. De 
PatientenProfielKaart biedt een visuele presentatie aan van de resultaten in groen-geel-rode 
‘stoplicht’ grafieken (zie Figuur 1 hoofdstuk 3). Daarnaast maakt de software het mogelijk 
om de vragenlijst thuis in te vullen en worden missende waarden voorkomen doordat er 
geen vragen overgeslagen kunnen worden. Het NCSI in combinatie met de 
PatientenProfielKaart bieden een gedetailleerd beeld van de integrale gezondheidstoestand 
van de patiënt en indiceert probleem gebieden en discrepanties tussen de diverse 
subdomeinen. 
 
 
Hoofdstuk 4 
De St George Respiratory Questionnaire (SGRQ) is een van de meest gebruikte vragenlijsten 
in COPD onderzoek. Van de SGRQ wordt afwisselend aangenomen dat het de 
gezondheidsgerelateerde kwaliteit van leven, kwaliteit van leven of de gezondheidstoestand 
meet. Alhoewel deze termen en definities door elkaar gebruikt worden in de literatuur 
referen deze verschillende termen naar verschillende concepten zoals in de introductie is 
uitgelegd. Voor de interpretatie van de resultaten is het van belang te weten wat er nu 
precies gemeten wordt met de secties symptomen, activiteit en impact van de SGRQ. In 
hoofdstuk 4 werd deze vraag onderzocht. De vergelijking van de SGRQ met de elf niet 
fysiologische subdomeinen van het NIAF lieten zien dat de SGRQ secties alleen subjectieve 
beperkingen en subjectieve symptomen, met name benauwdheid, meten. Dus de SGRQ 
meet maar twee aspecten van de integrale gezondheidstoestand, en biedt dus geen 
compleet beeld. Nog belangrijker, de SGRQ blijkt niet de kwaliteit van leven of 
gezondheidsgerelateerde kwaliteit van leven te meten. 
 
 
Hoofdtsuk 5 
In de afgelopen jaren zijn verschillende phenotypes geïdentificeerd in COPD die gebaseerd 
zijn op fysiologische en pathologische parameters. Deze phenotypes bleken verschillend op 
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farmacologische behandeling te reageren. Niet alleen de pulmonaire en extra-pulmonaire 
manifestaties van COPD, maar ook hun impact op de gezondheidstoestand verschilt per 
persoon. In de klinische praktijk rapporteert een patient soms meer symptomen, functionele 
beperkingen en een lagere kwaliteit van leven dan verwacht zou worden op basis van de 
resultaten op fysiologische testen en vice versa. Adaptatie aan de ziekte lijkt een belangrijke 
rol te spelen in deze geobserveerde discrepancie. In de studie beschreven in dit hoofdstuk 
identificeerden we drie klinische phenotypes, gebaseerd op een variatie van parameters die 
aspecten van de gezondheidstoestand meten, welke de mate van adaptatie aan COPD 
reflecteerden. Het tweede doel was om te onderoeken of deze klinische phenotypes 
verschillend reageren op gebruikelijke zorg en op een klinische longrevalidatie, welke een 
sterke focus heeft op het verbeteren van de adaptatie aan de ziekte. De 
gezondheidstoestand verbeterde in geen van de drie klinische phenotypes binnen een jaar in 
de gebruikelijke zorg. Er werden daarentegen verschillen gevonden na klinische 
longrevalidatie tussen de drie klinische phenotypes. Alwaar de geadapteerde phenotypes 
significante verbetering lieten zien op vier tot zes subdomeinen van het NCSI, vonden we bij 
de niet geadapteerde patiënten een significante verbetering op tien van de elf subdomeinen 
van de gezondheidstoestand. Deze verbeteringen resulteerden in een betere balans tussen 
de vier domeinen, wat een betere adaptatie indiceert. Weten tot welk phenotype een 
patient behoort zal de behandelaar helpen bij de optimalisatie van de behandeling op maat. 
 
 
Hoofdstuk 6 
Het NCSI is ontwikkeld gebaseerd op data van patiënten met COPD. Aangezien het NCSI 
zowel generieke- als ziektespecifieke instrumenten voor het meten van de integrale 
gezondheidstoestand bevat, lijkt het aannemelijk dat het NCSI ook bij andere ziekten met 
longklachten gebruikt kan worden. De relevantie van het NCSI in een groep patiënten met 
ernstig astma hebben we geëvalueerd door deze te vergelijken met de internationaal meest 
gebruikte astma vragenlijsten; de Asthma Control Questionnaire (ACQ) en de Asthma Quality 
of Life Questionnaire (AQLQ). Op alle subdomeinen van het NCSI werden substantiële 
proporties van patiënten met ernstige problemen gevonden, wat suggereert dat alle 
subdomeinen relevant zijn in patiënten met astma. Op de subdomeinen subjectieve 
symptomen, moeheid, subjectieve beperkingen en algemene kwaliteit van leven werden de 
grootste proporties van patiënten met ernstige problemen geidentificeerd. Ook was er 
heterogeniteit in het aantal subdomeinen waarop patiënten ernstige problemen 
rapporteerden. De ACQ vertoonde conceptuele vergelijkbaarheid met twee van de acht 
subdomeinen van het NCSI, namelijk subjectieve symptomen en subjectieve beperkingen. 
De AQLQ vertoonde conceptuele vergelijkbaarheid met drie van de acht subdomeinen van 
het NCSI: subjectieve symptomen, subjectieve beperkingen en emoties bij benauwdheid. In 
tegenstelling tot de andere subschalen van de AQLQ meet de subschaal omgevingsstimuli 
een aspect van de integrale gezondheidstoestand dat niet gemeten wordt met het NCSI. 
Zowel de ACQ als de AQLQ meten beide geen kwaliteit van leven. Uit deze resultaten mag 
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geconcludeerd worden dat de NCSI meer subdomeinen van de integrale 
gezondheidstoestand meet die relevant zijn in patiënten met astma. Meer specifiek 
belangrijke aspecten zoals moeheid en algemene kwaliteit van leven worden niet gemeten 
met de ACQ en AQLQ.  
 
 
Hoofdstuk 7 
In 2007 vond een uitbraak van q-koorts plaats in Nederland. De beschreven studie in 
hoofdstuk 7 evalueert de integrale gezondheidstoestand van patiënten met q-koorts een 
jaar na de uitbraak en vergeleek deze resultaten met op leeftijd en geslacht gematchte 
controles die geen q-koorts hadden gehad. In beide groepen werden proporties van 
personen met normaal, verhoogd en ernstige problemen op alle subdomeinen van de NCSI 
gevonden. Maar patiënten met positieve q-koorts serologie rapporteerden meer problemen, 
een jaar na infectie, op de domeinen symptomen en functionele beperkingen in vergelijking 
met de controle groep. Met name moeheid was een prominent symptoom bij patiënten met 
q-koorts. Opvallend was dat de controle groep ook een lagere algemene kwaliteit van leven, 
gezondheidsgerelateerde kwaliteit van leven en hogere moeheidscores rapporteerden. Veel 
patiënten hadden een verslechterde integrale gezondheidstoestand een jaar na het 
doormaken van een q-koorts infectie. Het is belangrijk om de integrale gezondheidstoestand 
te monitoren in patiënten met q-koorts voor het bepalen van de nodige behandeling met als 
doel reductie of preventie van de consequenties op lange termijn. 
 
 
Hoofdstuk 8 
De verschillende studies in dit proefschrift werden bediscussieerd en nieuwe research 
vragen en klinische implicaties werden geformuleerd in dit hoofdstuk. Centraal in dit 
proefschrift stond de vraag waarom en hoe de integrale gezondheidstoestand zou gemeten 
moeten worden in de individuele patiënt. Een chronische ziekte heeft invloed op de hele 
persoon, niet alleen op het aangedane fysiologische systeem. Dit verantwoord het meten 
van meer dan alleen de fysiologische parameters. De studies lieten zien dat integrale 
gezondheidstoestand bestaat uit vele relatief onafhankelijke subdomeinen van fysiologisch 
functioneren, symptomen, functionele beperkingen en kwaliteit van leven, die allemaal 
gemeten moeten worden om een compleet beeld van de integrale gezondheidstoestand van 
de patiënt te krijgen. Dit is mogelijk met het NCSI. Alhoewel het NCSI ontwikkeld is voor 
patienten met COPD, is aangetoond dat het ook bruikbaar is bij patienten met andere 
chronische (long)ziekten. De presentatie van de resultaten van het NCSI op de 
PatientenProfielKaart maakt het makkelijker om de bevindingen te bespreken met de 
patiënt en helpt bij het op maat maken van de behandeling. Het is essentieel om te bepalen 
in welke mate de patiënt geadapteerd is aan zijn/haar ziekte, omdat aangetoond is dat dit 
een belangrijke determinant van de integrale gezondheidstoestand is.  
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Eindelijk is het zover: mijn proefschrift is af. Toen ik met het onderzoek begon had ik nooit 
verwacht dat zo lang zou kunnen duren. Het waren leuke jaren waarin ik veel geleerd heb niet 
alleen over onderzoek, maar ook over mezelf. Ik wil dan ook graag iedereen bedanken die hier 
een bijdrage in gehad heeft en/of mij op de een of andere manier heeft gesteund. Zonder 
iemand tekort te doen wil ik graag enkele personen persoonlijk bedanken. 
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alle testen en vragenlijsten te ondergaan. Zonder deze bijdrage had dit proefschrift nooit 
geschreven kunnen worden.  
 
Graag wil ik mijn beide promotoren: Judith Prins en Richard Dekhuijzen, bedanken voor hun 
inzet en begeleiding bij het volbrengen van mijn proefschrift. Beste Judith, bedankt voor je 
betrokkenheid bij mijn promotie. Je duidelijke visie en vragen naar welke boodschap ik zelf zou 
willen overbrengen, hebben mij vooral bij de laatste loodjes van het proefschrift erg geholpen. 
Beste Richard, bedankt voor je altijd snelle en duidelijke feedback.  
Mijn dank gaat tevens uit naar mijn copromotoren: Jan Vercoulen, Johan Molema en Yvonne 
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te veranderen. Naast geduldiger zijn, minder perfectionistisch (en nog een heel aantal dingen) 
heb ik veel van je geleerd en hoop ik de komende jaren nog meer te leren. Beste Johan, bedankt 
voor je eeuwige enthousiasme en dezelfde betrokkenheid bij de artikelen als die je voor 
patiënten had/hebt, zelfs nu je met pensioen bent. Zonder jou hadden de artikelen ook zeker 
niet zo’n mooie titels gehad. Beste Yvonne, bedankt voor je kritische inbreng en je eerlijke 
feedback op de artikelen. Ook de duidelijkheid waarmee je aangaf dat ‘dokters dit niet snappen’ 
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C U R R I C U L U M  V I T A E  | 147 
 
 
Jeannette Jacobs-Peters werd op 23 september 1975 
geboren in Boxmeer. In 1991 behaalde zij haar 
MAVO diploma aan de Meere te Boxmeer, waarna zij 
in 1993 haar HAVO diploma behaalde aan het 
Elzendaalcollege te Boxmeer. Na een studiejaar 
maatschappelijk werk en culturele maatschappelijke 
vorming  te Arnhem met een propedeuse afgesloten 
te hebben startte zij in 1994 haar opleiding klinische 
psychologie aan de Katholieke Universiteit te 
Nijmegen, tegenwoordig Radboud Universiteit Nijmegen. In 2000 liep zij gedurende 9 
maanden haar klinische stage op de longrevalidatie afdeling van Dekkerswald te Groesbeek. 
Alwaar zij in 2001 in de functie als psychologisch medewerker aan de slag ging. Na een 
studie onderbreking besloot zij in 2005 alsnog haar scriptie af te ronden en haar diploma in 
de klinische psychologie te behalen. In 2006 startte zij in de functie academisch klinisch 
medewerker waarin naast onderzoek een van de kerntaken is om de vertaling van 
wetenschappelijke uitkomsten naar de klinische praktijk te maken.  
Jeannette Jacobs-Peters woont in Boxmeer en is getrouwd met John Jacobs.  Zij hebben 
twee zonen Mathijs (geboren in 2002) en Sven (geboren in 2004). 
  
148 | C u r r i c u l u m  V i t a e  
 
 
